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ABSTRACT 
 
Aims/ Hypothesis: Wolcott- Rallison syndrome (WRS) is a rare autosomal recessively 
inherited Mendelian disorder. It is characterised by a short trunk compared to arm span, 
multiple epiphyseal dysplasia, multiple fractures, hepatosplenomegaly and renal 
insufficiency in addition to insulin dependent diabetes. The onset of diabetes in WRS 
families is mainly below the age of 6 months and is characterised by permanent severe 
non-autoimmune insulin deficiency. Mutations of the gene encoding eukaryotic 
translational initiation factor 2 - alpha kinase 3 (EIF2AK3) were found to account for 
diabetes in WRS. The aim of our study was to determine whether common 
polymorphisms in the EIF2AK3 gene (Candidate gene association study) could be 
associated with type 2 diabetes.  
  
Methods: Direct sequencing was performed on all 17 exons/coding regions and 
intron/exon boundaries of EIF2AK3 gene in 48 diabetes and control subjects. Single 
Nucleotide Polymorphisms (SNPs) tagging the common haplotypes (tag SNPs) were 
identified and 11 SNPs were genotyped initially in 2,835 subjects with type 2 diabetes, 
3,538 control subjects in the British Irish, Bangladeshi and South Indian Populations and 
522 families (n= 1,722) in the British Irish and South Indian Populations. 
 
Results: We identified 19 SNPs by direct sequencing. There was no association (all 
p>0.05) between the SNPs and type 2 diabetes in the case–control study and in the family 
study. In the one marker, rs7605713, that showed a nominal significance in Warren 2 
European samples, further replication studies in the Dundee samples (3,334 diabetes 
cases and 3,456 controls) proved to be negative thereby avoiding a false positive result. 
The results also showed several of the SNPs had different minor allele frequencies 
between the British/Irish Caucasians as compared to the South Asians. 
 
Conclusions/interpretation: Common variations in the EIF2AK3 gene were not 
associated with type 2 diabetes in the British Irish and the South Asian population. 
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CHAPTER ONE:  INTRODUCTION TO DIABETES 
 
1.1 THE CLASSIFICATION OF DIABETES MELLITUS 
 
Diabetes mellitus is aetiologically and clinically heterogeneous group of disorders that 
share hyperglycaemia in common. The National Diabetes Data Group (NDDG) and 
World Health Organisation (WHO) Expert committee on Diabetes have come up with the 
classification for diabetes in 1979 (1) and in 1997, an international committee of 
Diabetologists recommended several changes in the classification that have been 
endorsed by the American Diabetes Association and WHO. The terms insulin dependent 
diabetes (IDDM) and non-insulin dependent diabetes (NIDDM) were eliminated as they 
were based upon pharmacologic rather than aetiological considerations. The two major 
forms of diabetes are type 1 diabetes and type 2 diabetes. Type 1 diabetes, an 
autoimmune disease, is due to pancreatic beta cell destruction resulting in insulin 
deficiency. Type 2 diabetes is a heterogeneous condition characterised by insulin 
resistance and also associated with impairment in compensatory insulin secretion. The 
current expert committee classification (Table 1.a) has proposed the above changes. 
 
Table 1.a: Aetiologic classification of diabetes mellitus
1
 
I. Type 1 diabetes (β-cell destruction, usually leading to absolute insulin deficiency)  
A. Immune mediated 
B. Idiopathic 
 
II. Type 2 diabetes (may range from predominantly insulin resistance with relative 
insulin deficiency to a predominantly secretory defect with insulin resistance) 
III. Other specific types  
A. Genetic defects of β-cell function  
1. Chromosome 12, HNF-1  (MODY3) 
2. Chromosome 7, glucokinase (MODY2) 
3. Chromosome 20, HNF-4  (MODY1) 
4. Chromosome 13, insulin promoter factor-1 (IPF-1; MODY4) 
5. Chromosome 17, HNF-1β (MODY5) 
6. Chromosome 2, NeuroD1 (MODY6) 
7. Mitochondrial DNA 
8. Others 
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B. Genetic defects in insulin action  
1. Type A insulin resistance 
2. Leprechaunism 
3. Rabson-Mendenhall syndrome 
4. Lipoatrophic diabetes 
5. Others 
 
C. Diseases of the exocrine pancreas  
1. Pancreatitis 
2. Trauma/pancreatectomy 
3. Neoplasia 
4. Cystic fibrosis 
5. Hemochromatosis 
6. Fibrocalculous pancreatopathy 
7. Others 
 
D. Endocrinopathies  
1. Acromegaly 
2. Cushing's syndrome 
3. Glucagonoma 
4. Pheochromocytoma 
5. Hyperthyroidism 
6. Somatostatinoma 
7. Aldosteronoma 
8. Others 
 
E. Drug- or chemical-induced  
1. Vacor 
2. Pentamidine 
3. Nicotinic acid 
4. Glucocorticoids 
5. Thyroid hormone 
6. Diazoxide 
7. β-adrenergic agonists 
8. Thiazides 
9. Dilantin 
10. -Interferon 
11. Others 
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F. Infections  
1. Congenital rubella 
2. Cytomegalovirus 
3. Others 
 
G. Uncommon forms of immune-mediated diabetes  
1. "Stiff-man" syndrome 
2. Anti–insulin receptor antibodies 
3. Others 
 
H. Other genetic syndromes sometimes associated with diabetes  
1. Down's syndrome 
2. Klinefelter's syndrome 
3. Turner's syndrome 
4. Wolfram's syndrome 
5. Friedreich's ataxia 
6. Huntington's chorea 
7. Laurence-Moon-Biedl syndrome 
8. Myotonic dystrophy 
9. Porphyria 
10. Prader-Willi syndrome 
11. Others 
 
IV. Gestational diabetes mellitus (GDM) 
 
 
1
Modified from American Diabetes Association: Diabetes Care 2008 31:S55-S60, 2008 
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1.2 Aetiology and Epidemiology of Diabetes 
 
  
 
Introduction 
 
Diabetes mellitus is a chronic metabolic disorder characterised by disturbance in glucose 
metabolism leading to a state of hyperglycaemia and is associated with microvascular and 
macrovascular complications in the long term. Diabetes is the leading cause of chronic 
diseases worldwide and has reached epidemic proportions in certain parts of the world 
and in certain ethnic groups. This has widespread implications for health resources. The 
two main types of diabetes, type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus 
(T2DM) are quite distinct from each other in their aetiology and epidemiology. T2DM is 
the most common form of diabetes world-wide accounting for 90% of cases globally (2) 
and affecting approximately 4% of the worlds adult population. Type 1 diabetes is an 
autoimmune disease that results in insulin deficiency.  
 
 
1.2.1 Type 1 Diabetes  
 
Worldwide prevalence 
 
In 1997 there were 11.5 million people with T1DM in the world; the figure has been 
estimated to rise to 23.7 million in the year 2010. These increasing figures will have most 
impact in Asia, where there are 4.5 million people with T1DM, estimated to rise to 12 
million by the year 2010. One of the best incidence studies has come from Europe as part 
of a European collaboration. The highest incidence of T1DM is found in Finland; the 
lowest rates in Europe are in Romania (Table 1.b). The incidence of T1DM follows a 
north-south gradient, with the notable exception of Sardinia. The figures from countries 
such as India are less precise, although one study in Chennai (3) suggested an incidence 
equivalent to that found in Southern European countries. These different rates of T1DM 
are likely to reflect both the genetic background of individual countries and differences in 
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exposure to environmental agents. In recent years in several different countries the 
incidence of T1DM is increasing. These changes must reflect environmental influences. 
 
 
Table 1.b: Incidence of type 1 diabetes mellitus in Europe 
 
                                                          Rate (a) 
Finland    42.9 
Sardinia    30.2 
Denmark    21.5 
Norway    20.8 
UK     16.4 
Luxembourg    12.4 
Netherlands    11.0 
Sicily     10.1 
Belgium      9.8 
France         7.8 
Italy         6.8 
Israel         5.5 
Poland         5.5 
Romania        5.1 
 
a Standardized incidence rates (per 100 000 per year), age 0-14 years, in a selection of 
countries in Europe taken from EURODIAB study 
 
Aetiology of Type 1 Diabetes 
Type 1 diabetes is due to autoimmune destruction of insulin secreting pancreatic β cells. 
T1DM typically occurs in young individuals with an age of onset in childhood or early 
adult life. The autoimmune reaction is likely to be triggered by an environmental agent in 
utero or in very early life (Figure 1.a). The earliest markers of β cell destruction are the 
appearance of autoantibodies to glutamic acid decarboxylase (GAD), islet cells and 
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insulin. Autoantibodies have been detected 10-15 years before the onset of disease and, 
furthermore, have been known to disappear without T1DM occurring in a few 
individuals. One to two years before onset of the disease, evidence of β cell impairment 
can be detected, initially evidenced by a reduction in the first phase of insulin response to 
intravenous glucose and in the later stages by an abnormal oral glucose tolerance. In 
contrast to the slow β cell destruction, the onset of T1DM is acute and is usually 
measured in weeks. At this stage in the aetiological process, it is likely that 70% of β 
cells have been destroyed and those remaining are inhibited by the action of cytokines. 
 
Figure 1.a: The aetiology of type 1 diabetes mellitus  
 
 
 
 
 
   
 
 
 
 
  
 
 
Time (Years) 
Figure 1.a: Gene- Environment interaction and decline in β cell mass in auto-immune diabetes 
 
There is a subgroup of patients who develop diabetes in adult life (> 25 years of age) and 
they do not require insulin during the first few years after diagnosis but progress rapidly 
to insulin dependence, and have an autoimmune component to their disease with positive 
GAD and islet cell antibodies (4). This condition is named Latent autoimmune diabetes in 
adults (LADA). There are several common features between T1DM and LADA, 
Environmental 
factors 
Genes 
Not Diabetic 
Type 1 DM 
 
 
(Irreversible autoimmunity) 
β cell 
mass 
 
LADA 
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including T cell mediated insulitis, islet and GAD antibody positivity and high rates of 
HLA DR3 and DR4 genes. The prevalence of LADA in newly diagnosed diabetics has 
been shown to range from 2.8% to 22.3% in different studies depending on the markers 
used and characteristics of the patients. Although these patients present as type 2 
diabetes, they have been shown to progress quickly to insulin dependency especially if 
the diabetes is diagnosed at a younger age and the patient is not overweight (5). Therefore 
measuring GAD antibody and C- peptide levels, in newly diagnosed young, non-obese 
―type 2 diabetes patients‖ and no family history of T2DM, to identify the LADA sub 
group should be considered in routine clinical practice.  
 
 
Genetics of type 1 Diabetes  
Type 1 diabetes is a multi-factorial disease with both genetic and environmental 
components. The largest genetic contribution to T1DM is determined by genes in the 
major histocompatibility complex (MHC) located to the short arm of chromosome 6 
(IDDM1-HLA, 6p21). Initial associations between T1DM and the MHC were described 
for the HLA class I antigens A1-B8 and B15. With advent of HLA class II serology, 
closer associations were found with HLA –DR with an increased frequency of DR3 and 
DR4 alleles and a decreased frequency of DR2 allele in T1DM subjects. At the 
population level the strongest genetic association with T1DM is with HLA-DQ alleles   
(6). This is best defined by DNA typing of HLA- DQ1, DQB1 and DRB1 (7). However, 
due to the strong linkage disequilibrium between these loci it has been very difficult to 
study the effect of individual HLA DQ or HLA DR Genes separately. For the individual, 
susceptibility is best defined by allelic combinations of MHC genes located to all three 
major regions (classes I, II, and III), called HLA haplotypes. Haplotypes occur because of 
strong linkage disequilibrium observed in the MHC whereby the combinations of alleles 
are seen more frequently than would be expected by their individual gene frequencies. An 
example of a haplotype would be A2, Cw1, B56, TNFa6, DRB1*401, DQA1*0301, 
DQB1*0302. In a recent study there has been a re-focus on the MHC class I genes HLA-
B and HLA-A- principally involving HLA-B*39, contributing to the aetiology of type 1 
diabetes.(8)  
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The MHC accounts for approximately 40% of the genetic component to T1DM. Evidence 
from genome scans and candidate gene studies indicates the existence of a large number 
of putative non-MHC genes contributing to the aetiology of T1DM, although all of 
comparatively small effect compared to the MHC (9). The most reproducible T1DM 
associations have been found with the insulin gene and Cytotoxic T lymphocyte antigen 4 
gene (CTLA4). An association between the insulin gene [located on chromosome 
11p15.5; INS), and T1DM was described in the 1980s and subsequently confirmed by 
linkage studies. The INS locus on chromosome 11p15.5 contains a major polymorphism 
5'  to the transcription site, which is a variable number of tandem repeats (VNTR) region 
(10). One functional hypothesis to explain the association between the insulin gene and 
T1DM is that ‗hypersecretors‘ of insulin determined by the disease- associated 
polymorphism might induce thymic intolerance to insulin, thus increasing a risk of 
autoimmune reaction. Studies have showed association of the T- cell regulatory gene 
CTLA4 with susceptibility to autoimmune disease, including type 1 diabetes (11). CTLA4, 
gene located on chromosome 2q33, plays an important role in the counter regulation of 
CD28 T cell antigen receptor activation of T cells. In the mouse model of T1DM, 
susceptibility was also associated with variation in CTLA4 gene splicing with reduced 
production of a splice form encoding a molecule lacking the CD80/CD86 ligand-binding 
domain.  
 
A single nucleotide polymorphism in the gene Protein Tyrosine Phosphatase N22 
(PTPN22) encoding the lymphoid protein tyrosine phosphatase (LYP), a suppressor of T-
cell activation, has been shown to be associated with T1DM (12). The variants encoded 
by the two alleles, 1858C (Arginine) and 1858T (Tryptophan), differ in a crucial amino 
acid residue involved in association of LYP with the negative regulatory kinase Csk. 
Unlike the variant encoded by the more common allele 1858C, the variant associated 
with T1DM does not bind Csk. The PTPN22 allele 1858T was more frequent in 
individuals with T1DM than in healthy individuals: 30.6% of individuals with T1DM 
were heterozygous with respect to 1858T, compared with only 21.3% of the healthy 
controls and 3.7% of individuals with T1DM were homozygous with respect to 1858T, 
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compared with only 1.0% of the healthy controls. These results suggest that the PTPN22 
allele 1858T predisposes an individual to developing T1DM. 
 
A joint Genome wide association study (GWAS) in the British population has examined 
2000 individuals for each of 7 major diseases and a shared set of 3000 controls, identified 
association signals at 7 regions in type 1 diabetes (13). There are six genes/regions for 
which there is strong pre-existing statistical support for a role in T1DM-susceptibility: 
these are the major histocompatibility complex (MHC), the genes encoding insulin, 
CTLA-4 (cytotoxic T-lymphocyte associated 4) and PTPN22 (protein tyrosine 
phosphatase, non-receptor type 22), and the regions around the interleukin 2 receptor 
alpha (IL2RA/CD25) and interferon-induced helicase 1 genes (IFIH1/MDA5). However, 
these signals can explain only part of the familial aggregation of T1DM. Five of these 
previously identified associations were detected in this scan. In this study, single-point 
analyses revealed three novel regions (on chromosomes 12q13, 12q24 and 16p13) 
showing strong evidence of association. Four further regions attained similar levels of 
significance either through multi-locus analyses (chromosomes 4q27 and 12p13), or 
through the combined analysis of autoimmune cases (chromosomes 18p11 and the 10p15 
CD25 region). The associations with T1DM for chromosomes 12q13, 12q24, 16p13 and 
18p11 have been confirmed in independent and multiple populations. The two signals on 
chromosome 12 (at 12q13 and 12q24) map to regions of extensive linkage disequilibrium 
covering more than ten genes. Several of these represent functional candidates because of 
their presumed roles in immune signalling, considered to be a major feature of T1DM 
susceptibility. These include ERBB3 (receptor tyrosine-protein kinase erbB-3 precursor) 
at 12q13 and SH2B3/LNK (SH2B adaptor protein 3), TRAFD1 (TRAF-type zinc finger 
domain containing 1) and PTPN11 (protein tyrosine phosphatase, non-receptor type 11) 
at 12q24. For these signal regions in particular, extensive resequencing, further 
genotyping and targeted functional studies will be essential steps in identifying which 
gene, or genes, are causal. Of those listed, PTPN11 is a particularly attractive candidate 
given a major role in insulin and immune signalling. It is also a member of the same 
family of regulatory phosphatases as PTPN22, already established as an important 
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susceptibility gene for T1DM and other autoimmune diseases. A further GWA study 
confirmed unequivocally the associations at 12q24, 12q13, 16p13 and 18p11  (14). 
Results from other candidate gene studies and GWAS have identified other chromosomal 
regions, which may be involved in disease pathogenesis. The finding that so many genes 
are involved in T1DM, raises the possibility that there are several disease processes that 
might lead to β cell destruction. The identification of the variants, genes and pathways 
involved in disease through these approaches offers 1) a potential route to new therapies, 
2) improved diagnosis and 3) better disease prevention. 
 
 
Environmental factors- Type 1 Diabetes 
Environmental factors play a significant part in the aetiology of T1DM and have been 
implicated in both initiation and progression of β cell damage. The majority of evidence 
points to the effects of viruses and/or dietary factors as aetiological agents. 
 
Many viruses have been implicated in the pathogenesis of T1DM (15); they may have a 
direct effect on β cells by infection and cell lysis or alternatively they may act as triggers 
to the autoimmune process. Amongst the viruses that have been implicated in humans are 
coxsackie A, coxsackie B, rubella, cytomegalovirus, mumps and Epstein- Barr viruses. 
The Enteroviruses (coxsackie A, coxsackie B and echovirus) are the most commonly 
associated viruses with diabetes and serve as a major trigger for T1DM in the young 
possibly by induction of islet cell antibodies. The evidence for viral involvement in type 
1 diabetes came from several sources, including anecdotal case reports, epidemiological 
studies, seasonal incidence studies and animal models. There is data to support that 
enterovirus infection either accompanies or precedes the development of T1DM in young 
people in many instances (16).  
 
Coxsackie B was first implicated in the early 1970s by Gamble, who found an increased 
titre of coxsackie B antibodies in newly diagnosed T1DM patients. Coxsackie virus has 
been identified in very young onset type 1 diabetes (in patients under 5 years of age) 
using the polymerase chain reaction (17). Furthermore, when the coxsackie virus was 
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sequenced, although it had extensive homology to coxsackie virus B4, there was some 
unique sequence variation indicating an T1DM variant (18). There have also been many 
anecdotal reports of coxsackie B virus causing T1DM, presumably by a direct cytolytic 
effect on β cells. A previously fit child died in diabetic ketoacidosis three days after flu- 
like illness. At, necropsy, there was an extensive lymphocytic infiltration into the β cells 
of pancreas and coxsackie B4 was found in the child‘s serum. This virus was extracted 
from the pancreas and, when used to infect mice, led to diabetes.  
 
There is a high incidence of T1DM among patients with the congenital rubella syndrome 
(19). Clearly, this results from an in utero infection, but the diabetes that ensues is 
indistinguishable from type 1 diabetes; the disease presents in the second decade of life, 
the onset is preceded by islet cell antibodies and the genetic predisposition is defined by 
the same HLA association as T1DM. This is likely to be a good example of virus 
triggering the immune process. 
 
Dietary factors have also been implicated in the development of T1DM. Amongst the 
dietary factors indirectly linked to either susceptibility or protection to T1DM are cow‘s 
milk protein (including bovine serum albumin and β - lactoglobulin), β cell toxic drugs 
(alloxan, streptozotocin, rodenticides), dietary toxins (in particular nitroso-containing 
compounds) and other such as coffee and sugar. There is an interesting interplay between 
vitamin D, vitamin D receptor (VDR) and association with T1DM. The contribution of 
vitamin D as a potent modulator of the immune system is well recognised. The main 
sources of vitamin D are ergocalciferol and cholecalciferol found in dietary sources and 
cholecalciferol produced in the skin by ultraviolet radiation of 7 dehydrocholesterol. 
Vitamin D deficiency in infancy and VDR polymorphisms may be risk factors for T1DM. 
In non-obese diabetic (NOD) mice, long term treatment with high doses of vitamin D3 
reduced the incidence of diabetes by changing the cytokine balance at the local pancreatic 
lesion (20).  
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The Future 
 
The working out of the complete genetic basis of type 1 diabetes will lead to a better 
understanding of disease pathogenesis and will be further aided by studies of genetic and 
environmental interaction. T1DM may be the first multi-factorial disease to benefit from 
primary prevention of both insulitis and of T1DM (once autoantibodies have been 
detected). Diapep277 immune modulator- Immune modulation has been attempted to 
attenuate the process of autoimmune destruction of insulin-producing pancreatic beta 
cells. The 60 kDa heat-shock protein (hsp60) is one of the many different self antigens 
involved in this process. Treatment with DiaPep277, a peptide derived from human 
HSP60, has been shown to save residual beta-cell function in NOD mice (21). In humans, 
C-peptide concentrations were maintained in the DiaPep277 treated group as opposed to 
a fall in the placebo group, insulin requirements were lower in the treatment group 
compared to placebo (22). T-cell reactivity to hsp60 and p277 in the DiaPep277 group 
showed an enhanced T-helper-2 cytokine phenotype.  
 
Anti-CD3 monoclonal antibodies can affect immune responses and possess the unique 
capacity to induce immunological tolerance. Short-term treatment with CD3 antibody has 
been shown to preserve residual beta-cell function for at least 18 months in patients with 
recent-onset type 1 diabetes (23). In the Diabetes Prevention Trial, low dose insulin was 
administered to persons with high risk of T1DM as ascertained by family history, islet 
antibodies and HLA typing. It concluded that low dose insulin does not delay or prevent 
the onset of T1DM. In a European study (24) (ENDIT) high dose nicotinamide was being 
used to protect the β cell in high risk individuals for type 1 diabetes; unfortunately this 
trial also failed to show benefit on active treatment (25). However, 90% of type 1 
diabetes patients do not have a family history of type 1 diabetes. The approach in this 
latter group might be to identify the genetically susceptible by the use of genetic markers 
and then test for autoantibodies. If the latter subjects are autoantibody positive then 
intervention may be considered in the future. The sensitivity and specificity that would be 
required of such testing would depend on how safe and effective the proposed 
intervention would be. 
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1.2.2 Type 2 diabetes 
 
Worldwide prevalence 
 
Type 2 diabetes is one of the most common non-communicable diseases in the world 
with an estimated 147.2 million people suffering from this disorder; by 2010 this figure is 
estimated to reach 212.9 million people (26). Furthermore, it has been predicted that by 
the year 2010 over half the people with T2DM will be living in Asia. This trend is likely 
to be due to increasing urbanization and industrialization (27). According to WHO 
estimates the figure is likely to double by the year 2025. The prevalence of diabetes in a 
selection of studies is given in Table 1.c.  
 
Table 1.c: Extremes of prevalence rates of type 2 diabetes mellitus in different 
ethnic groups 
 
Higher  Rate (a)  Lower   Rate (a) 
 
Pima Indians  50.3  Hispanic Central  5.6 
Nauruans  41.3    Mexico 
Australian   22.5  Micronesian     4.3 
 Aborigines    European (Poland)  3.5 
Fijian Indians  22.0  Rural Asian Indians  2.7 
US Mexican   14.1  Rural Melanesian  1.9 
  (Hispanic)      (Fiji) 
Mauritian Chinese 13.1  Rural Chinese   1.6 
US African  10.3  Rural African   1.2 
Southern Italy  10.2   (Tanzania) 
  
a Age –specific prevalence rates in percentages estimated for 1994 (28)  
 
  
25 
As with T1DM, the incidence of diabetes in different countries is likely to reflect the 
different genetic architecture as well as the differing environment. A good example is 
afforded by the population of Nauru; in full- blooded Nauruans over the age of 60 years 
the prevalence of T2DM is 83%, whereas in those with genetic admixture as adduced by 
the HLA typing the prevalence of diabetes is 17%; this clearly reflects the genetic 
component. However, rapid increase of T2DM in the world in the last few decades can 
only be ascribed to environmental factors. This illustrates the multi-factorial nature of 
T2DM, with strong genetic and environmental contributions. 
 
Aetiology of Type 2 Diabetes 
 
Type 2 diabetes is a multi-factorial disease with genetic and environmental factors 
playing a key role in its pathogenesis. Central to the aetiology is a defect in insulin action, 
increased hepatic glucose output and impaired insulin secretion. Although insulin 
resistance is frequently the first detectable abnormality in the progression of T2DM, 
insulin resistance by itself does not cause the disease, and is only manifested when there 
is a coexisting insulin secretory defect. T2DM typically occurs in middle aged and 
elderly people but there is increasing trend of T2DM occurring in young individuals. The 
main question yet to be answered is whether T2DM is one disorder, or a group of 
disorders with hyperglycaemia as the end point in disease pathogenesis. Insulin resistance 
is common to several other disorders, including ischaemic heart disease, hypertension, 
dyslipidaemia, central obesity and coagulation defects; the clustering of these disorders is 
known as metabolic syndrome or the insulin resistance syndrome or Syndrome X. The 
interface of T2DM with obesity is complex one, highlighted by the discovery of leptin 
and adiponectin. The cause of obesity and T2DM in the ob mouse is a mutation of the ob 
gene. With administration of the ob gene protein (leptin) the ob mouse decreases its food 
consumption and increases exercise, leading to a dramatic weight loss; if given earlier 
enough it will also prevent diabetes. Common human obesity, by contrast is associated 
with increased leptin levels, and leptin levels have been found to correlate with 
hyperinsulinaemia suggesting a degree of leptin resistance. The protein adiponectin 
signals adipose tissue mass and reduced levels are found in obese subjects and there is an 
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important interplay between adiponectin, insulin resistance, T2DM and atherosclerosis 
(29).  Ghrelin is a gut hormone that is a signal of satiety and therefore has a direct effect 
on obesity (30).  In the obese diabetic subject, therefore, there may be interplay between 
leptin, adiponectin, ghrelin and insulin, contributing to insulin resistance and the 
metabolic syndrome. 
 
 
The Genetic contribution to Type 2 Diabetes mellitus  
 
Type 2 Diabetes is a classic example of multi-factorial disease with the phenotype of an 
individual being influenced by an interaction of genes and environment. Some of the 
most common chronic diseases in the modern world, including heart disease, cancer, 
diabetes, arthritis and osteoporosis, are a result of environmental/lifestyle factors, 
including diet and nutrition, activity levels and smoking, superimposed on genetic 
predisposition. Such environmental factors have an inter-play with genetic predisposition, 
from foetal development to childhood and adult life, resulting in disease manifestation. 
The global increase in T2DM over the last century is a salient example of how interaction 
of lifestyle changes with genotype can dramatically impact on the health of entire 
populations.  
 
Evidence for a genetic basis for T2DM and the metabolic syndrome has been derived 
from studies of families, twins and populations with genetic admixture. In some genetic 
diseases, the basis is mutation of a single gene and this is a feature of monogenic 
diabetes, which will be discussed later. More commonly however the genetic basis of 
T2DM and other chronic diseases is polygenic, i.e. many genes are involved, each with 
relatively modest effect on the phenotype. Genetically complex diseases such as type 2 
diabetes may exhibit the following properties: incomplete penetrance - not all susceptible 
individuals with at risk genes are affected, involvement of several disease-predisposing 
loci, some of which may have a major effect, but many of which may have a relatively 
minor effect i.e. polygenic, interaction between genes and the environmental factors, 
  
27 
heterogeneity so that different loci and/or alleles cause disease in different ethnic 
groups(31). 
 
Family aggregation studies have shown that siblings of family members with T2DM are 
four times more likely to develop T2DM in their lifetime than the general population 
(λsib ~4) (32). Evaluation of familial aggregation of metabolic syndrome components 
(Framingham Heart Study data) suggest some components have genetic determinants: 
lipid levels and BMI were found to correlate between siblings and between parents and 
offspring (33). Heritability studies have also provided support for the role of genetic 
factors in susceptibility to T2DM. For example, high heritability estimates for fasting 
blood glucose, β-cell function and components of the metabolic syndrome has been found 
in non-diabetic relatives from families with T2DM of Northern European extraction (34), 
while in a comparable study of families from the same background, but healthy families 
not characterized by a high degree of insulin resistance, the heritability estimate for 
fasting glucose was significantly lower (0.77 vs 0.21, P < 0.001) (35). 
 
Further evidence for the role of genetic factors in predisposition to T2DM comes from 
studies of populations with genetic admixture and twins. There is a higher prevalence of 
T2DM in full-blooded Nauruans aged 60 years or older than in those with ancestral 
foreign admixture (83 vs. 17%) (36). Twin studies have shown a much higher 
concordance rate for T2DM among monozygotic (28–34%) versus dizygotic (14–16%) 
twins. In addition, long-term follow-up of monozygotic twins has shown that if one has 
T2DM, the concordance rate for type 2 diabetes/ IGT in monozygotic twin is very high, 
even in twins initially ascertained discordant for diabetes. (37).  
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Study of genes involved in complex disease like Type 2 Diabetes 
 
There has been a significant change in approaching the study of genes that confer 
susceptibility to a complex disease like type 2 diabetes and other such chronic diseases 
over the past few years. 
There is the  
1) Traditional approach by Linkage analyses (Positional cloning)  
2) Candidate gene approach  
3) Recently popular methodology of Genome wide association studies (GWAS). 
 
Linkage analysis (positional cloning) involves investigating the entire genome to search 
for genetic causes of disease (38). This kind of random gene search assumes no 
knowledge of the underlying defects. Instead, positional cloning aims at localizing the 
disease gene on the basis of its position in the genome. The tools utilized for linkage are 
microsatellite markers. Linkage analysis studies are performed in family pedigrees, 
affected sib- pairs. Once a chromosomal region has been linked to the disease, the next 
step would be the search for attractive candidate genes in the region or narrowing the 
region by linkage disequilibrium mapping. Linkage analysis tests for the segregation of a 
marker and disease phenotype in a pedigree and has been particularly useful in detecting 
genes involved in monogenic diabetes (Hepatocyte nuclear factor-1 alpha -HNF1α 
mutations in MODY).  
 
Many groups worldwide have completed the genome scans for genes predisposing to 
T2DM, although the results are generally disappointing. In the UK Warren 2 sib pair 
repository, an autosomal genome scan was carried out on 743 UK sib pairs with T2DM 
(39). This was followed by nonparametric linkage analysis of the entire dataset, which 
identified seven regions showing linkage located on chromosomes 1q24.2, 5q13, 5q32, 
7p15.3, 8p21–22, 8q24.2 and 10q23.3 (LOD scores ≥1.18). Five of the regions were 
found to coincide with loci previously identified in other genome scans of French, 
Finnish, American (European descent), Mexican American and Native American (Pima 
Indians) pedigrees. It was hoped this data should aid positional cloning of genes 
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associated with susceptibility to T2DM. Only two genome scans have lead to gene 
discovery with the identification of the calpain10 gene (located to chromosome 2q37) as 
a major T2DM susceptibility gene in Mexican-Americans (40) and TCF7L2 (encoding 
transcription factor 7-like 2) in Icelandic population. However, it is pertinent to note that 
calpain10 gene was not picked out in recent Genome wide association studies whereas,  
TCF7L2 was identified in GWAS and has been recognized as the most important T2DM-
candidate gene to date. 
 
The candidate gene approach aims at the identification of genes based upon information 
of their biological function(41). Association studies are based on candidate gene 
approach, frequently using single nucleotide polymorphisms (SNPs) and tag SNPs. 
Tagging SNPs exploit the extensive linkage disequilibrium that is present in the genome. 
A candidate gene association study tests for significant differences in the genotype/ allele 
frequencies of the gene between cases and controls. When choosing a candidate gene for 
association studies in polygenic disease like T2DM (see Figure 1.b) the following 
information helps to arrive at a candidacy for the gene (a priori evidence) - 1) Biological 
significance 2) Animal models 3) Human models (monogenic syndromes) 4) Linkage 
evidence (positional cloning). Therefore for the study of T2DM, choosing a gene 
involved in insulin secretion and pancreatic beta cell function or a gene involved in 
insulin action on the muscle, adipose tissue and liver would be an appropriate candidate 
gene. An animal model with the gene defect expressing the T2DM phenotype would give 
further credence to the candidate gene. Extrapolation by studying genes contributing to 
monogenic diabetes in T2DM has proved fruitful in some candidate gene association 
studies. Positional cloning with positive LOD scores of >+3 indicates that two gene loci 
are close to each other on a chromosome and provide evidence for linkage. The more of 
the above criteria that a gene satisfies the higher is the chance of finding a successful 
candidate gene. The Hapmap project has catalogued majority of the common variants 
(single nucleotide polymorphisms-SNPs and tag SNPs) in the human genome(42). This 
publicly available database has been a huge resource for candidate gene testing.  
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Figure 1.b: Pathway for posititional cloning and candidate gene testing 
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Figure 1.b: The selection of a candidate gene based on putative biological action of the 
gene product, animal model and human model with genetic defect leading to disease 
manifestation, linkage evidence of the gene for the condition of interest, in our case 
T2DM. Tests are carried out between cases and controls looking into association of the 
candidate gene variants with the disease. A positive candidate gene association study 
needs further replication in independent datasets to establish its candidacy. Further 
studies into the functional basis of the gene with relevance to its effects on T2DM would 
shed light on possible mechanistic pathways(43). 
 
 
Genome wide association studies (GWAS) 
Genome wide association studies are hugely popular at present (44). Three recent 
advances mean that Genome Wide Association studies that are powered to detect 
plausible effect sizes are now possible. 1) The International Hapmap resource, which 
documents patterns of genome-wide variation and linkage disequilibrium in four 
population samples, greatly facilitating both the design and analysis of association 
studies. 2) The availability of dense genotyping chips, (up to a million of single 
nucleotide polymorphisms (SNPs) that provide good coverage of much of the human 
genome, means that for the first time GWA studies for thousands of cases and controls 
are technically and financially feasible. 3) Appropriately large and well characterized 
clinical samples have been assembled for many common diseases like diabetes. 
 
A GWA study is defined by the National Institutes of Health as a study of common 
genetic variation across the entire human genome designed to identify genetic 
associations with observable traits. The typical GWA study has 4 parts: (1) selection of a 
large number of individuals with the disease or trait of interest and a suitable comparison 
group; (2) DNA isolation, genotyping, and data review to ensure high genotyping quality; 
(3) statistical tests for associations between the SNPs passing quality thresholds and the 
disease/ trait; and (4) replication of identified associations in an independent population 
sample or examination of functional implications experimentally. The most frequently 
used GWA study design has been the case-control design, in which allele frequencies in 
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patients with the disease of interest are compared to those in a disease-free comparison 
group. 
 
The approach in a GWA study involves rapidly scanning markers across the complete 
sets of DNA, or genomes, of many people to find genetic variations associated with a 
particular disease. Once new genetic associations are identified, researchers use the 
information to conduct further replication studies for robust associations in various 
datasets, and to develop better strategies to detect, treat and prevent the disease. Such 
studies are particularly useful in finding genetic variations that contribute to common, 
complex diseases, such as type 2 diabetes. The tools include computerized databases that 
contain the reference human genome sequence, a map of human genetic variation and a 
set of new technologies (Affymetrix Gene Chip, illumina, perlegen) that can quickly and 
accurately analyze whole-genome samples for genetic variations that contribute to the 
onset of a disease. DNA is placed on tiny chips and scanned on automated laboratory 
machines. The machines quickly survey each individual‘s genome for strategically 
selected markers of genetic variation, single nucleotide polymorphisms, or SNPs.  
 
If certain genetic variations are found to be significantly more frequent in people with the 
disease compared to people without disease, the variations are said to be "associated" 
with the disease. The associated genetic variations can serve as powerful pointers to the 
region of the human genome where the disease-causing problem resides. However, the 
associated variants themselves may not directly cause the disease. They may just be in 
linkage disequilibrium with the actual causal variants. The large number of tests in a 
Genome wide association studies, up to 400,000, mean that p-values of ~5X 10–7 are 
necessary to provide a study-wide p-value of 0.05. 
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Genome-wide association study of 14,000 cases of seven common diseases and 3,000 
shared controls by The Wellcome Trust Case-control Consortium describe a joint GWA 
study (using the Affymetrix Gene Chip 500K Mapping Array Set) undertaken in the 
British population (45). 
The most widely replicated associations for T2DM in various populations are limited to 
variants in three genes: PPARG (encoding the peroxisomal proliferative activated 
receptor gamma; (P12A), KCNJ11 (the inwardly rectifying Kir6.2 component of the 
pancreatic beta-cell KATP channel; E23K
 
and TCF7L2 (transcription factor 7-like 2; 
rs7903146). All three of these signals were detected with effect-sizes in this GWA study 
consistent with previous reports. A cluster of SNPs on chromosome 10q, within TCF7L2, 
represented by rs4506565 (trend test, OR 1.36, P = 5.7  10
-13
) generated the strongest 
association signal for T2DM. rs4506565 is in tight linkage disequilibrium (r
2
 of 0.92 in 
the CEU component of HapMap) with rs7903146, the variant with the strongest 
aetiological claims. The signals associated with variants within the other established 
T2DM-susceptibility genes, KCNJ11 (rs5215, r
2
 of 0.9 with rs5219, E23K) and PPARG 
(rs17036328, r
2
 of 1 with rs1801282, P12A) are less dramatic (trend test, OR 1.15 and 
1.23 respectively, both P = ~ 0.001). Apart from TCF7L2, the scan revealed two signals 
for T2DM with p-values less than 5  10
-7
. The first of these maps within the FTO (fat-
mass and obesity-associated) gene on chromosome 16q. Several adjacent SNPs 
(including rs9939609, rs7193144 and rs8050136) generate signals characterized by a per-
allele OR for T2DM of ~1.25 and a risk-allele frequency of ~ 40% in controls.  
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Genes and Type 2 Diabetes 
 
Genome scanning, candidate gene studies and GWA studies have facilitated the 
identification of a number of loci for T2DM and the metabolic syndrome, including 
TCF7L2, KCNJ11, CAPN10, and PPARγ and many other genes. (Table 1.d) 
 
Table 1.d: Gene discovery in type 2 diabetes 
 
 
TCF7L2 
TCF7L2 was identified by Decode Genetics group. This group was following up a type 2 
diabetes linkage peak on chromosome 10q in Icelandic individuals, when they found very 
strong association of type 2 diabetes with variants of the TCF7L2 gene. There was 
reported suggestive linkage of type 2 diabetes mellitus to chromosome 10q in earlier 
studies. The investigators then genotyped 228 microsatellite markers in Icelandic 
individuals with type 2 diabetes and controls throughout a 10.5-Mb interval on 10q. A 
microsatellite, DG10S478, within intron 3 of the transcription factor 7-like 2 gene 
Linkage Studies Candidate wide 
association studies 
Genome wide association 
studies (Incomplete list) 
TCF7L2 TCF7L2 TCF7L2 
 
Capn10 KCNJ11 ( E23K variant of 
Kir 6.2) 
HHEX–IDE 
 
 PPARG  
(P12A)  
SLC30A8 
 
 TCF2   CDKAL1 
 
 WFS1 FTO 
 
  PPARG  
(P12A) 
  IGF2BP2 
 
  KCNJ11 
  CDKN2A–2B 
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(TCF7L2) was associated with type 2 diabetes (P = 2.1 x 10
-9
) (46). The variants were all 
strongly correlated with each other and represent one risk allele that is present in ~28% of 
control subjects and ~36% of individuals with type 2 diabetes. The risk allele confers an 
estimated RR of 1.50 per copy carried compared to the risk of non-carriers. These were 
followed up by replication studies in other cohorts/ ethnic groups and there were similar 
findings confirming TCF7L2 (encoding transcription factor 7-like 2) as the most 
important T2DM susceptibility gene to date. It has the largest allelic odds ratio (OR) of 
any established common variant for T2D and is ~1.35. 
 
In the Diabetes Prevention Program (47) participants with the risk conferring TT 
genotype at rs7903146 were more likely to have progression from impaired glucose 
tolerance to diabetes than were CC homozygotes (hazard ratio- 1.55). The TT genotype 
was associated with decreased insulin secretion but not increased insulin resistance at 
baseline. Similar results were obtained for rs12255372.  
 
A case-control study and family based association study in UK using four TCF7L2 single 
nucleotide polymorphisms (SNPs: rs7903146, rs12255372, rs4506565, rs12243326) was 
performed (48). All SNPs were significantly associated with T2DM. In the family-based 
analyses strongest signal was seen for rs4506565. Similar positive replication studies in 
other populations clearly established TCF7L2 as a type 2 diabetes susceptibility gene. 
 
The TCF7L2 gene product is thought to act through regulation of proglucagon gene 
expression in enteroendocrine cells via the Wnt signalling pathway. The proposed 
mechanism by which Variants of TCF7L2 contribute to T2DM suggests impaired GLP-1-
induced insulin secretion. This seems to be rather the result of a functional defect in the 
GLP-1 signalling in beta cells than a reduction in GLP-1 secretion. This defect might 
explain the impaired insulin secretion in carriers of the risk alleles and confers the 
increased risk of type 2 diabetes (49). 
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KCNJ11 
Inwardly rectifying potassium channels (Kir channels) control cell membrane K (+) 
fluxes and electrical signalling in diverse cell types, like pancreatic  cells. KCNJ11 
encodes Kir6.2, which is an essential subunit of the pancreatic  cell potassium ATP 
(KATP) channel controls insulin secretion. Rare mutations of this locus lead to the 
monogenic syndrome of familial hyperinsulinaemia, confirming the important role of 
KCNJ11 in insulin secretion. For some, mutations lead to permanent neonatal diabetes 
mellitus, and accompanied by neurological sequelae- developmental delay, muscle 
weakness, and epilepsy. Polymorphisms
 
in the gene KCNJ11
 
E23K (glutamate is 
exchanged by lysine at codon 23) have been shown to be associated with type 2 diabetes
 
in several populations. The
 
K allele was associated with diabetes in a large case-control
 
study (odds ratio [OR] 1.18 [95% CI 1.04–1.34], P = 0.01) suggesting E23K variant of  
KCNJ11 increases the risk of type 2 diabetes (50). 
 
PPARγ 
Variants of the PPARγ gene are strong candidates for conferring susceptibility to T2DM 
and obesity, as PPARγ regulates adipocyte differentiation, and lipid and glucose 
metabolism. Two PPARγ isoforms, PPARγ1 and PPARγ2, have been characterised, and 
are encoded by a single PPAR gamma gene. The PPARγ gene has been mapped to human 
chromosome 3p25 by somatic cell hybridization and linkage analysis (51). The 
peroxisome proliferator-activated receptor γ (PPARγ) gene is mainly expressed in adipose 
tissue and is the target of the thiazolidinedione class of drugs used to treat T2DM by 
improving insulin action and secretion.  
 
One of the first examples of a meta-analysis in complex disease demonstrated that the 
Pro12Ala variant of PPARγ2 (proline to alanine change at position 12) is associated with 
predisposition to T2DM. They found a modest (1.25-fold) but significant (P=0.002) 
increase in diabetes risk associated with the more common proline allele (~85% 
frequency) (52). The less frequent alanine allele (16%) was associated with decreased 
diabetes risk (odds ratio 0.78, P<0.045).  
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CAPN10 
Calpains (CAPNs) are ubiquitously expressed cysteine proteases that regulate a variety of 
cellular functions. CAPN10 is expressed in β cells where evidence suggests it mediates 
apoptosis and insulin exocytosis (53,54); in fat and muscle CAPN10 modifies insulin-
mediated glucose transport. It also appears to be involved in myoblast/preadipocyte 
differentiation (55). 
 
Calpain 10 was the first T2DM gene identified by genome-wide scan of Mexican-
American families. Initially linkage was found on chromosome 2  (LOD 4.03) (56), an 
interaction of this locus with genes on chromosome 15 was then found and used to 
narrow the chromosome 2 interval (57). The critical interval was then sequenced and 
informative SNPs identified and the gene was identified as calpain 10. Three intron 
variants account for most of the haplotype diversity and accounted for 14% of the 
population attributable risk of T2DM in Mexican-Americans (58). Meta-analyses of 
association studies assessing CAPN10 and T2DM risk have confirmed a role for CAPN10 
polymorphisms in T2DM susceptibility (59) increasing risk by ~ 14 % for T2DM. In one 
of the analyses, SNP44, a rare CAPN10 allele, was shown to be over-transmitted from 
heterozygous parents to their affected offspring with T2DM. However it is pertinent to 
note Calpain 10 was not identified in GWA studies casting possible doubts on the 
previous observations. 
 
In contrast to the inconsistent SNP data, exciting new data is emerging on the functional 
significance of Calpain in insulin signalling and secretion. In Pima Indians, a CAPN10 
polymorphism (SNP43) correlates with impaired insulin action and reduced expression of 
CAPN10 in the skeletal muscle of prediabetic subjects (60).  
 
CAPN10 polymorphisms have also been associated with insulin secretion, adipocyte 
biology and microvascular function. Data from our lab (Prof. Hitman‘s lab) has 
demonstrated a role for calpain 10 isoform in both phase 1 and phase 2 insulin secretion 
(61). Particularly calpain 10 interacts with snare proteins leading to vesicle fusion and 
insulin release. Secondly we identified an important role of Calpain 10 on actin, 
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proposing that calpain plays a role in facilitating the actin reorganization required for 
glucose-stimulated insulin secretion in INS-1 cells (62). Additionally another group has 
found calpain 10 to be an important molecule for fuel sensing in beta cell of mouse islets 
(63). Lastly, mirroring the beta cell work it has been shown calpain 10 facilitates GLUT4 
translocation and actin reorganization of the adipocytes (64).  
 
 
 
Environmental factors- Type 2 Diabetes 
Evidence of a strong environmental element to T2DM has come from the studies of 
Barker and Hales (65). In a number of separate studies, a strong relationship of the 
development of glucose intolerance and other associated factors of the insulin resistance 
syndrome with low birth weight or thinness at birth has been demonstrated. Furthermore, 
these associations are not confined to those with growth retardation in utero but extend to 
through the whole range of birth weight. As a consequence of these epidemiologic 
studies, the ‗thrifty phenotype‘ hypothesis has been proposed, whereby nutritional 
deficiencies in utero lead to poor foetal and infant growth and the subsequent 
development of T2DM in later life, especially when combined with obesity due to excess 
food intake and lack of physical activity. These changes are recognised to be due to 
insulin resistance, which is favourable for survival in the immediate post natal period but 
plays a significant role in the progression to T2DM and metabolic syndrome, and to a 
certain extent insulin secretion (66). While there is much discussion regarding this 
hypothesis, it illustrates the importance of environmental factors in early life, which 
might prime the foetus for T2DM in later life.  
 
Dietary factors and physical inactivity undoubtedly affect the progression of abnormal 
glucose tolerance to diabetes in a genetically predisposed individual. The best way to 
lower the risk of diabetes is to lead a healthy lifestyle by eating a healthy balanced diet, 
engaging in regular physical activity and balancing the energy intake with energy 
expenditure. Indeed evidence would suggest that the adoption of a healthy lifestyle in 
high risk subjects can decrease the risk of developing T2DM by ~ 60% (67,68). There is 
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a close relationship between diabetes and obesity, especially when the later has central 
distribution (69). Apart from obesity, several other nutritional factors affect glucose 
metabolism and the risk of T2DM. Evidence suggests association between different types 
of fats and carbohydrates and insulin resistance and T2DM (70). Diets rich in saturated 
fats are associated with insulin resistance; a multi-centre study in a group of healthy 
individuals showed that a diet high in saturated fat decreased insulin sensitivity compared 
with a diet high in monounsaturated fat with the same total fat content (71).  Prospective 
and cross- sectional studies suggest a role of specific types of fat rather than the total fat 
content in the development of T2DM, where high intake of vegetable oils, oils consisting 
primarily of polyunsaturated fat was associated with reduced risk of developing diabetes 
(72) and a positive association between saturated fat and hyperglycaemia or glucose 
intolerance. In a 20-years follow-up of the Finnish and Dutch cohorts of the Seven 
countries study, it was found that a high intake of fat (73) (in particular saturated fatty 
acids) contributed to the risk of glucose intolerance and T2DM.  
 
Dietary carbohydrates are classified into simple or complex carbohydrates depending on 
their chemical structure. The traditional view is that simple carbohydrates be avoided and 
substituted with complex (starchy) carbohydrates to reduce postprandial glucose 
response, but this has been challenged by various studies that recognised starchy foods 
such as baked potatoes and white bread produce even higher glycaemic responses than 
simple sugars. Glycaemic index (GI) was developed to quantify the different glycaemic 
responses induced by different carbohydrate foods. A low GI diet with a greater amount 
of fibre and minimally processed whole grain products seem to improve glycaemic and 
insulin responses and lower the risk of T2DM. This goes to show that dietary 
recommendations to prevent and manage diabetes should focus more on the quality of fat 
and carbohydrate than the quantity alone. 
 
A number of environmental toxins have also been shown to cause diabetes in humans, 
including nitrosated compounds, as well as streptozotocin, the rat poison Vacor and foods 
such as smoked mutton; depending on the amount consumed could either lead to T1DM 
or T2DM, presumably dependent on the amount of direct β cell destruction. It has also 
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been proposed that vitamin D might modulate the diabetic process. Vitamin D deficiency 
has been shown to reduce insulin secretion. In a UK study of Bangladeshi subjects (74) 
living in east London who were particularly prone to vitamin D deficiency, vitamin D 
levels were found to be low in those most at risk of diabetes. Furthermore, there was a 
correlation between vitamin D levels and 30 min oral glucose tolerance test, blood 
glucose, insulin and C-peptide levels. 
 
 
 
1.2.3 Maturity onset diabetes of the young (MODY) 
 
The most common forms of monogenic syndromes causing diabetes are maturity onset 
diabetes of the young (MODY) and maternal inheritance of diabetes and deafness 
(MIDD) accounting for 2–5% of ‗T2DM‘ cases. Maturity onset diabetes of the young, are 
a group of monogenic disorders inherited in an autosomal dominant pattern (75). MODY 
is characterised by early onset of ‗type 2 diabetes‘ (usually before the age of 25 years), β 
cell dysfunction and a family history (at least two generations) of early onset diabetes. 
The defect is in insulin secretion due to mutations in the glucokinase and β cell 
transcription factor genes (Table 1.e) (76). HNF1α also known as hepatic transcription 
factor 1 (TCF1), HNF1β (also known as TCF2) and 4, insulin promoter factor (IPF1) 
and neurogenic differentiation-1 (NEUROD1) have an important role in the normal 
development and function of the β cell of pancreas.  
 
In the UK mutations in HNF1α is the commonest cause of MODY accounting for 63% of 
cases, followed by mutations in the glucokinase gene (20% of the cases) (77). The 
clinical presentation and progression of diabetes is different between patients with 
mutations of glucokinase, HNF1α and HNF1. Subjects with glucokinase mutations are 
frequently asymptomatic or detected with gestational diabetes and when diagnosed 
associated with a milder form of diabetes, which is frequently treated with diet alone and 
not associated with the complications of diabetes. In contrast those subjects with HNF1α 
mutations are more like lean T2DM with susceptibility to microvascular complications 
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and progressive loss of β cell function made worse by increasing body mass index. In 
comparison to patients with T2DM, subjects with HNF1 mutations are very sensitive to 
sulphonylurea treatment as might be predicted from the genetic defect (78). Patients with 
HNF1 in addition to T2DM have renal cysts that may lead to renal failure and hence 
such patients are more frequently found in the renal clinic. Due to its monogenic 
aetiology, MODY is a good example of a disease for which genetic diagnosis is clinically 
useful. 
   
 
Table 1.e:  Maturity onset diabetes of the young 
 
Gene   Chromosome  MODY frequency 
 
HNF 4 α (MODY1)  20q   5% 
GCK (MODY2)  7p   10-15% 
HNF1 α (MODY3)  12q   20-75% 
IPF1 (MODY4)  13q    rare 
HNF1 β (MODY5)  17q    rare 
NEUROD1 (MODY6) 2q    rare 
 
 
 
GCK 
Genes known to be involved in β-cell function are obvious candidates for conferring 
predisposition to diabetes. GCK (Glucokinase) is one such gene, acts as a pancreatic 
glucose sensor by catalysing the rate-limiting step of glucose to glucose-6-phosphate in β 
cells. Investigation of GCK as a candidate gene in large families and nucleotide 
sequencing demonstrated it as a cause of MODY in some families (79). Mutations in the 
GCK gene are associated with glucose-sensing defects in β cells. These mutations tend to 
be associated with ‗mild‘, asymptomatic or gestational diabetes, or IGT and patients are 
free of diabetes related complications.  
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HNF1α  
Hepatocyte nuclear factor-1 alpha (HNF1α) also known as hepatic transcription factor 1 
(TCF1), functions as a regulator of multiple genes, including insulin like growth factor 
and insulin in rodents. The HNF1α gene is located on chromosome 12q and was 
identified from positional cloning and genome scans in 12 families with MODY 
(80,81)The clinical features associated with HNF1α variants are markedly different to 
those seen in patients with GCK defects and are more typical of T2DM. HNF1α 
associated diabetes is characterised by insulin secretory defects and hyperglycaemia and 
weight gain worsens the metabolic control. Unlike GCK mutations, patients with HNF1α 
mutations are at risk of microvascular complications. Although approximately 40% of 
patients are treated with insulin, diabetic patients with HNF1α mutations are sensitive to 
sulphonylureas and treatment with sulphonylurea is effective in a subset of patients (82). 
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THE WRS GENE- EIF2AK3 GENE 
 
1.3 THE WOLCOTT- RALLISON SYNDROME-EIF2AK3  
 
Wolcott- Rallison syndrome (WRS) is a rare autosomal recessively inherited disorder. 
The syndrome is characterised by a short trunk compared to arm span, multiple 
epiphyseal dysplasia, bone demineralisation, multiple fractures, tooth discolouration, 
abnormal skin, hepatosplenomegaly, renal insufficiency, exocrine pancreatic dysfunction 
in addition to endocrine pancreatic dysfunction leading to insulin dependent diabetes 
(83). The onset of diabetes in WRS families is mainly below the age of 6 months and is 
characterised by permanent severe insulin deficiency. In those families examined, islet 
cell antibodies were not detected in the diabetic subjects excluding autoimmunity as a 
cause and in a case of WRS that came to autopsy the pancreas was found to be 
hypoplastic (84), with interstitial fibrosis and poor staining for insulin. It is therefore 
possible that the diabetes of WRS is due to beta cell dysfunction and represents a non-
autoimmune cause of insulin requiring diabetes.  Mutations of the gene encoding 
eukaryotic translational initiation factor 2 - alpha kinase 3 (EIF2AK3) were found to 
account for WRS in 2 families (85). Initial investigators studied 2 consanguineous 
families and carried out genome -wide linkage study which mapped WRS gene to a 
region of less than 3 cM on chromosome 2p12, with maximum evidence of linkage at 4 
microsatellite markers (D2S113, D2S1786, D2S2181 and D2S2222). The gene encoding 
eukaryotic translational initiation factor 2- alpha kinase 3 (EIF2AK3) resides in this 
interval.  
 
Markers D2S1994/WI-6863 was assigned to the segment between D2S1786 and 
D2S2181 and all 3 markers are located in a single YAC clone from the Whitehead contig 
WC2.7. D2S1994/WI-6863 was identified as EIF2AK3 encoding a serine/threonine 
kinase (also known as pancreatic eukaryotic initiation factor 2-alpha kinase, PEK). 
Previous mapping of EIF2AK3 to chromosome 2p12 was carried out by Hayes et al (86). 
EIF2AK3, also designated as  pancreatic eIF2-alpha kinase PEK/ PERK by various 
authors, was considered as a possible candidate gene for WRS as it was highly expressed 
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in pancreatic islets and has a role to play in endoplasmic reticulum stress (to be discussed 
in detail in next chapter) and apoptotic pancreatic beta cell death. They identified distinct 
mutations in both index cases in homozygous state in both the families. The other 
affected siblings were homozygous for the mutation and the unaffected siblings and 
parents were heterozygous. In WRS1 (family one), the EIF2AK3 mutation consisted of an 
insertion (T) at position 1103 (1103insT) creating a frameshift at position 345 and 
premature termination. This probably results in complete loss of function of the protein as 
it is devoid of part of the regulatory domain (aa 1-576) and the entire catalytic domain (aa 
577-1,115). In WRS2 (family two) the mutation is a 1832 G to A transition resulting in a 
change of glutamine for arginine at position 587 (R587Q) within the catalytic domain 
(87). This amino acid is completely conserved in the gene of different organisms 
(humans, mouse and rat). These results showed that mutations in EIF2AK3 are 
responsible for WRS in the two consanguineous families studied. (Figure 1.c) 
 
Following the initial studies, direct sequencing of the WRS gene in a girl with clinical 
features of WRS revealed the presence of a homozygous T to C mutation in exon 13 
leading to a missense S877P (Serine to Proline) mutation in the catalytic domain of the 
EIF2AK3 protein (88). Serine 877 is conserved in human, mouse and rat proteins. 
Functional studies of the particular mutation showed the P877 (Proline) mutated protein 
is less efficient than the wild type kinase in phosphorylating itself and is completely 
unable to phosphorylate eIF2alpha. 
 
Case studies on WRS (89) looked into the genetic composition for the EIF2AK3 gene and 
reported 2 further mutations. In the 1
st
 case the offspring of a consanguineous Saudi 
parents presented with diabetic ketoacidosis and was treated with insulin, had skeletal 
dysplasia and direct sequencing of EIF2AK3 revealed a homozygous deletion of four 
nucleotides (1563delGAAA) at the site of a GAAA 4 base pair direct repeat in exon 9 
which results in an immediate premature termination codon at amino acid 523. 
Heterozygous deletions were seen in the parents and unaffected sibling. In the 2
nd
 case 
with similar clinical presentation and family background sequencing of EIF2Ak3 gene 
showed a homozygous G to A substitution in Intron 14 resulting in splicing 
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abnormalities. Both of these mutations were novel and result in truncated proteins that 
lack the critical kinase domain. 
 
 
Figure 1.c: Mutations within EIF2AK3 in Walcott-Rallison Syndrome 
families 
 
 
Figure 1.c: 110insT- Insertion (T) at position 1103, 1563delGAAA- 4 base pair direct 
repeat in Exon 9 leading to premature termination codon and loss of function. R587Q- 
Glutamate for Arginine at position 587, S877P Proline for Serine at position 877 in the 
catalytic domain leading to loss of function. G to A substitution in Intron 14 leading to 
splicing abnormalities and truncated protein. 
 
In a more recent study of 12 families (18 patients) with WRS (90) the age at onset was 
generally very young: the mean age at onset was 3 months. There was multiple 
epiphyseal dysplasia common to all patients and various degrees of osteopenia, with 
multiple fractures, slight to severe mental retardation or developmental delay in the 
majority of the patients. Four patients showed signs of exocrine pancreas dysfunction, 
with pancreatic hypotrophy observed in one patient and fibrotic infiltrations in pancreas 
in another. Sequencing of the coding regions of EIF2AK3 was performed in all the WRS 
cases and in available parents and siblings. EIF2AK3 mutations were identified in 11 of 
the 12 families, in the homozygous state in the patients of 10 of them, and as a compound 
heterozygote in one individual, whose parents were not consanguineous. None of these 
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12 mutations were found in a control population of 95 Caucasian individuals. The gene 
defects- nonsense mutations, frameshift mutations, splice-site mutations, missense 
mutation, resulted in truncated proteins. All of the EIF2AK3 mutations that resulted in 
truncated proteins are missing all or part of the kinase domain, which would be expected 
to lead to a complete loss of function. The functional consequence of the missense 
mutations was evaluated by measuring the EIF2AK3 activity using the yeast translational 
assay. There was defective autophosphorylation of EIF2AK3 protein and of eIF2α 
phosphorylation activity in the mutant variants of EIF2AK3 as compared to normal 
function in the wild type indicating loss of EIF2AK3 function.  
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1.4 THE EIF2AK3 GENE REGION AND TYPE 1 DIABETES IN SUBJECTS       
FROM SOUTH INDIA 
 
Researchers in our lab, Dr. Rebecca Allotey et al, were involved in investigating whether 
there is an association between the EIF2AK3 gene and T1DM (91). Using a family based 
approach (234 South Indian families) they studied markers from the 3' flanking region of 
the locus: D2S113 (the linked marker in the T1DM Scandinavian genome scan), 
D2S1786 and an AT insertion/deletion at intron 15 (15INDEL). The families had been 
ascertained through a proband with T1DM, with both parents also available for study. 
The D2S1786 marker was found to be significantly transmitted to the affected offspring 
(overall allele-wise ETDT; P=0.0098 uncorrected; P=0.03 corrected); this was partly 
attributable to allele 4 (215 bp) being transmitted 142 times compared to 102 non-
transmissions (P=0.010) and decreased transmission of allele 5 (219 bp) (46 
transmissions vs. 71 non-transmissions; P=0.021). Excess transmission was also found of 
the common allele of 15INDEL. Allele 1 was transmitted 99 times and not transmitted 69 
times (allele wise ETDT; uncorrected P=0.02; P=0.06 corrected); this could be largely 
explained by a paternal effect (P=0.005; allele 1, 33 transmissions vs. 11 non-
transmissions). No association was found between T1DM and D2S113 (13 alleles) in the 
South Indian families. D2S113 is located on a separate YAC (WC 2.8) to the disease-
associated marker D2S1786 (WC2.7 that also includes EIF2AK3). TRANSMIT was used 
to analyse the potential effects on diabetes risk of the D2S1786 and 15INDEL marker 
combinations. Of 14 possible combinations, only four were found to have a frequency 
greater than 5%. There was evidence for an association between T1DM and particular 
EIF2AK3 marker combinations (overall global P<0.001), with excess transmission of 
both the 15INDEL allele 1/D2S1786 allele 4 and 15INDEL allele 1/D2S1786 allele 3 
combination (both P<0.0001), and decreased transmission of 15INDEL allele 1/D2S1786 
allele 5 combination (P<0.001). Since there were a large number of D2S113 alleles, it 
was not possible to perform an accurate TRANSMIT analysis of all the three markers 
(15INDEL two alleles, D2S1786 five alleles and D2S113 13 alleles), because of the large 
number of haplotypes generated. Since there was evidence for an association between 
markers from the EIF2AK3 region and T1DM, the researcher‘s proceeded to compare 
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allele frequencies of the disease associated 15INDEL and D2S1786 markers in ethnically 
matched unaffected subjects, with normal glucose tolerance and the previously typed 
probands with T1DM. The frequencies of the 15INDEL genotypes (1/1, 1/2 and 2/2) in 
286 subjects without diabetes were 40.9, 47.9 and 11.2%, respectively, and the 
corresponding figures in the 225 probands with T1DM were 68.9, 30.2 and 0.9% 
(Fisher‘s exact two-sided P<0.0001; odds ratio for 1/1 genotype 3.3, 95% CI 2.2–4.7). 
Genotype frequencies in the subjects were in Hardy–Weinberg equilibrium. Supporting 
the family data, allele 4 of D2S1786 was present in 82.4% of the probands compared to 
60.9% of subjects without diabetes (P<0.0001). Similarly, there were fewer subjects with 
allele 5 of D2S1786 in the probands (22.5%) compared to subjects without diabetes 
(35.4%; P=0.001). The allele frequencies in the control subjects therefore support an 
association between T1DM susceptibility and EIF2AK3 in this ethnic group. The allele 
frequency of the 15INDEL in South Asians is more frequent to that previously reported 
in Europeans. In order to validate the genotyping, sequencing was carried out in 48 
subjects (30% possessing the uncommon allele); in all cases, the sequencing results were 
concordant with the PCR-RFLP assay. 
 
Based on this evidence of a disease association with the two markers closest to the 
EIF2AK3 gene, 24 subjects were selected for comprehensive sequencing studies of all 17 
exons and exon/intron boundaries of the gene to identify any novel mutations and define 
haplotype blocks within the gene. These subjects comprised 10 South Indian T1DM 
probands with the disease-associated combination (allele 1 of 15INDEL and allele 4 of 
D2S1786, subsequently referred to as the 1:4 combination) that had been transmitted 
from a parent, 12 South Indian subjects (three parents, two probands and six controls), 
who did not possess the 1:4 combination, and two European controls (untyped). The 
previously reported mutations leading to WRS were not found in this study. Researchers 
would not have anticipated detecting the mutations in our subjects given that they did not 
have any features of WRS and the small sample size of the population studied has 
insufficient power to detect rare variants. However, single nucleotide polymorphisms at 
11 different loci of the EIF2AK3 gene were detected, corresponding to nine previously 
reported polymorphisms and two novel SNPs found in exon 1 (position 242 G/T; 
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Arg57Leu) and intron 6 (position 2661 A/G), respectively. Inspection of the sequences in 
these subjects suggests linkage disequilibrium (LD) of all SNPs apart from the 15INDEL, 
and that five possible haplotypes were defined by the four SNPs 2, 3, 10 and 11. 
Researchers therefore genotyped the families for the four relevant SNPs by a PCR RFLP 
assay. LD between all markers used in this study was assessed using the PM (permutation 
and model-free analysis) and PM plus programmes. These programs allow for both a 
permutational approach, as well as analysis between two loci and between haplotype 
blocks, and they confirmed the results from the 24 sequenced subjects. SNPs 2, 3, 10 and 
11 were all in tight LD and formed a specific haplotype block. Of 16 possible haplotypes, 
only 14 were observed, and five of these were present at a frequency of greater than 5%. 
The haplotype block composed of SNPs 2, 3, 10 and 11 was in linkage equilibrium with 
all other surrounding markers. No individual marker or haplotype was transmitted in 
excess to the diabetic offspring (TRANSMIT global P= 0.18) from within the block. The 
two disease-associated markers in the study (D2S1786 and 15INDEL) were in LD with 
D2S113 (the marker linked to T1DM in the Scandinavian population), thereby placing 
disease susceptibility in the 3' flanking region of the EIF2AK3 locus. To confirm the 
preliminary findings that disease susceptibility lies 3' of the gene, Dr.R. Allotey used a 
PCR-RFLP assay to investigate two other reported SNPs, SNP C (rs2364564) and SNP E 
(rs1606803) (located approximately 4 and 6 kb, respectively, 5' of EIF2AK3) in the study 
population. No association was found between SNP C and SNP E and T1DM 
susceptibility. Analysis using the PM plus programmes revealed that SNP C and E are in 
LD with each other and also with markers located to the central haplotype block (SNPs 2, 
3, 10 and 11). The two SNPs located 5' of the gene were not in linkage with the disease-
associated markers, 15INDEL and D2S1786, which are 3' position, further supporting the 
hypothesis of disease susceptibility located either 3' or downstream of the EIF2AK3 locus 
in this population. 
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1.5 STRUCTURE OF THE EIF2AK3 GENE AND CHROMOSOMAL   
LOCATION (Figure 1.d)  
 
 
 
 
EIF2AK3 gene is found on Chromosome 2 at location 88,637,376-88,708,209 (OMIM 
*604032). It is also known by other names- PEK/ PERK. Researchers identified a rat 
eIF2-alpha kinase that they designated PEK (pancreatic eIF2-alpha kinase) (92). The 
EIF2AK3 gene was mapped to chromosome 2p12 (93). A targeted mutation of the mouse 
EIF2AK3 gene, which they called Perk, abolished the phosphorylation of eIF2-alpha in 
response to accumulation of malfolded proteins in the ER, resulting in abnormally 
elevated protein synthesis and higher levels of ER stress (94). Mutations (nonsense 
mutations, frameshift mutations, splice-site mutations, missense mutation) in the gene 
contributing to Wolcott- Rallison syndrome (monogenic Mendelian disease) in humans 
have been reported (95) (96). EIF2AK3 gene size is 7.8 kb and it has 17 exons. 
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PANCREATIC β CELL, APOPTOSIS AND ER STRESS 
   
1.6 ROLE OF APOPTOSIS IN PANCREATIC β CELL DEATH IN DIABETES 
 
Type 2 diabetes is the result of two major defects – insulin resistance and pancreatic β 
cell dysfunction leading to chronic hyperglycaemia. Insulin resistance in the muscle and 
liver is thought to be the primary defect in individuals with type 2 diabetes. However, 
pancreatic β cell dysfunction plays a critical role in manifestation of T2D. The disease 
progression from IGT to type 2 diabetes involves not only peripheral insulin resistance 
but also a defect in β cell insulin secretory capability due to relative reduction in β cell 
mass (Figure 1.e). There is compensatory hyperinsulinaemia in insulin resistant 
individuals in the early stages of the disease. This increased insulin secretion maintains 
normal blood glucose levels in the initial stages but as time progresses there is 
progressive decline in β cell function leading to impaired glucose tolerance and finally to 
the manifestation of T2D. Studies in non-diabetic relatives of type 2 diabetes patients 
show evidence of defects in insulin secretory pattern. There are animal and human 
studies, which show conclusive evidence that apoptosis may be involved in β cell failure 
in type 2 diabetes. Pancreatic β cells are sensitive to a number of proapoptotic stimuli. 
The critical role of endoplasmic reticulum (ER) stress in the process of apoptosis and the 
specific role of EIF2AK3 in regulation of protein translation and ER stress will be 
discussed later in the chapter.  
 
Figure 1.e: Relative reduction in beta cell mass, although not reduced compared to lean 
normoglycaemic individuals β cell mass is reduced in type 2 DM patients when 
compared to obese normoglycaemic individuals. 
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Apoptosis or programmed cell death occurs during normal cellular development and is an 
energy dependent process characterised by cell shrinkage, condensation of nuclear 
chromatin, membrane blebbing and the formation of apoptotic bodies that undergo 
phagocytosis (97). Activation of apoptosis in β cells is elicited by various stimuli- death 
receptor activation by proteases, oxidative stress, Ca dependent processes, endoplasmic 
reticulum stress, mitochondrial dysfunction etc (Table 1.f). 
 
Table 1.f:  Potential inducers of β cell apoptosis 
 
Death receptors 
Fas ligand/Fas receptor 
Perforin 
Cytokines (IL-1β, IFN-γ, TNF-α ) 
Membrane permeable mediators 
Reactive oxygen species (hydrogen peroxide, hydroxyl radicals) 
Reactive nitrogen species (nitric oxide, peroxynitrite) 
Alkylating agents (streptozotocin, MMS) 
Ceramid 
Inadequate growth factors 
IGF-1 
EGF 
FGF 
Perturbation of the metabolic and signal pathways 
  Increased 
glucose 
Free fatty acids 
Amylin 
Calcium 
  Decreased 
Cell cycle regulator (cyclin dependent kinase4) 
Transcription factor (BETA/NeuroD,HNF-1α) 
Mitochondria function (mitochondrial transcription factor A) 
ER stress transducer (PERK/EIF2AK3) 
 
 
In a study that was done to determine whether β cell apoptosis increased in type 2 
diabetes in humans, pancreatic tissue from post-mortem samples in lean and obese type 2 
diabetes patients, and lean and obese controls was looked into for relative β cell volume, 
frequency of β cell apoptosis and replication, and new islet formation from exocrine 
pancreatic tissue; neogenesis (98). Pancreatic tissue from 124 autopsies was examined: 
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91 obese cases; 41 with type 2 diabetes, 15 with impaired fasting glucose, and 35 non 
diabetic subjects and 33 lean cases; 16 type 2 diabetic and 17 non diabetic subjects. They 
measured relative β-cell volume, frequency of β cell apoptosis and replication, and new 
islet formation from exocrine ducts. Relative β cell volume was increased in obese versus 
lean non-diabetic cases (P = 0.05) through the mechanism of increased neogenesis (P < 
0.05). (Figure 1.f) 
  
Figure 1.f: β cell replication, apoptosis and β cell volume   
 
Figure 1.f: The frequency of β cell replication (A) and β cell apoptosis (B) normalized to 
relative β cell volume in each case. ND, nondiabetic; TTDM, type 2 diabetes. (99) 
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Figure 1.f: The mean β cell volume in obese (nondiabetic [ND], IFG, and diabetic 
subjects [TTDM]) and lean cases (nondiabetic and type 2 diabetic subjects). (100) 
 
 
Obese humans with IFG and type 2 diabetes had a 40% (P < 0.05) and 63% (P < 0.01) 
deficit and lean cases of type 2 diabetes had a 41% deficit (P < 0.05) in relative β cell 
volume compared with non diabetic obese and lean cases, respectively. The frequency of 
β cell replication was very low in all cases and no different among groups. Neogenesis, 
while increased with obesity, was comparable in obese type 2 diabetic, IFG, or non-
diabetic subjects and in lean type 2 diabetic or non-diabetic subjects. However, the 
frequency of β cell apoptosis was increased 10-fold in lean and 3-fold in obese cases of 
type 2 diabetes compared with their respective non-diabetic control group (P < 0.05). 
This study shows that β cell mass is decreased in type 2 diabetes and that the mechanism 
underlying this is increased beta-cell apoptosis. 
 
There could be several mechanisms contributing to β cell apoptosis in type 2 diabetes. 
Hyperglycaemia in T2DM individuals can potentially induce apoptosis in several types of 
cells. The processes involve high glucose activated NFB, mitochondrial cytochrome C-
mediated caspase 3 activation and formation of reactive oxygen species (ROS). Similar 
pathways have been suggested to be activated by glucose in pancreatic β cells (101). 
 
The toxicity in T2DM may in part indirectly be caused by "lipo-toxicity" implicating 
alterations in β cell malonyl-CoA, peroxisome proliferator activated receptors α and  and 
steroid regulatory element binding protein expression (102). Free fatty acid induced β cell 
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apoptosis was suggested to involve formation of ceramide, increased production of nitric 
oxide and mitochondrial pathways (103). (Figure 1.g) 
 
Figure 1.g: A model of β-cell apoptosis in type 2 diabetes 
  
Figure 1.g: Free fatty acids (FFA) cause β cell apoptosis by induction of free oxygen 
radicals (O2), nitric oxide (NO) synthesis as well as down-regulation of anti-apoptotic 
proteins such as bcl-2 (B-cell lymphoma). The toxic effect of free fatty acids can be 
blocked by nicotinamide (NA) or aminoguanidine (AG) both blockers of nitric oxide 
synthase. Glucose-induced β cell apoptosis involves the induction of free oxygen radicals 
and β-cell synthesis of IL- 1 (Interleukin-1) and activation of IL-1 signalling leading to β 
cell apoptosis. The pro-apoptotic effect of glucose on human islets can be blocked by 
interleukin-1 receptor antagonist (IL-1Ra) (104).  
 
Hyperglycaemia up-regulates the Fas-receptor in human islets (105) which might cause 
induction of apoptosis in neighbouring β cells constitutively expressing Fas-ligand. The 
mechanism underlying glucose induced β cell Fas-expression was explained by glucose-
induced production of IL-1-β (106). Thus β cells exposed to high glucose expressed IL-1-
 thereby inducing apoptosis. These events were associated with NFB activation, DNA 
fragmentation and impaired β cell function. The apoptotic effect of glucose could be 
blocked by the natural antagonist of IL-1 action interleukin-1 receptor antagonist (IL-
1Ra). A recombinant interleukin-1 receptor antagonist has been used in clinical trials for 
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the treatment of type 2 diabetes and showed improved glycaemic control and beta-cell 
secretory function and reduced markers of systemic inflammation (107). 
 
Thus, inflammatory mediators expressed as part of the autoimmune response in type 1 
diabetes or inflammatory mediators expressed in β cells in response to high glucose in 
type 2 diabetes may be a common denominator for β cell apoptosis in these two 
diseases(108).  
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1.7 ENDOPLASMIC RETICULUM STRESS AND ROLE OF EIF2AK3 IN ER 
STRESS 
 
There is a highly developed endoplasmic reticulum (ER) in pancreatic β cells to facilitate 
insulin secretion. Pancreatic β-cells utilise nearly 70% of its protein synthesis for insulin 
production. The ER is a highly dynamic organelle and plays a central role in lipid and 
protein biosynthesis (109). The ER produces the transmembrane proteins and lipids for 
most cell organelles and is responsible for the synthesis of almost all secreted proteins. 
The ER also has an important role in calcium storage and signalling. Due to its ability to 
store and secrete Ca
2+
, the ER controls a wide range of cellular processes such as 
organogenesis, transcriptional activity, stress responses, and apoptosis. The ER with its 
several important functions- synthesis, folding and assembly of proteins, post- 
translational modifications, lipid synthesis and a cellular calcium store, and disruption of 
any of these processes leads to ER stress. The ER stress (110) inducers include 
hyperglycaemia, high free fatty acids, inhibition of protein glycosylation or disulphide 
bond formation, calcium depletion from the ER lumen, expression of mal-folded proteins 
and impairment of protein transport from the ER to the Golgi apparatus. Therefore it 
could be argued ER stress is of particular relevance in type 2 diabetes. Chronic 
hyperglycaemia leading to pancreatic β cell stimulation and increased insulin synthesis 
could potentially activate ER stress pathways. A high fat diet and obesity may contribute 
to the development of type 2 diabetes by causing β cell lipotoxicity and insulin resistance. 
FFAs activate an ER stress response in β cells, with palmitate being more potent than 
oleate. Glucotoxicity and lipotoxicity have been shown to contribute to the β cell insulin 
secretory failure and potentially precipitate β cell apoptosis and failure and play a role in 
the pathophysiology of T2DM (111-113).  
Animal studies have shown that interfering with normal ER function can result in 
apoptosis (114).  To survive under ER stress conditions, cells have a self- protective 
response, termed the ER stress response or also known as unfolded protein response 
(115). ER stress and unfolded protein response can be protective to the β cells under 
euglycaemic and normal physiological conditions. Moreover, the same response has the 
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potential for triggering β cells dysfunction through apoptosis under the conditions which 
potentiate ER stress. 
The four distinctive responses in unfolded protein response under ER stress include 
1. Upregulation of genes encoding ER chaperone proteins to increase protein folding 
activity and to prevent protein aggregation.  
2. Translational attenuation. 
3. ER associated degradation of malfolded proteins.  
4. Apoptosis when ER function is severely impaired. 
 
Translational attenuation- Role of EIF2AK3 on endoplasmic reticulum stress 
In response to various environmental stresses, eukaryotic cells downregulate protein 
synthesis by phosphorylation of the alpha subunit of eukaryotic translation initiation 
factor-2 (eIF2-alpha). The EIF2AK3 gene has an essential role in protecting the cell from 
endoplasmic reticulum stress. mRNA translation is attenuated as part of ER stress 
response due to malfolded proteins. This occurs at the level of translational initiation via 
eIF2α phosphorylation. There are four protein kinases known to phosphorylate eIF2α- 
GCN2 (general control non-derepressible-2), heme-regulated inhibitor (HRI), double-
stranded RNA dependent protein kinase (PKR), and EIF2AK3. EIF2AK3 (protein 1115 
amino acid) enriched in pancreatic cells, is uniquely located to the endoplasmic reticulum 
and is activated by the accumulation of unfolded proteins in the ER lumen. EIF2AK3 is 
the kinase responsible for this phosphorylation during ER stress. EIF2AK3 
phosphorylates eukaryotic initiation factor- 2 alpha (eIF2 α) which then inhibits eIF2 β, 
leading to cellular events that inhibit mRNA translation (116). This is one of the 
fundamental responses to ER stress and prevents further cell damage by apoptosis.  
Conversely, prolonged activation of EIF2AK3 as part of unfolded protein response can 
induce apotosis of β cells and potentially implicating this response in the 
pathophysiology of T2D suggesting a dual role of ER unfolded protein response(117). 
The ER stress pro- apoptotic downstream signals include CHOP, IRE 1, JNK, CFOS/ 
JUN, IL- 1β(118).  
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As was discussed in the previous section, increased β cell apoptosis is known to occur in 
the diabetes state in both obese and non obese individuals and this contributes to their 
diabetes phenotype. Type 2 diabetes is characterized by decreased insulin secretion in the 
presence of increased insulin resistance. The susceptibility to endoplasmic reticulum 
stress and thereby apoptosis differs from cell to cell and β cells of pancreas may be one of 
the most susceptible cells given their extensive role in protein synthesis and secretion. 
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1.8 HYPOTHESIS AND AIMS OF THE STUDY 
 
We propose that common polymorphisms in the EIF2AK3 gene (Candidate gene 
association study) could be associated with type 2 diabetes based on the following 
observations: 
 
Monogenic syndrome 
Mutations in EIF2AK3 have been discovered in humans and the resultant syndrome, 
Wolcott-Rallison syndrome results in severe insulin deficiency due to a non-autoimmune 
process in infancy and a particular phenotype as was discussed in the earlier chapter, 
clearly establishing the role of the EIF2AK3 mutations in WRS. Other clinical features of 
WRS include mental retardation, hepatic and kidney dysfunction, cardiac abnormalities, 
exocrine pancreatic dysfunction, and neutropenia. 
 
Genomic and cDNA clones encoding human PEK/ EIF2AK3 have been isolated. And it 
was shown EIF2AK3 is specifically expressed in pancreatic islets. The EIF2AK3 gene is 
expressed ubiquitously and the highest expression of EIF2AK3 was shown to be in the 
delta cells of the pancreas, which is the main site of secretion of somatostatin hormone 
(119). Subsequent studies in humans have shown expression of EIF2AK3 in the β cells of 
pancreas. Study of fixed sections of human adult pancreas by immunohistochemistry with 
a polyclonal antibody to EIF2AK3 showed EIF2AK3 to be expressed extensively in the 
islet, with a predominance in β cells (120). 
 
The islets of Langerhans in the pancreas play a critical role in maintaining 
normoglycemia in humans. They secrete different hormones in a highly regulated fashion 
in response to changes in environmental conditions. In the pancreatic islets- α cells 
secrete glucagon, β cells secrete insulin, δ cells secrete somatostatin, and PP cells secrete 
pancreatic polypeptide. The changes in blood glucose levels are an important factor that 
affects the synthesis and secretion of various islet hormones. The action of several 
hormones including insulin and glucagon helps to maintain the blood glucose in a narrow 
range under physiologic conditions. Somatostatin also plays an important role in 
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maintaining normal blood glucose levels by modulating secretion of both insulin and 
glucagon. Therefore any defects in the islet formation during embyrogenesis as happens 
with transcription factor mutations in MODY or pancreatic damage related to apoptosis 
as occurring with EIF2AK3 mutations in WRS leads to manifestation of diabetes. 
 
 
Animal Studies 
The EIF2AK3 gene has an essential role in protecting the cell from endoplasmic 
reticulum stress as discussed in the previous section. Targeted mutation of the mouse 
EIF2AK3/PERK gene abolishes phosphorylation of eIF2 α, and the resultant phenotype in 
mice homozygous for the mutation is characterised by insulin deficiency, 
hyperglycaemia, growth retardation, steatorrhoea and high mortality between 2 and 4 
weeks of life (121). In contrast, heterozygous mice are phenotypically similar to wild 
type mice, although they are glucose intolerant following intra-peritoneal injection of 
glucose. Pancreatic islets at postnatal day 12 are reduced in size, with decrease in insulin 
containing cells and an increase in glucagon secreting cells. PERK ‒/ ‒  mice show rapid 
and progressive decline in both the endocrine and exocrine pancreatic function. 
Furthermore, there is evidence of increased programmed cell death/ apoptosis of the beta 
cells.  
 
Biology of EIF2AK3  
EIF2AK3/ PERK/ PEK is an endoplasmic reticulum transmembrane resident protein and 
is activated by ER stress. EIF2AK3 by its actions of phosphorylating eIF2α leading to 
attenuating effect on protein synthesis in the β cell of pancreas helps protect the cell from 
ER stress. Targeted mutation of the PERK gene in the mouse embryonic stem cells was 
undertaken to highlight the effects of such experimentation. The PERK ‒/ ‒  mice cells 
were unable to phosphorylate eIF2 α and thereby unable to lead to translational 
repression in response to ER stress (122). When the cells were exposed to 
pharmacological agents that induce ER stress, the wild type mice cells exhibited a 
significant attenuation in protein synthesis rates. However the PERK ‒/ ‒ mice cells did 
not reduce protein synthesis. Furthermore, the PERK mutation lead to increased parallel 
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ER stress pathways leading to IRE1 phosphorylation and caspase 12 processing thereby 
leading to increase in pro-apoptotic activity by these proteins. In PERK ‒/ ‒ mice studies 
histological analysis and immunochemistry demonstrate the normal development of 
pancreas but rapid deterioration in the pancreatic function indicating the tissue 
dysfunction being acquired post natally. The progressive loss of β cell function is well 
recognised in type 2 diabetes. Therefore it could be plausible that variations in EIF2AK3 
could contribute to T2DM by way of chronic endoplasmic reticulum stress pathways. 
 
Linkage evidence (T1DM)/ Preliminary data on type 2 diabetes- EIF2AK3  
At the time of initiating the hypothesis LOD scores of > 2 were observed on chromosome 
2, at D2S113 near EIF2AK3 (LOD score 2.1) in a Genome wide Scan for type 1 diabetes 
Susceptibility in Scandinavian Families (123). The evidence of linkage at this locus was 
increased in the HLA DR3/4
+
 sib pairs (multilocus LOD score 2.6), compared with that 
observed in the complete data set. This suggests that EIF2AK3—or another gene located 
in this region—may contribute to T1DM susceptibility. Since endoplasmic reticulum 
stress is common to type 1 diabetes and type 2 diabetes it might be hypothesised that 
common variants of the EIF2AK gene could be associated with type 2 diabetes.  
 
As a preliminary study, we examined the disease associated INDEL15 in 96 South Indian 
families, selected for a proband with T2DM. Excess transmission was found of the 
T1DM associated allele 1 of INDEL15 (p=0.03). However, similar results were not 
obtained in a separate case-control study of 72 South Indian subjects with T2DM. As part 
of the Diabetes UK Warren 2 study, we (in collaboration with Prof. Mark McCarthy‘s 
group) have also studied 150 British/Irish trios, ascertained through a proband with 
T2DM. Five polymorphisms- SNP 2, 10, 11 and 13 and INDEL15 were genotyped 
through this cohort. Although no single marker including INDEL15 was statistically 
significant of itself, marked deviation from expected transmission was found for 
haplotypes with a frequency of >5% (p=0.002). These are unpublished data. The two 
datasets in different ethnic groups would therefore suggest an association between 
EIF2AK3 gene and T2DM, but again the exact aetiological variants that might account 
for the association have not been identified. There appeared to be a positive signal albeit 
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a minor signal for association of EIF2AK3 gene variants with T2D. In the preliminary 
study only a few SNPs were studied thereby lacking adequate coverage of the gene. 
Furthermore only a small cohort of individuals was studied, thereby lacking power. This 
has the potential of leading to false positive or false negative associations. A 
comprehensive study of gene variants in the exonic and intronic location along with study 
of SNPs 5' and 3' of EIF2AK3 gene was planned for T2DM and control groups. Given the 
biology of the EIF2AK3 gene and the links with pancreatic β cell dysfunction noted with 
gene variants, albeit in monogenic WRS, we felt it was worthwhile to pursue the gene in 
polygenic Type 2 diabetes. 
 
As we have a  
1) Human model of monogenic disease with EIF2AK3 mutation, the WRS syndrome  
2) Animal model of PEK deficient mice showing insulin secretory defects 
3) Linkage evidence for EIF2AK3 though in T1DM and preliminary evidence of     
association of the gene with T2DM in South Indian and Warren 2 trios 
4) Biological significance of this protein kinase in regulating ER stress 
It could therefore be hypothesised that in some subjects with type 2 diabetes, 
dysregulation of the EIF2AK3 gene may contribute to beta cell apoptosis and cause 
relative insulin deficiency leading to diabetes. 
 
Therefore the hypothesis that polymorphic variants in the EIF2AK3 gene could be 
associated with T2DM in different population groups is the basis of our investigation. 
 
Aims of the study 
1) Compiling a SNP inventory by sequencing and reference to Hapmap projects 
2) To determine whether common polymorphisms in the EIF2AK3 gene 
(Candidate gene association study) could be associated with type 2 diabetes in 
the British/Irish, the Bangladeshi and the South Indian cohorts comprising of 
8,095 individuals  
3) Replication study in SNPs of EIF2AK3 gene showing positive association 
with type 2 diabetes. 
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CHAPTER TWO: SUBJECTS 
  
The study included genotype analysis of subjects from the British/Irish and the South 
Asian populations for the association of polymorphisms of the EIF2AK3 gene and type 2 
diabetes. For the purpose of case- control study we studied diabetes cases from the 
British Irish population- Warren 2 cases, W2 Sib pair probands and population based 
controls from the 1958 MRC birth cohort, ECACC samples. Furthermore, we also 
conducted a case-control study in the South Asian population- the Bangladeshi and the 
South Indian. For the family based association studies, we studied the British Irish 
resources- Warren 2 trios and the South Indian families. (Table 2.a)  
 
The common Single nucleotide polymorphisms and the tagged SNPs were genotyped (11 
SNPs) in 2,835 subjects with type 2 diabetes and in 3,538 control subjects and 522 
families. Finally, we utilised the Dundee replication resources for a case-control study for 
the analysis of one marker (rs7605713) after the initial studies (n=6790). 
 
 
2.1 SUBJECT DEFINITIONS 
 
Controls  - A person aged 25 years and above with no history of type 2 diabetes with a 
fasting blood glucose of less than 7 mmol/l and random blood glucose of less than 7.8 
mmol/l and no history of diabetes and diabetes related symptoms. 
 
Cases/Type 2 DM- A person aged 25 years and above with a history of type 2 diabetes 
and is on diet control, oral hypoglycaemic medication or on insulin treatment (Not started 
on insulin for at least 1 year after diagnosis)/ fasting glucose above 7 mmol/l and/or 
random glucose above 11 mmol/l or contemporary laboratory evidence of hyperglycemia 
satisfying the diagnosis of T2D at the time of recruitment (as defined by World Health 
Organization). 
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Table 2.a: Subjects for type 2 diabetes association study (n=14,885)   
 
 
 
 
 
 
 
 
 
 
 
 
 Cases Controls Family (Trios) 
British/Irish 
subjects (n= 12,902) 
   
UK Warren 2  
n=6112 
 
2206 
 
(W2 Cases, 
OCDEM_OXGN= 
1713  + Sib pair 
probands= 493)
  
 
2652  
 
(MRC Birth 
cohort= 2088 + 
ECACC= 564) 
 
418 trios 
(1254 subjects) 
Dundee Replication 
resources n=6790 
3334 3456 
 
 
South Asian 
subjects (n=1983) 
 
   
Bangladeshi n=985 
 
426 
 
Young n=330  
  
T2DM n=96 
559 
 
Young n=374   
 
Non DM n=155 
IGT n=30 
Total= 155+30 
 
South Indian n=998 203 
 
Urban Survey n=85 
Newham n=118
  
327 
 
Urban Survey 
n=215, (IGT n=45) 
215+45 
Newham n=67 
104 families 
 (468 subjects)  
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2.2 INDIVIDUAL ETHNIC GROUPS 
 
We studied the Caucasian British Irish population, and the South Asian populations from 
South India and Bangladesh for the type 2 diabetes candidate gene association study. The 
purpose of studying the EIF2AK3 gene common variants in a candidate gene association 
study in different ethnic groups is due to the realisation differences in genetic architecture 
might exist among the different populations- i.e. minor allele frequencies might be 
different in different ethnic populations. Moreover, there could also be population 
differences in gene variants associated with the disease, with SNP variations showing 
positive associations in one ethnic group which cannot be replicated when studied in 
another ethnic group and vice-versa. We had access to genetic resources for the different 
ethnic groups, and were closely working with collaborators from the Warren 2 group in 
UK, Chennai diabetes research group in India and Bangladeshi diabetes research group, 
for conducting a comprehensive candidate gene association study. The pros and cons of 
choosing subjects from different populations, especially in relation to power of the study 
will be addressed later in the thesis. 
 
2.2.1 British Irish resources 
The case-control resources: This group includes the 1713 W2 cases and 493 W2 sib-
pair probands totalling 2206 T2DM cases. As a control resource we have utilised the 
ECACC (n= 564) and MRC 1958 birth cohort (n=2088) samples totalling 2652 controls.  
 
Warren 2 Cases 
All type 2 diabetic subjects were unrelated
 
U.K. Caucasians who had diabetes defined by 
either World Health
 
Organization criteria at the time of diagnosis or being treated with 
medication for diabetes.
 
Clinical criteria and/or genetic testing excluded known subtypes 
such as maturity-onset diabetes of the young or mitochondrial-inherited diabetes and 
deafness. The type 2 diabetic
 
case group was a collection of type 2
 
diabetic subjects from 
the Warren 2 repository with
 
an age of diagnosis between 35 and 65 years but not 
selected
 
for having a family history. The cases tested positive for GAD autoantibodies
 
had been excluded. 
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Warren 2 Sib
 
Pair probands 
The Warren 2 Sib
 
Pair Repository currently
 
comprises sibship pedigrees
 
ascertained   
through
 
six U.K. research centers
 
(two in London and
 
one each in Exeter,
 
Oxford, 
Cambridge/Norwich, and Newcastle),
 
according to a unified
 
ascertainment protocol. All 
ascertained
 
families include, at minimum,
 
a sib pair with
 
T2DM, together with parents
 
and 
additional siblings when
 
available. Validation of the
 
diagnosis of diabetes in
 
the index sib 
pair
 
was based on either
 
current prescribed treatment with
 
sulphonylureas, biguanides, 
and/or
 
insulin or, in the
 
case of individuals treated
 
with diet alone, historical
 
or 
contemporary laboratory evidence
 
of hyperglycemia (as defined
 
by World Health 
Organization
 
guidelines in place
 
at the time of
 
recruitment). Age at diagnosis
 
of both 
members
 
of the index sib
 
pair, was initially restricted
 
to the age range
 
35 75 years and 
subsequently
 
was narrowed to 35 70
 
years, with 97.6% families
 
meeting the latter 
criterion.
 
Other forms of diabetes
 
(e.g., maturity-onset diabetes of
 
the young, 
mitochondrial diabetes,
 
and type 1 diabetes)
 
were excluded by standard
 
clinical criteria 
based personal
 
and family history, including
 
an absence of first-degree
 
relatives with type 
1
 
diabetes and an interval
 
of 1 year between
 
diagnosis and institution of
 
regular insulin 
therapy. In
 
addition evidence for autoimmunity
 
to islet antigens was
 
sought by 
measurement of
 
titres of antibodies to
 
glutamic acid decarboxylase (anti-GAD).
 
All 
sibships were of
 
European descent, with all
 
four grandparents having exclusively
 
British 
and/or Irish origin,
 
both by self-reported ethnicity
 
and by place of
 
birth. Finally, pedigrees 
either
 
reporting bilineal inheritance (both
 
parents diabetic) or having
 
a high proportion of
 
affected individuals within large
 
sibships were excluded from
 
collection.
 
 
     
 
 
Controls 
 
ECACC (European collection of cell cultures) 
These are nationally recruited random UK population control samples from the European 
Collection of Cell Cultures (ECACC) without a diagnosis of type 2 diabetes, providing a 
control population totalling 564 samples. Trait information is not available for these 
individuals from the ECACC collection. (Website: www.hpacultures.org.uk) 
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1958 MRC birth cohort Controls  
The 1958 British birth cohort study includes all children born in Scotland, Wales, and 
England between 3 and 9 March 1958. A proportion of these samples were released by 
MRC, Bristol, for Genetic studies and provided a control population totalling 2088. 
These were control individuals without a diagnosis of type 2 diabetes. However trait 
information is not available for this population. (Website: www.mrc.ac.uk) 
 
 
The British/Irish resources for the family studies 
 
The Warren T2DM trios collection for family based association studies 
 The families consist of a proband with T2DM (who are GAD negative) and both parents 
(n=418 families, 1254 subjects). The DNA and clinical characteristics were obtained by 
establishing a nationwide collection run from 6 UK centres. Recruitment of patients was 
principally from hospital diabetes clinics, general practitioners, and the questionnaire 
survey. Subjects were considered suitable for the trios collection if the proband had type 
2 diabetes and had two living parents and four grandparents of European descent (>98% 
were of UK/ Irish origin). To avoid inadvertently recruiting subjects with type 1 diabetes, 
recruitment was limited to trios for whom the proband was diagnosed after the age of 25 
years, had been treated without insulin for at least 1 year after diagnosis, and did not have 
a family history of type 1 diabetes. Potential maturity-onset diabetes of the young 
(MODY) families were excluded if there were two generations with an autosomal 
dominant history of diabetes and at least one family member diagnosed before the age of 
25 years. Maternally inherited diabetes and deafness was excluded if there was a maternal 
transmission of diabetes and deafness. 
 
 
 
 
 
 
  
69 
2.2.2 South Asian Resources  
The Case-control resources: The 2 main resources of subjects are from Bangladesh and 
South India. 
 
Bangladeshi subjects for a case-control study  
The
 
first group (n =
 
330) consisted of Bangladeshi
 
subjects presenting with diabetes
 
before the age of
 
30 years (subsequently referred
 
to as "under-30 diabetes"
 
[mean age at 
onset
 
18.7 ± 6.2 years;
 
mean BMI 18.3 ±
 
5.1 kg/m
2
]) at the
 
Bangladesh Institute of 
Research
 
and Rehabilitation in Diabetes,
 
Endocrine and Metabolic Disorders
 
(BIRDEM) 
clinic. The leaner, under 30 age group subjects likely to be the more insulin dependent 
group closely matches the hypothesis we were testing of gene variants of EIF2AK3 
contributing to pancreatic insufficiency and T2DM. The controls were recruited from 
Bangladesh totaling 374 subjects with a mean age of 23 ± 5 years at recruitment and 
mean BMI 19.9 ±
 
3.3 kg/m
2.
   
 
The second cohort we
 
studied were Bangladeshi subjects
 
from Sylhet in Bangladesh, and 
those ascertained either
 
from a diabetes clinic
 
at the Royal London
 
Hospital, London-
diabetes subjects (n=96), non diabetic subjects (n=155), impaired glucose tolerance 
subjects (n=30). The subjects with T2D had a mean age at onset of diabetes of 44.7 ± 
10.0 years and a mean BMI 26.5 ± 3.4 kg/m
2
. The ethnically matched control individuals 
had a mean age of 41.5 ± 10.4 years and a mean BMI 26.9 ± 9.7 kg/m
2
.  
 
Subjects from Sri Lankan Tamil and South Indian Dravidian population for a case-
control study 
 The subjects (cases n= 118 and controls n= 67) were recruited from East London 
(Ethical committee approval from East London health authority) and were Sri Lankan 
Tamil and South Indian Dravidian population. They were identified through the hospital 
diabetes clinics and the local community centres. The inclusion criteria for cases included 
those who had type 2 diabetes for more than 1 year, aged above 25 and 70 years old, not 
started on insulin for at least 1 year after diagnosis. The diagnosis was based on the WHO 
classification of diabetes (as of 1997 classification) and information of their glycaemic 
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status was obtained from the diabetes database (Diamond). The inclusion criteria for 
controls included those who were aged between 25 and 70 years of age, family members 
(Parents and 1
st
 degree relatives) were not taking part in the study, had no complaints of 
osmotic symptoms and had random blood glucose in the normal range (< 7.8 mmol/l). 
The subjects with T2D had a mean age of 59.8 ± 11 years and a mean BMI 27 ± 3.8 
kg/m
2
. The ethnically matched control individuals had a mean age of 50 ± 14 years and a 
mean BMI 26.8 ± 4.5 kg/m
2
.  
 
South Indian cross-sectional urban survey 
DNA samples were available from 345 South Indian subjects initially
 
recruited as part of 
an urban population-based survey of the
 
prevalence of type 2 diabetes and associated risk 
factors, using
 
a cluster analysis design across all socio-economic groups. Of these 
subjects, 48.6% were female, with mean age of 42 years
 
(range 34–53), a mean BMI of 
23.1 ± 4.6 kg/m
2
. The other 51.4% were male,
 
with a mean age of 47 years (40–55), a 
mean BMI of 22.0
 
± 3.7 kg/m
2
. In the urban survey,
 
glucose tolerance was defined by the 
most recent WHO criteria (124). Male type 2 diabetic subjects were
 
recruited at a mean 
had a mean
 
BMI of 23.4 ± 3.3 kg m
2
;
 
the females had a mean BMI of 24.1 ± 4.1. In the 
total study population, 215 subjects had normal glucose tolerance, 45 subjects had 
impaired glucose tolerance, and 85 had type 2 diabetes. 
South Indian families 
A total of 104 South Indian families (468 subjects) were recruited from a diabetic
 
clinic 
in Chennai, India. Ascertainment was via an offspring
 
with type 2 diabetes, as defined by 
World Health Organization
 
(WHO) criteria. Of the probands,
 
63.5% were male, with a 
mean age of onset for type 2 diabetes
 
of 34 years (range 29–38), a mean BMI of 26.5 ± 
4.5 kg/m
2
. Clinical details for female probands were: a mean age
 
of onset of type 2 
diabetes of 32 years (range 23–37), a mean BMI of 27.8 ± 4.6 kg/m2. Maturity onset 
diabetes of the
 
young was excluded in families if the proband had an age of
 
onset of 
diabetes before 25 years and an autosomal-dominant
 
history of diabetes in two 
generations. Type 1 diabetes was
 
excluded on clinical grounds. None of the diabetic 
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subjects
 
in the family had a history of ketoacidosis or ketonuria, an
 
acute onset of 
symptoms, or weight loss before diagnosis, nor
 
was there a family history of type 1 
diabetes. Furthermore,
 
if the proband was insulin treated, then this did not commence
 
within a year of diagnosis.  
 
 
2.2.3 Dundee Wellcome Trust UK T2DM Genetic consortium Case-control 
Collection for replication study  
 
The cases (n=3334) were European White descent and validation of the diagnosis of type 
2 diabetes was based on either current prescribed treatment with sulphonylureas, 
biguanides, and/or insulin or, in the case of individuals treated with diet alone, historical 
or contemporary laboratory evidence of hyperglycemia. (As defined by World Health 
Organization) No clinical or laboratory diagnosis of other forms of diabetes (e.g., 
maturity-onset diabetes of the young, mitochondrial diabetes, and type 1 diabetes). At 
least 1 year between diagnosis and institution of regular insulin therapy. Antibodies to 
glutamic acid decarboxylase (anti-GAD) were measured and were negative. The age 
range of individuals was 35-70 years inclusive. The controls (n=3456) were of European 
White descent not diagnosed with diabetes and not likely to be diabetic on biochemical 
testing of fasting glucose < 7mmol/l, HbA1c< 6.2%, aged 35-80 years.  
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CHAPTER THREE: MATERIALS AND METHODS 
 
3.1 Collection of blood samples and DNA preparation 
 
I was involved in the collection of blood and DNA preparation for the Newham South 
Indian/ Sri Lanka Tamil case-control resource (T2DM subjects n = 118 and Non DM  n = 
67) recruited from the boroughs of Newham and Tower Hamlets in East London and a 
small proportion of Bangladeshi Whitechapel case-control resource. The samples were 
collected after appropriate ethics approval by the East London health authority.  
 
Majority of the DNA samples used for our study were previously collected and DNA was 
plated in a 96 well format. The UK Warren 2 British Irish resources were collected as 
part of a combined effort through six UK centers (two in London and one each in Exeter, 
Oxford, Cambridge/Norwich and Newcastle). We obtained the samples from Prof. 
Hattersley‘s laboratory in Exeter and stored the DNA in our lab at - 20
°
 Celsius. 
KBioSciences were also in receipt of Warren 2 resources which were utilized for our 
experiments. The control samples ECACC were obtained from Prof. Hattersley‘s 
laboratory in Exeter. 1958 birth cohort samples were provided by Prof. David Strachan at 
St.George‘s Hospital medical school, University of London after appropriate approval. 
 
The rest of the South Asian resources- South Indian and Bangladeshi samples were 
previously collected in those countries by our collaborators and were already available in 
our laboratory and they were stored at - 20
°
 Celsius in the lab. The South Asian resources 
have been utilized in previous genetic association studies conducted by the researchers in 
our unit.  
 
The Dundee replication set (Wellcome Trust UK Type 2 Diabetes Genetics Consortium 
Case- control samples collected in Tayside region of Scotland by Dr. Palmer‘s group and 
were provided to KBioSciences) was utilized for the replication study. 
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Identification of suitable candidates for South Asian resource 
The Diabetes cases for the Newham and Tower Hamlets East London resources were 
identified from the local Diabetes Register, Diamond by me. The controls were included 
from the same population by seeking the help of the local Tamil community forums and 
district nurses. The Bangladeshi Whitechapel case-control resource was identified from 
the diabetes centre at Royal London hospital with the help of Prof. Hitman. 
 
We collected demographic data and data for weight, height, BMI, waist hip ratio, blood 
pressure for each individual. And blood samples were collected in 2 X 10 ml EDTA tube 
for DNA extraction, 1 X 7 ml clotted serum for Cholesterol estimation, 1 X 4 ml sodium 
fluoride tube for glucose estimation, were taken from each individual. The blood samples 
were stored at - 20
°
 Celsius in the lab prior to DNA extraction. I did majority of this work 
and created a database for the South Asian resource. 
 
 
 
DNA preparation 
 
Protocol: DNA Purification from Blood (blood samples collected in EDTA tube) 
(Spin Protocol)  (QIAGEN DNA extraction protocol) (Website: www.qiagen.com) 
The method used for DNA extraction for the South Asian resource was spin protocol for 
purification of total genomic DNA from whole blood using a microcentrifuge. First step 
involves pipetting 20 μl QIAGEN Protease into a 1.5 ml microcentrifuge tube. Add 200 
μl blood sample and 200 μl Buffer AL to the microcentrifuge tube. Mix by pulse-
vortexing for 15 seconds and incubate the solution for 10 minutes at 56°C. Centrifuge the 
tube to remove drops from the inside of the lid. Then add 200 μl of ethanol (96–100%) to 
the sample, and vortex and centrifuge the tube to remove drops from the inside of the lid. 
 
Take Qiamp spin column and transfer the whole mixture without wetting the rim. 
Centrifuge at 8000 rpm for 1 minute. Discard the tube containing the filtrate and keep 
spin column in a 2 ml collection tube. Add 500 μl Buffer AW1 to the QIAamp Mini spin 
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column without wetting the rim and centrifuge at 8000 rpm for 1 minute. Then add 500 
μl Buffer AW2 to the QIAamp Mini spin column without wetting the rim and centrifuge 
at full speed (14,000 rpm) for 3 minutes. 
 
Place the QIAamp Mini spin column in a new 2 ml collection tube and discard the old 
collection tube with the filtrate. Centrifuge at full speed for 1 min. Then place the 
QIAamp Mini spin column in a clean 1.5 ml microcentrifuge tube, and discard the 
collection tube containing the filtrate. Add 200 μl Buffer AE to the QIAamp Mini spin 
column. Incubate at room temperature (15–25°C) for 10- 30 minutes, and then centrifuge 
at 8000 rpm for 1 minute. Run the DNA (5 μl) on a gel with 2 μl of loading buffer. 
A 200 μl sample of whole blood typically yields 6 μg of DNA in 200 μl water (30 ng/μl).  
 
 
 
3.2 DNA SEQUENCING  
 
Nucleotide sequencing reactions 
Samples were sequenced on the ABI 3100 capillary sequencer. The direct automated 
sequencing of the double stranded PCR generated templates for this system was 
performed using cycle sequencing with fluorescent ddNTPs and electrophoresis 
(reference- Applied Biosystems Sequencing protocol) (125). ABI PRISM TM Dye 
terminator Cycle Sequencing Ready Reaction Kit containing the ABI Big Dye version 3 
sequencing kit (Perkin Elmer) for the ABI 3100 sequencer was used. 
 
ABI Dye-Deoxy Terminator Cycle Sequencing  
ABI 3100 reaction 
Fluorescence-labelled cycle sequencing reactions were performed in 10µl volumes using 
the ABI Big Dye version 3 sequencing kit (Perkin Elmer). Each reaction contained 100ng 
of PCR products template DNA, 8µl of Terminator Ready Reaction Mix (containing 
AmpliTaq DNA polymerase, ddNTPs, magnesium, fluorescent dichlirorhodamine dye 
Terminators, Tris-HCl) (PE Biosystems) and 3.2pmol primer. The mixture was overlaid 
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with one drop of paraffin oil, and the reaction was performed in a PTC-100 
Programmable Thermal Controller (MJ Research, Inc.). Reaction profiles included 25 
cycles of 30 seconds denaturation at 96
o
C for 15 seconds, annealing at 50
o
C for 1 minute, 
and 4 minutes of extension at 60
o
C. After PCR, extension products were purified from 
unincorporated dye-labelled terminators by ethanol/sodium acetate precipitation. All 20µl 
of the reaction contents were transferred to a 1.5ml Eppendorf tube that contained 2µl of 
3M sodium acetate (pH 4.6) and 50µl of 95% ethanol. The tube was vortexed and kept on 
ice for 30 minutes. Then the tubes were placed in a centrifuge and spun at 13000 rpm for 
30 minutes. Supernatant was carefully removed and the pellet rinsed with 125µl of 70% 
ethanol. After re-centrifugation at 13000 rpm for 5 minutes, the supernatant was again 
removed and the tubes left on bench uncapped for 10-15 minutes for DNA pellet to air 
dry. The dried DNA sample was resuspended by adding 5µl of auto-sequencing gel 
loading buffer and completely dissolved by vortexing. Then, the DNA sample was 
denatured at 95
o
C for 5 minutes, and placed on ice until all of the sample solution was 
loaded in a sequencing gel  
 
Automated ABI 3100 analysis 
The calibration was done according to manufacturer instructions and all functions were 
controlled by PC. The samples were electrophoresed through a 16 x 47 cm sequencing 
capillaries using a POP6 polymer (PE Biosystems) with recommended electrophoresis 
buffer (PE Biosystems). Raw data was converted to Macintosh sequence chromatograms 
and analysed as described in following section. 
 
Sequence Analysis using Computer Software 
Following visual inspection of the analysed digitised raw sequence data and the 
attainment of correct and optimal base spacing (between 9-12 scans), sample files were 
imported into the Sequence Navigator Software (ABI) version. The wild type sequence 
corresponding to the target template was retrieved from Genbank (GDB), imported into 
the Sequence Navigator programme and designated as a reference sequence. The multiple 
alignment comparisons using the Cluster algorithm were performed between the 
reference sequence and imported sequences. Forward and reverse (reversed and 
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complementary) sequences were included for all template comparisons. The mismatch 
option of the programme identified mismatched/mis-aligned sequence compared with the 
reference sequence within the sequence text file. Mismatched regions were examined on 
the electrophoregrams to establish whether they were genuine mutations or sequence 
artefacts. All potential mutations had to be confirmed by being present in both forward 
and reverse sequence data for each sample. Potential mutations/polymorphisms in 
individual samples were further confirmed by repeating the sample PCR-sequencing 
reactions. This was necessary to eliminate false positives due to random non-template 
incorporation of dNTPs by Taq polymerase during the PCR reaction. 
 
 
 
EIF2AK3  5' AND 3' SEQUENCING   
 
To detect all possible disease associated variants at a given gene it would be necessary to 
examine, in large samples, every base at which variation might alter gene function or 
expression. Only then could we be confident that an association had not been missed just 
because the wrong markers had been typed. This is difficult to achieve, in terms of costs 
and procedural constraints, if not impossible given the technology available at the present 
time. However this was definitely not the case in 2002 when we were working on the 
EIF2AK3 project. We therefore required sequencing data for the candidate gene- 
EIF2AK3 to identify SNPs to use in a case-control study thereby having a substantial 
effect on the power and quality of the study.  
 
EIF2AK3 gene together with 1800bp 5' prime and 3000bp 3' prime were sequenced on 48 
individuals from different ethnic backgrounds (Table 3.a). The 48 individuals included all 
the 3 ethnic groups and both T2D cases and controls. At the time the study was designed 
in the year 2002, sequencing of 24- 48 individuals was deemed more than adequate to 
gather adequate information on SNP variants. The sequencing work would enable us to 
identify common polymorphisms with minor allele frequencies of around 30% in the 
gene of interest, in our study the sequencing of EIF2AK3 gene. This was in keeping with 
our plans to study common disease common polymorphism association. If we were to 
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hypothesise common disease rare polymorphisms we would have needed to sequence a 
lot more individuals to capture the rare alleles. However, we were not pursuing rare 
polymorphisms to be associated with T2D. 
 
 
Table 3.a: Selection of samples for sequencing (n= 48) 
 
 
Subjects Number of individuals 
WRS family,Chennai (WRS 
proband, affected sibling, 4 
non affected) 
6 
Caucasian controls                5 
British/Irish T2DM (Warren 
2 samples)                
12 
SI T2DM   (Newham 
samples) 
8 
SI T2DM (Indian)                                 9
Bangladeshi controls                    8 
 
 
 
 
Direct sequencing of all 17 exons/coding region and intron/exon boundaries was 
performed using the Big Dye Terminator chemistry on the ABI 3100 sequencer. Single 
nucleotide polymorphisms, already in the public databases and novel SNPs, were 
identified in this preliminary group. Further investigations of the SNPs in a larger group 
revealed which of them were truly polymorphic and the ones that were monomorphic. 
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3.3 TAQMAN HIGH THROUGHPUT GENOTYPING 
 
Taqman is a powerful high throughput assay, which can be used for genotyping large 
number of samples in a relatively short period of time (reference- Applied Biosystems 
real time PCR protocol). The technology uses an ABI Prism 7900 instrument (Taqman) 
to detect accumulation of PCR products continuously during the PCR process, real time 
quantitative PCR. The polymerase chain reaction (PCR) is a common technique used to 
rapidly amplify several copies of a specific region of DNA exponentially (126). It 
requires a thermally stable DNA Taq polymerase, each of the four nucleotide dNTPs in 
equimolar concentration, and a source of template DNA, usually a double stranded 
genomic DNA but may also be from a cDNA. The technique also requires synthetic 
oligonucleotide primers, designed to complement DNA sequences flanking the region of 
interest. The taqman technology is based on the polymerase chain reaction to amplify and 
simultaneously quantify a targeted DNA sequence- real time PCR (127). 
 
The system integrates 4 major elements: 
1. Fluorogenic chemistry for target –specific oligonucleotide probes. 
2. Exploitation of the polymerisation dependant 5' nuclease activity of the DNA 
polymerase. 
3. Instrumentation to measure fluorescence signal within a closed PCR reaction 
tube. 
4. Software to process and analyse data. 
 
Steps in real time quantitative PCR 
A taqman probe is designed to anneal at the target sequence between the traditional 
forward and reverse primers (Figure 3.a). Two fluorescent dyes, a reporter (R) and a 
quencher (Q), are attached to the probes used with the TaqMan PCR Reagent Kit. The 
probe is labelled at the 5' end with a reporter fluorochrome and a quencher fluorochrome 
at the 3' end. The 3' end of the probe is blocked, so it is not extended during the PCR 
reaction.  
 
  
79 
 
 
 
 
 
 
 
 
Polymerisation 
Forward primer 
Probe 
Reverse primer 
Strand displacement 
Cleavage 
Polymerisation 
completed 
 
 
R- Reporter 
 
 
Q- Quencher 
Figure 3.a: Taqman SNP genotyping  
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Figure 3.a: Taqman probe with its attached reporter and quencher fluorescent probes 
anneals between forward and reverse primer onto the target sequence. TaqDNA 
polymerase cleaves reporter dye from the probe, whereby emitting characteristic 
fluorescence. Depending on the characteristic fluorescent signal the common allele, rare 
allele or a heterozygote are identified. 
 
When both dyes are attached to the probe, reporter dye emission is quenched due to 
fluorescence energy transfer from the reporter dye to the quencher dye.  During each 
extension cycle, the probe is displaced at the 5' end by the DNA polymerase. Taq DNA 
polymerase then cleaves the reporter dye from the probe via its 5'-3' exonuclease 
activity. Once separated from the quencher, the reporter dye emits its characteristic 
fluorescence, which can then be measured by the 7900.  The amount of fluorescence 
measured is proportional to the amount of PCR product made.  
 
The design of TaqMan probes and primers is critical to the success of the experiment. 
The target sequences with the necessary SNP information were sent to Applied 
Biosystems (Commercial enterprise) and the Taqman primers and probes were designed 
by Applied Biosystems. (Website: www.appliedbiosystems.com). Optimisation of PCR 
reaction was performed at the Genome centre. 
 
WRS Taqman primers and probes 
 
 EXON 2 SNP C/G rs867529 
 
GTAAAAAGCAGTGGGATTTGGATGT [C/G] CATCCAGCCTTAGCAAACCAGAG 
 
 Intron 10 SNP A/T rs6750998 
 
CCAATGACAGTAGCTGGAATGACA [A/T] caaccatctgaatcaaagaagaaatgac 
 
 Exon 11 SNP A/G rs1805164 
 
CCACAAAATTTAAAACTGTTGCAAACCTTTAT [A/G] GACGTGGTGGCTTTGGAGT  
 
 Exon 13 SNP T/G rs1805165 
 
GCACCATCAGTTAAAATACGCAGAA [T/G] AATCATAGCTCCTTCACCACAAAGA 
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In my work Taqman chemistry was used for allelic discrimination of SNPs 2, 10, 11 and 
13 of the EIF2AK3 gene. The genotyping was performed on various data sets using the 
ABI 7900 taqman at the Genome centre, Queen Mary University of London. 
Optimisation of the PCR reaction is required for each primer and probe set. The taqman 
reaction requires two primers for amplification of the sequence of interest (Primer 
information given below) and the two allele specific probes labelled with the reporter 
dyes VIC and FAM at the 5' end and a non fluorescent quencher bound to the 3' end of 
allele specific probe. VIC label detects the common or the wild type allele and FAM 
detects the rare or the mutant allele. 
   
Table 3.b: PCR reaction mix for Taqman 
 
DNA 2 ul 
Taqman Universal 
master mix 2 X 
2.5 ul 
40 X primers & 
probes 
0.125 ul 
Water 0.375 ul 
Total Volume of 
reaction 
5 ul 
 
 
 
Table 3.c: Temperature settings for PCR 
 
 
 Step 1 50° C 2 minutes 
 Step 2 95° C 10 minutes 
 Step 3 95° C 15 seconds 
 Step 4 60° C 60 seconds 
 Step 5 Repeat step 3-4 
for 40 cycles 
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The primers, taqman mix and water were mixed (PCR reaction mix) in a 1.5 ml 
eppendorf (Table 3.b) and the eppendorf is vortexed to mix the components and 
centrifuged. 2 μl DNA was pipetted (robotic) into each well of an ABI PRISM™ 384-
Well Clear Optical Reaction Plate. Subsequently 3 μl of PCR reaction mix was added in 
each well. PCR amplification was performed on DNA Engine Tetrad (MJ Research) as 
per the temperature settings in Table 3.c. 
 
Steps in PCR- Thermocycling  
1. DNA denaturation by heating - The first step involves heat denaturation at 95° C, of 
DNA template and separation of the 2 strands of DNA 
2. Annealing of primers to DNA strands-The forward and reverse primer anneal to the 
DNA strands and involves primers binding to their complementary sequences in the 
DNA template and the annealing temperature is at 95° C.  
3. Extension of DNA strands in both 5' and 3' directions- The DNA strands extend in 
both directions and as the PCR process continues the extension is limited to the 
sequence of interest between the 2 primers. 
4. Amplification of DNA segments by manifold- the cycle is repeated up to 40 times 
and this result in a manifold increase in the target sequence. 
Optimisation of the PCR reaction is required for each primer and probe set. This was 
performed with the temperature settings for PCR reactions as mentioned in Table 3.c. 
The temperature settings were set constant for the denaturation of the DNA, annealing of 
the primers and the extension of DNA of the PCR process for all the experiments. The 
amplification step was repeated for 40 cycles in one set of experiments and another set of 
experiments with 60 cycles. Both the settings generated consistently good results. 
Therefore, the majority of taqman assays were performed with the settings as mentioned 
above with the amplification cycle repeated for 40 cycles. After PCR amplification an 
endpoint plate read was performed using SDS software on ABI Prism 7900 instrument 
(Taqman), which calculates the fluorescence measurements made during the plate read 
and plots fluorescent values based on the signals from each well. Thus, the different 
alleles (homozygous wild allele, heterozygote, homozygous rare allele) can be 
determined. 
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3.4 AMPLIFLUOR HIGH THROUGHPUT GENOTYPING 
 
The Amplifluor SNPs Genotyping System is based on competitive allele-specific PCR, 
allowing the simultaneous amplification and detection of DNA within a closed reaction 
vessel (128). This homogenous assay utilizes two fluorescently labelled Amplifluor SNP 
Primers and three unlabelled standard oligonucleotides – two Z-tailed, allele-specific 
forward primers and a common reverse primer – in a one-step, single-tube reaction with 
standard PCR reaction components (Reference- Flowgen Bioscience Amplifluor 
protocol). 
 
First, the two Z - tailed, unlabelled, allele-specific primers with the common reverse 
primer initiate a competitive allele-specific PCR reaction. During early rounds of PCR, 
the allele-specific primer with its unique ―Z‖ tail is incorporated into the amplicon. The 
corresponding Amplifluor SNP Primer recognizes the complement of the ―Z‖ tail 
sequence and is able to prime off of that sequence. Incorporation of the Amplifluor 
Primer into an allele-specific amplicon melts its hairpin structure, thus separating the 
fluorophore from the quencher and generating a fluorescent signal. Depending on which 
base is present in the target SNP, either a green or red signal is generated. Heterozygotes 
produce a yellow signal combined for both fluorophores. The fluorescent signal can then 
be measured on a real-time PCR instrument or fluorescent plate reader. Technology 
similar to Amplifluor is KASpar (KBiosciences allele specific PCR) technology. 
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Figure 3.b: Amplifluor SNP Genotyping 
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85 
Figure 3.b: Amplifluor SNP genotyping process for a G/T SNP is being shown. Two 
fluorescently labelled Amplifluor SNP Primers and three unlabelled standard 
oligonucleotides – two Z-tailed, allele-specific forward primers and a common reverse 
primer – in a one-step, single-tube reaction with standard PCR reaction components. 
Primers are: multiplex forward (MF), common reverse (R), allele-specific forward 
primers for the T allele (F-T) and G allele (F–G), and Amplifluor universal primers. The 
tail sequences on the 5' ends of the allele-specific forward primers and at the 3' end of the 
Amplifluor universal primers are labelled A-tail 1 and A-tail 2. Dabsyl quencher is 
represented by Q. Fluorophores FAM and JOE are represented by F and J. Incorporation 
of the Amplifluor Primer into an allele-specific amplicon melts its hairpin structure, thus 
separating the fluorophore from the quencher and generating a fluorescent signal. 
 
In my work Amplifluor chemistry and KASpar (KBiosciences allele specific PCR) 
genotyping with underlying principle very similar to amplifluor, were used for allelic 
discrimination of all 11 SNPs of the EIF2AK3 gene. Genotyping was outsourced to 
KBiosciences. The Amplifluor and KASpar technology was utilised for genotyping 
performed on all the data sets at KBiosciences. 
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3.5 GENOTYPE ERRORS – QUALITY CONTROL (QC)  
 
Quality control checks of the genotyping forms an important step to generate reliable data 
prior to carrying out the statistical analysis for disease association. There are set rules to 
be followed for QC checks whilst doing candidate gene association studies(129). We 
performed a variety of QC checks in our study to this effect. 
 
Steps for passing QC checks: 
 Checks on genotyping quality should include careful visual inspection of 
genotype plots. 
 The proportion of samples for which a SNP can be measured (the SNP call rate, 
typically >95%) 
 Concordance rates in duplicate samples (typically >99.5%). 
 The minor allele frequency often >1%, as rarer SNPs are difficult to measure 
reliably 
 Severe violations of Hardy-Weinberg equilibrium (HWE) to be excluded 
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CHAPTER FOUR: STATISTICS 
 
The statistical methodologies utilised in our study include Hardy-Weinberg equilibrium 
tests for quality control, UNPHASED-Output log- likelihood ratio test for the purpose of 
candidate gene association study in case- control study and family study,  Likelihood 
ratio tests as implemented in  LDPAIRS program for the linkage disequilibrium statistics. 
Power calculations were not performed prior to our candidate gene association study. 
However, prior power calculations would have been ideal to investigate the candidate 
gene in the three ethnic groups, thereby providing a robust study design. In our defence, 
when the study was envisaged in the year 2002, published candidate gene association 
studies included hundreds of cases and controls unlike the thousands of individuals we 
were studying(130). Furthermore, we did not have the minor allele frequencies for the 
South Asian population to enable us to do appropriate power calculations. Further 
detailed discussion of power of the study and the drawback to our study is discussed in 
the final chapter. 
 
4.1 HARDY- WEINBERG EQUILIBRIUM TESTS  
Hardy- Weinberg equilibrium tests were conducted for the purpose of quality control 
issues to detect genotyping errors in our candidate gene association study. Gene 
frequencies and genotype ratios in a randomly breeding population remain constant from 
generation to generation. This is the basis for the Hardy-Weinberg principle (131). The 
total number of genes in a population is its gene pool and allele/genotype frequencies 
remain constant through the generations if certain conditions are met. HWE is an 
important tool for understanding population structure and can be tested by mathematical 
formula(132). If p represents the frequency of one allele, for example a, and q the 
frequency of the other allele, for example b, then p + q = 1 in the total population. 
 p2 = the fraction of the population homozygous for a 
 q2 = the fraction homozygous for b 
 2pq = the fraction of heterozygotes  
Then HW equilibrium states that (p+q)
2
 = p
2
+2pq+q
2
= 1. 
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However, there are times when there is deviation from HW equilibrium in the studied 
population-  
 Non-random mating in the population increases the chances of homozygosity in 
the genes. Selective mating leads to changes in gene frequencies. 
 Gene flow-migration is whereby members of one population group may breed 
with immigrants from another population group. This has the propensity to 
introduce new genes or alter existing gene frequencies. 
 New mutations in the genes within the population. 
 Genetic drift is whereby a random change in the genotype frequencies occurs in a 
small population size. There could be chance elimination and changes in allele 
frequency due to a sampling effect in a small population.  
HWE testing was carried out by the χ 2 test using an excel spreadsheet supplied by Prof. 
Curtis. Any significant deviation from HWE was taken into account as a data quality 
check and those samples which were not in HWE were excluded from the final statistical 
analysis. 
 
 
4.2 GENOTYPING ANALYSIS- UNPHASED-Output FOR CASE- CONTROL 
STUDIES AND FAMILY STUDIES 
 
The statistical methodology used in our study was based on the principle of calculating 
log likelihood ratios as implemented in the program UNPHASED (133). The overall test 
of association is a likelihood ratio test comparing the log likelihoods for the null 
hypothesis that a marker or allele is not associated with the disease and alternative 
hypotheses that the marker or allele is associated with the disease. We tested whether 
case/ control status is associated with disease i.e. is there a difference in the distribution 
of alleles between cases and controls.  
 
The log-likelihoods for the null and alternative hypotheses are displayed in the analysis 
section of UNPHASED- Output. The results generated show the relevant information 
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pertaining to the Allele, the estimated count of the alleles in cases, the estimated count of 
the alleles in controls. Case frequency is the marginal frequency of the alleles in cases. 
Control frequency is the marginal frequency of the alleles in controls. Odds ratio are 
generated for the allele and diseases association and are shown relative to one allele, 
termed the reference allele.  
 
The likelihood ratio statistic is minus twice the difference in log likelihoods, and is 
asymptotically distributed as χ 2 with degrees of freedom (df) equal to the difference in 
number of free parameters between the two hypotheses. The p-value is the probability of 
observing a likelihood ratio statistic at least as large as this one, if the null hypothesis 
were true. 
 
A candidate gene association study tests for significant differences in the –
genotype/allele frequencies of the markers within a gene between cases and controls, the 
aim being to detect association with a trait of interest, which in our study is type 2 
diabetes (134).  
 
A brief discussion of alternative methodologies to log- likelihood ratio tests is given 
below. The classic case-control study design compares allele frequencies or genotypes in 
a sample of unrelated affected individuals for T2D and a sample of matched controls. 
This can be done by testing the null hypothesis of no association between rows and 
columns of the 2 X 3 table that contains the counts of the three genotypes (the wild type 
homozygote, rare type homozygote and the heterozygote) among cases and controls using 
a Pearson test (2 df) or a Fisher exact test. For complex traits like T2D, it is thought that 
contributions to disease risk from individual SNPs will be additive. That is, the 
heterozygote risk will be intermediate between the two homozygote risks. One way to 
improve power to detect additive risks is to count alleles (i.e. major allele and minor 
allele in a 2 X 2 table) rather than genotypes so that each individual contributes twice to a 
2 X 2 table and a Pearson 1-df test can be applied.  
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The case-control design has frequently been criticized because of the potential for 
spurious associations due to population stratification. Population stratification implies the 
existence of genetically different groups in the population under study. It occurs, for 
example, when cases and controls are not well matched ethnically or when people in the 
population under study have not mated randomly for at least several generations. This 
problem can be overcome by careful selection of the subjects- by matching for ethnicity, 
age and a random selection from the population for control subjects. However, in a 
complex disease like T2DM selecting young cases of T2DM and having a group of 
‗hyper normal controls‘ (i.e. older individuals who have not got T2DM) has the potential 
to detect gene variants associated with the disease.  
 
One of the approaches to overcome the problem of population stratification is doing a 
family based association study utilising the transmission disequilibrium test (TDT) (135). 
The rationale behind the TDT is that, in the absence of both linkage and association 
between marker and disease loci, marker alleles will be transmitted randomly from 
parents to offspring. The TDT compares the transmission vs. nontransmission of marker 
alleles to affected offspring by means of a simple chi-square statistic. The TDT is widely 
known and used as a test for association in the presence of linkage, that is, as a tool for 
fine-mapping of disease genes. The undisputed strength of the TDT is that it eliminates 
population stratification effects completely. The original formulation of the TDT was 
based on a biallelic, one-marker model. Extension for multiallelic markers is done by 
extended TDT (ETDT), based on a logistic regression procedure (136). All these TDT-
like tests share the method of comparing the transmission and nontransmission of marker 
alleles to affected offspring. While family-based association study designs are generally 
more robust to population stratification, they are less powerful than case-control designs. 
The numbers required for a family based association study, say for example 1000 trios 
will have the same power as 1000 case vs. 1000 control subjects but this would mean that 
there are nearly 3000 samples to be genotyped in the trios. 
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The reasons why our statisticians Anna Vine and Prof. Curtis chose the log likelihood 
ratio test as in the program UNPHASED- Output for our study- 1) implements 
maximum-likelihood inference on genotype effects while allowing for missing data such 
as uncertain phase and missing genotypes. Data imputation consists of replacing missing 
genotypes with predicted values that are based on the observed genotypes at 
neighbouring SNPs.  Data imputation can be reliable for tightly linked markers and it 
allows better use of the observed data. 2) The UNPHASED program can analyse both 
case-control studies and the family association study which is an added advantage.  
 
4.3 LINKAGE DISEQUILIBRIUM (LD) STATISTICS 
In order to measure marker-marker association we calculated a likelihood ratio test 
comparing the likelihood for the genotypes assuming LD to that assuming no LD, as 
implemented in the LDPAIRS program (137). The p-values measure the statistical 
significance of the test for linkage disequilibrium between the markers. LD plot was 
obtained using the program Haploview. (Website: www.broadinstitute.org/haploview) 
 
GENECOUNTING is a program utilising the estimation- maximization algorithm to 
estimate haplotype frequencies in a group of unrelated subjects. Moreover the program 
allows the estimation of haplotype frequencies even if some subjects are not genotyped at 
some markers.  GENECOUNTING inputs a set of multi- locus genotypes along with the 
count of how often each one occurs, and outputs the log likelihood and estimated 
haplotype frequencies under the null hypothesis of no linkage disequilibrium between 
markers, and under the alternative hypothesis of LD being present between all markers 
according to maximum likelihood haplotype frequencies. There are a range of programs 
which enhance the usability of GENECOUNTING. LDPAIRS is one such program 
enhancing the usability of GENECOUNTING.  LDPAIRS facilitates obtaining measures 
of linkage disequilibrium (LD) between markers. The LDPAIRS program measures LD 
between all pairs of markers in the dataset and produces the results in a tabular format. 
The p-values measure the statistical significance of the test for linkage disequilibrium 
between the markers. The absolute value of D' as measured between the commonest 
allele at each of the two markers is also output. 
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CHAPTER FIVE: SEQUENCING RESULTS 
 
Compiling a complete SNP inventory of the EIF2AK3 gene  
For the type 1 diabetes work we had previously sequenced the coding region and 
immediate flanking sequences. In this study the EIF2AK3 gene together with 1800bp 5' 
and 3000bp 3' were sequenced in 48 subjects which included 31 T2DM cases and 17 
controls (Figure 5.a).  
 
 
 
 
 
Figure 5.a: The EIF2AK3 gene was sequenced together with 1800bp 5' upstream and 
3000bp 3' downstream were sequenced. UTR refers to untranslated regions. A few SNPs 
are shown highlighting INDEL15 to be present near the 3' region of the gene. (SNP 2 -  
rs867529, SNP 10- rs6750998, SNP 11- rs1805164, SNP 13- rs1805165, INDEL15- 
rs1805185) 
 
 
 
  5' sequence 3'  sequence 
             SNP 2                10  11   13  indel15         
                                                                                                   
Figure 5.a: Sequencing of the 5' and 3' regions of the EIF2AK3 gene [in 
48 selected individuals] 
5 UTR   3 UTR 
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SNPs identified (all by sequencing unless otherwise stated) 
 rs1606803 
 rs2364564 
 rs867529 
 rs13045 
 rs6750998 
 rs1805164 
 rs1805165 
 rs1805185 
 rs1554098 
 rs13425096 
 rs7579242 
 rs7605713 
 SNP5F (C/A) subsequently monomorphic 
 SNP3B (T/C) subsequently monomorphic 
 SNP3C (A/G) subsequently monomorphic 
 SNP3D (C/G) subsequently monomorphic 
 rs10189080 
 rs6740205 
 rs4449134 
 rs867014 (HapMap2) 
 rs17689440 (HapMap2) 
 
 
 
 
DNA sequencing resulting in SNPs identified for further genotyping 
 
The path that was followed which lead us to the 11 SNPs that were finally genotyped in 
the datasets began with the sequencing data that was generated on type 1 diabetes. 
Further sequencing of EIF2AK3 gene together with 1800bp 5' and 3000bp 3' of the gene 
in type 2 diabetes individuals and controls (n=48) was subsequently undertaken. 19 SNPs 
were identified by direct sequencing and by comparison with HapMap2, 5 of the SNPs 
were novel. 2 further tagging SNPs were identified from HapMap2 – these 21 SNPs 
formed the core of the analysis. Four of these SNPs were monomorphic, four SNPs failed 
genotyping due to assay problems (genotyping performed on amplifuor and KASpar at 
Kbiosicences) leaving 11 SNPs to be studied in all datasets. A sample sequence 
chromatogram for INDEL15 of EIF2AK3 gene is being shown in Figure5.b. 
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Figure 5.b: INDEL15 AT
+
/
-   
Sequence chromatogram   
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Figure5.b: A sample sequence chromatogram of INDEL 15 of EIF2AK3 gene. This is 
the insertion deletion of AT sequence of EIF2AK3 gene. Figure showing the wild type 
AT
+
/
+ 
sequence at the top, the rare type AT 
-
/
-
 sequence in the 3
rd
 row and the 
heterozygote AT
+
/
-
 sequence in the 2
nd
 and 4
th
 row.  
 
 
 
EIF2AK3 SNPs: Nucleotide sequences identified 
 
1. WRS/SNP 2  [C/G]        rs867529   
GTCATTAGTAATTATCAGCACTTTAGATGGGAGAATTGCTGCCTTGGATCCTG 
AAAATCATGGTAAAAAGCAGTGGGATTTGGATGTGGGATCCGGTT[C/G]CTTG 
GTGTCATCCAGCCTTAGCAAACCAGAG 
 
 
 
2. WRS/SNP 10 [T/A]     rs6750998 
TCAAACTGAAAATAAATATGATTCTGTAAGTGGTGAAGCCAATGACAGTAGC 
TGGAATGACATAAAAAACTCTGGATATATATCACGGTAAG[T/A]GTCTTATAA 
AATACAACCATCTGAATCAAAGAAGAAATGACCTAAGATCTTGTTTAACTTTT 
TTTTTAATGTGTGGATATCTAGAAA 
 
3. WRS/SNP 11 [A/G]   rs1805164 
ATATCTAACTGATTTTGAGCCAATTCA[A/G]TGCCTGGGACGTGGTGGCTTTG 
GAGTTGTTTTTGAAGCTAAAAACAAAGTAGATGACTGCAATTATGCTATCAA 
GAGGATCCGTCTCCCCAATAG 
 
 
4. WRS/SNP 13 [G/T]      rs1805165 
CACAGACTGGCCACTCAGCTCTCCTAGCCCAATGGATGCACCATCAGTTAAA 
ATACGCAGAATGGATCCTTTC[G/T]CTACAAAAGAACATATTGAAATCATAG 
CTCCTTCACCACAAAGAAGCAGGTCTTTTTCAGTAGGGATTTCCTGTGACCA 
GACAAGTTCATCTGAGAGCCAGTTCTCACCACTGGAATTCTCAGGAATGGAC 
CATGA 
 
 
5. WRS/INDEL 15 [AT+/-AT]    rs1805185 
TTTTTAAATTTTTTAAATATTTTCATTCTGTGGTTGGTTGAATCCTTGGATGTG 
GAATCTGTGGATGTGGAAGACCAGCTGTATATTTTGAGGATATTTGATGGAG 
TGTACATCTGTGCTCAGGAAACAT[AT
+/-
]GTAGTTATTAAATCAGGAAAAGCT 
ATTGATAAATTTTCCATTTGATAGATGTACAACCTCTTAGTCATTTTGTTAGA 
GTATCAAAAAATATTTTCATGTTGTATGTCA 
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6. SNP5C  [T/C]     rs7579242 
TATTTGGAGATAAGATCTTTAAAGCAGTGATTAAGTTAAAATGAGGCTGTTA 
AAGGTAGCCCCACACTCCAATCTGACTGGTGTTAGAAGAATAGGAAGAGAC 
ATCAGAGGGAAGAGGAAGTAAGAGGGCTG[T/C]CATCGGCAAGCCAAGGAG 
AGAGGCCTCAGAATCCCACCTTGATCTTGGACTTCTAGCCTCCAGAACTTCG 
AGAAAATAAACTAGTTTTGT     
 
 
7. SNP5D [C/A]   rs7605713  
TCAGGCCACCTGGTCTGTGGTATTTGTTAGGGCAACTCTAGCAAACTCATAT 
ACCTGGGAAGTTTCCTAGGCAGGCAAAACAACAAAGGAAAACCCCC[C/A]A 
GGTGGGTCTTGATTGGCCCAGTGGAGTGAGCAAAGACAGTATGAAATGAGA 
TCAGAAAAGCCATAGGAACCAGATGCTGTAGCACCCTGTAGTCTATTTTAA 
GGACTTGACTTTTA 
 
 
8. SNP3E [A/G]     rs 10189080 
CTGTGATTTGTTCAAGGCCACAAAGACAGCAAGAGCAGAACCGGGATCAAA 
AGGGATTGGTAAATTCTTACATGATGT[A/G]ATCAGGTTTTCTTTCATTTTAA 
CCTGGGTTTGCCTTTGCTGACCACCAGCAGGAAAGCAGGCATAGGGTTGGG 
GAAGTTAAGAGCCTGGGCCAGCAACACTTAAGTCCGT 
 
9. SNP3G [T/C]     rs 4449134 
TGCAATGGACTGTGGTGAAGTTTAGATTTATTTCAGCCCTTCTCCTGTACTGG
CCCTACCCTGACTACTTCTGGGATAGGCTGGCACTAACAAGATAAAATGCAC
CTGGGCCA[T/C]GGTTCTTTCTACTAACATCTCCCAAGCAATTCCTAAGAGGA
AGGGACTATTCTAGAAGGGACCTATAACCATTCCCCCAGATCCCTAAGCTCT
GGATGGACAAATGCAGGCCGA  
 
 
SNPs identified for genotyping via HAPMAP 
 
1. WRS Intron 1   [A/C]   rs867014 (HAPMAP SNP) 
 
CTGATAAACTTCCAAGGTTCCCTGTGCCCACTGAAAAAGAAAGGTCACACTG
CTTGGTGTGGCACAT[A/C]AAGCCTTTCACAATTTGGTTTCGGTGTACTTTCCT
AATCTCATTTTTCTGCCTCTTGTACCAGCCCAACCCTCTCTCCCCTCTCCTTCC
CAGCTCCACACTCCCCCCTTTCCATGGGGTG 
 
 
2. WRS Intron 2    [C/T]  rs17689440 (HAPMAP SNP) 
 
GTGCATTATTTATTCTAAGACACACAAACATGCACCTTAACGGTTTTAGCTTG
GTTATGTATCCACACTCTTTTCAGGAGATAGTGGCAAATGAGATGTG[C/T]GT
CCCAAGGTACACAATTCATACAATTCATTCTAAATGTAATTTAAAACATCTGT
TCTTAGTGGAACTGTCAATTTCCCTTATCTTCCAGGA GCTTATTT 
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The non-random association of alleles at nearby loci (Linkage disequilibrium (LD), 
which is an important and widespread feature of the genome, facilitates survey in an 
association study a significant proportion of the common variation of a large number of 
SNPs that occur in regions of high LD by genotyping a few TagSNPs. Tagging SNPs 
exploit the extensive linkage disequilibrium that is present in the genome. We found that 
rs6750998 (SNP10) is a tagSNP and has allele capture for SNPs -rs4972060, rs12478762, 
rs4972059, rs7563643. There were four other SNPs that were tagging at least one other 
marker SNP with r
2 
of 1.0 (Table 5.a). By this method we could genotype a few variants   
with extensive linkage disequilibrium resulting in extensive coverage across the whole 
gene- EIF2AK3 and also have significant cost savings. The SNPs genotyped in our 
candidate gene association study are shown in table 5.b. 
Table 5.a: Tagging SNPs as per HAPMAP for EIF2AK3 gene 
rs numbers Tagging SNPs r
2 
rs1805165 rs4972221 1.0 
rs1805164 rs17037621 1.0 
rs867014 rs17037621 1.0 
rs6750998 rs7563643 1.0 
 
Table 5.b: Polymorphisms genotyped in EIF2AK3 gene 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
**- INDEL15 AT
+/- 
*- Novel SNPs : no MAF quoted in the public database/ OMIM. 
Intron/exon 
EIF2AK3 
cDNA position/SNP Minor Allele 
Frequency 
according to 
HAPMAP (CEU) 
Exon2  C/G rs867529 0.26 
Intron 10 A/T rs6750998 0.24 
Exon 11 A/G rs1805164 0.35 
Exon 13 T/G rs1805165 0.35 
Intron 15 AT
+/-
 rs1805185 —** 
SNP5C - 5'  T/C  rs7579242 —* 
SNP5D- 5' C/A  rs7605713 —* 
SNP3E- 3' A/G rs10189080 —* 
SNP3G- 3' T/C rs4449134 —* 
Intron 1 A/C rs867014 0.35 
Intron 2 C/T rs17689440 0.008 
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CHAPTER SIX: QUALITY CONTROL 
 
6.1 GENOTYPE ERRORS – QUALITY CONTROL (QC)  
 
Quality control checks were carried out for generating reliable data prior to carrying out 
the statistical analysis for disease association.  
 
 
Steps for passing QC checks in our study: 
 Checks on genotyping quality included careful visual inspection of genotype plots 
 The proportion of samples with a SNP call rate typically >95% 
 Concordance rates in duplicate samples (typically >99.5%) 
 The minor allele frequency often >1%, as rarer SNPs are difficult to measure 
reliably 
 Severe violations of Hardy-Weinberg equilibrium (HWE) were excluded 
 
The process of internal quality control for the genotyping included identifying the 
duplicates and comparing for concordance for the genotypes among the duplicates. The 
second method involved use of blanks with no DNA in the plates and to check that they 
were showing negative signals. External quality control included genotyping and 
comparing the concordance for the same SNP analysis on 2 different platforms, i.e. 
Taqman and Amplifluor technology for different datasets. We performed SNP analysis 
for SNP 2, 10, 11 and 13 for the 1958 birth cohort and Bangladeshi case-control study on 
Taqman methodology at the Genome centre and Amplifluor technology at the 
KBiosciences. 
 
In the final analyses, we performed statistical analysis only on those SNPs that were 
successfully genotyped in > 95% of the samples and discarded those datasets that failed 
QC. Those datasets/ genotypes that showed excessive discordant results for the duplicates 
and wrong calls on the blanks, not in HWE were also excluded from the final statistical 
analysis. 
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QC failure for rs1805185/ INDEL15 
 
In the type 1 diabetes study this marker had been typed manually using a PCR-RFLP 
method.  The number of samples to be genotyped and the amount of DNA that would be 
required prohibited the use of this assay in our study, despite in Rebecca Allotey‘s hand 
having a good QC.  
Samples were genotyped by taqman but we only had successful genotyping in less than 
95% of the sample set and failed the duplicate checks for QC. This marker therefore was 
outsourced to KBiosciences using their in house assay. However, it did not pass their 
initial QC steps in 2 separate assays (Amplifluor and KASpar). Since INDEL15 failed on 
3 assays we did not further pursue this marker nor use any of the generated data. The 
exact reasons for failure of INDEL15 by high throughput genotyping on three different 
platforms were not identified. The probable reasons which accounted for INDEL15 
failure on high throughput genotyping were likely to be - 1) INDEL15 being a 2 base pair 
as opposed to a single base pair polymorphism 2) Selected primers for INDEL15 
attaching to numerous sites in the genome due to base pairs being identical 3) Sequence 
of interest being in a highly methylated region. 
 
Quality control for SNPs by Taqman genotyping by visual check 
 
Taqman genotyping for SNPs 2,10,11 and 13 in British Irish and South Asian cohorts 
generated allelic discrimination plots. Visual check for the allelic discrimination plots 
was undertaken and the quality of calling the wild type allele, the rare allele and the 
heterozygote was an important factor that formed part of the QC measures.  The allelic 
discrimination plots for SNPs 2, 11 and 13 are shown as an example of the sample in 
Figures 6.a-6.e. 
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Figure 6.a: ECACC 1 (rs1805164) Allelic discrimination plot 
 
 
Figure 6.a: The quality of allelic discrimination plot was excellent in ECACC controls 
with clusters being clear and distinct. The wild type allele shown as red and is 
represented by Allele X, i.e. Allele A of rs1805164. The rare allele represented shown as 
blue and is represented by Allele Y, i.e. Allele G of rs1805164. The heterozygote alleles 
AG are shown as green and is represented as both. There were very few undetermined 
samples and they were the negative controls (blanks). 
  
101 
Figure 6.b: ECACC 1 (rs1805165) Allelic discrimination plot 
 
 
 
Figure 6.b: The quality of allelic discrimination plot was excellent in ECACC controls 
with clusters being clear and distinct. The wild type allele shown as red and is 
represented by Allele X, i.e. Allele T of rs1805165. The rare allele represented shown as 
blue and is represented by Allele Y, i.e. Allele G of rs1805165. The heterozygote alleles 
TG are shown as green and is represented as both. There were very few undetermined 
samples and they were the negative controls (blanks). 
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Figure 6.c: ECACC Raw data plots 
 
 
 
 
Figure 6.c: Raw data plots are shown above demonstrating the genotyping quality of 
individual DNA samples for the marker studied. Each of the coloured lines represents the 
individual DNA specimen showing the amplitude of the signal. The raw data plot in the 
top panel with a smoother amplitude indicating homozygote wild type/ rare alleles for the 
marker and the raw data plot in the bottom panel with a notch in the signal indicating 
heterozygote alleles. 
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Figure 6.d: W2 new trios plate 1 (rs867529) Allelic discrimination plot 
 
 
 
 
 
Figure 6.d: The quality of allelic discrimination was good in W2 trios plate 1 for 
rs867529 with clusters being clear and distinct for the wild type allele, the rare allele and 
the heterozygote. But there was a high failure of genotyping being shown as 
undetermined samples shown in black and marked as × in the above figure. 
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Figure 6.e: W2 new trios plate 2 (rs867529) Allelic discrimination plot 
 
 
 
 
 
Figure 6.e: The quality of allelic discrimination was good in W2 trios plate 2 for 
rs867529 with clusters being clear and distinct for the wild type allele, the rare allele and 
the heterozygote. But there was a high failure of genotyping being shown as 
undetermined samples in the above figure. 
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Quality control for SNPs by Taqman Genotyping 
 
Quality control checks for genotyping performed by Taqman methodology at the 
Genome centre are shown below. (Table 6.a) The genotyping error rates- i.e. percentage 
of failed genotyping/drop outs for each subset. Those markers with < 95 % genotyping 
rate were discarded and not utilised for the final analysis.  
 
 
Table 6.a: Quality control checks   
 
 
W2 trios W2 Sib 
Pair 
Probands 
CCS 
BAN 
MRC 
1958 
BC 
ECACC 
SNP2 = 
Failed 
Genotype  
17% 1.7% 4.8% 2% <1% 
SNP 10 = 
Failed 
Genotype  
 8% 4.6% 8.4% 3% <1% 
SNP11 = 
Failed 
Genotype  
 17% 4.6% 9.2% 4% <1% 
SNP 13 = 
Failed 
Genotype  
 7% 10.4% 4.3% 1% <1% 
 
 
 
Combined SNP genotype failure for W2 trios was 12.3%. Therefore, the genotyping data 
for these markers was not analysed further. Combined SNP genotype failure for Warren 2 
sib pair Probands was 5.3%. This dataset just passed QC. Combined SNP genotype 
failure for Bangladeshi CCS was 6.7% but genotyping data for final analysis was 
supplied by KBiosciences which passed the criteria for > 95% successful genotyping. 
Combined SNP genotype failure for MRC 1958 Birth cohort was 1.9%. Combined SNP 
genotype failure for ECACC was 0.46%. Concordance rates for duplicate samples was 
>99 % in W2 Sib Pair Probands, Bangladeshi CCS, ECACC and MRC 1958 BC cohorts. 
Concordance rates for W2 trios was <90 % and was unsuitable for further analysis. 
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QUALITY CONTROL ISSUES FOR TAQMAN GENOTYPING 
 
The Warren 2 family trios, ECACC, 1958 BC Control samples and the South Asian 
resources were genotyped using taqman technology for SNPs 2, 10, 11 and 13 of the 
EIF2AK3 gene at the Barts and The London Genome Centre by myself and supervised by 
Rebecca Allotey and Charles Mein. The genotyping data needed thorough quality control 
checks, especially for the Warren 2 trios data set.  
 
High throughput genotyping was performed by taqman on ABI 7900. Initial results of the 
genotyping on the Warren 2 new trios plates 1-3 showed a much higher than expected 
failed genotyping (> 5% of the samples), i.e. the results were undetermined for either of 
the alleles. In the 1
st
 plate there were 20 % genotyping failures. In the 2
nd
 there were 8 % 
and in the 3
rd
 there were 24 % genotyping failures (see table 6.b and 6.c below). The 
assay was set up in such a way that the 4 markers, SNPs 2, 10, 11 and 13 were being 
genotyped on a single plate of DNA in each run, i.e. 4 × 96= 384 plate. The results 
showed a clear pattern, in that the same DNA sample in the 384 well plate turned out to 
be undetermined for each of the SNP marker and this would not have been anticipated to 
be the case if the problem were the primers or taqman probe for one of the 4 SNPs 
accounting for the excess failure rate. This indicated a problem with the DNA rather than 
the taqman assay being the source of the dropouts. I went through the details of the 
process of DNA aliquoting performed by R. Allotey and myself at Prof. A. Hattersley‘s 
lab at Exeter. The original DNA samples were in eppendorf‘s in a concentration of 200 
ng/ul. The datasets that were in eppendorf were the W2 old trios, new trios. Whereas W2 
sib pair probands and ECACC samples were in working dilution of 20 ng/ul in a 96 well 
plate.  The W2 sib pair probands and the ECACC samples in the 96 well plate format 
provided good results for the same SNPs using the taqman assay with a high genotyping 
call rate (> 95%). The samples in eppendorf were vortexed, centrifuged and then 
collected in a 96 well plate. We took 20 ul of the original DNA and diluted with 180 ul of 
water to give a final concentration of 20 ng/ul. The samples were brought to our lab in 
London and stored in – 20
°
 C freezer on the same evening.  
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The original samples were already quantified for DNA by picogreen at the lab in Exeter. 
Therefore, we planned to do a gel run with the DNA. This experiment was performed for 
all the data sets collected in Exeter. In the experiment I took 2 ul of DNA and 2 ul of 
loading dye and running it on a 3% agarose gel. The product was visualised under UV 
light. The results of this experiment showed us the lack of a DNA band in some wells 
from the W2 trios data sets with the exception of ECACC control samples. In our initial 
collection from Exeter it is pertinent to note that the ECACC collection was in a 96 well 
format from which we took the aliquots and this could explain the good results we 
observed on the gel run with these samples. 
 
Table 6.b: W2 New trios plate 1-genotyping failures on taqman and gel run  
 
 1 2 3 4 5 6 7 8 9 10 11 12 
    A X (Plate 
ID) 
X (Plate 
ID) 
X (Plate 
ID) 
X 
(17/75/1) 
        
B 
    X 
(13/4/2) 
X  
(13/4/3) 
 X 
(13/12/2) 
 X  
(13/36/1) 
X  
(13/36/2) 
X  
(13/36/3) 
C 
   X  
(18/1/1) 
X  
(18/1/2) 
X  
(18/1/3) 
      
D 
    X  
(13/6/2) 
       
E 
      X  
(13/23/1) 
     
F 
       X  
(12/78/2) 
X  
(12/78/3) 
   
G 
      X (water)      
H 
 X  
(12/98/2) 
X  
(12/98/3) 
    X  
(13/30/2) 
X  
(13/30/3) 
X  (Blank) X (Blank) X  (Blank) 
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The next step involved checking if the initial failed genotypes on taqman assays and the 
empty DNA wells (Agarose gel run) tallied. I found in the three W2 new trios plates there 
was a clear pattern of this being the case (Represented by X for the empty DNA and the 
sample ID number for the failed genotype as shown in Table 6.b & 6.c). This suggested 
the problem was DNA quality rather than a problem with taqman assay.  
 
 
 
Table 6.c: Warren 2 New trios plate 2 genotyping failures on taqman and gel run  
 
 1 2 3 4 5 6 7 8 9 10 11 12 
    A 
            
B 
X (Plate 
ID) 
X (Plate 
ID) 
X (Plate 
ID) 
X 
18/25/1 
X 
18/25/2 
X   
18/25/3 
   X 
(Water) 
X  
(Water) 
X 
(Water) 
C 
      X 
13/87/1 
     
D 
            
E 
            
F 
            
G 
            
H 
      X 
13/53/1 
X 
13/53/2 
    
 
 
 
To confirm the problem lay with DNA being of poor quality I genotyped SNP 44 of 
Calpain 10 by taqman on a South Asian data set with very small genotype failure rate (4 
%), and typed the same marker on W2 New trios plate and the genotype failure rate was 
much higher in the W2 New trios plate 1 (20%) and the failed DNA wells were identical 
to those obtained with EIF2AK3 markers.  
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This suggested the problem was the lack of DNA in the some of the wells rather than the 
taqman assay; either the plates dried up or less likely that they were incorrectly aliquoted 
in the first place. We therefore decided to genotype the rest of the data sets for SNPs 2, 
10, 11 and 13 by taqman as we were confident of the taqman assay not being the 
problem. 
 
Warren 2 trios failed the pre-set QC targets likely to be due to varying DNA 
concentrations in the plates. Therefore results from these plates were discarded. The Sib 
Pair probands, South Indian and Bangladeshi cohorts and the controls- ECACC, MRC 
birth cohort all had good genotyping data generated by taqman methodology for the 4 
markers, except INDEL15, which coincidentally failed at KBiosciences as well. 
 
This process highlights the importance of 1) good quality DNA to be available for 
genotyping and 2) robust quality control measures in genotyping to give reliable data. 
 
The DNA resources that were available at KBiosciences were of better quality and all the 
10 SNPs that were analysed by Amplifuor technology passed QC according to their 
internal quality control measures, except INDEL15, which also failed by taqman 
previously. Indeed the majority that was successfully genotyped were those DNA that 
were available at KBiosciences from the GWA and replication studies. 
 
 
 
 
 
 
 
 
 
 
  
110 
6.3 QUALITY CONTROL AMPLIFUOR AND KASpar GENOTYPING 
 
The majority of the genotyping was outsourced to KBiosciences for cost effectiveness. 
After initial set up and the exclusion of either monomorphic markers or those not able to 
be typed by the KBioscience in house assays 11 SNPs were studied in British Irish, 
Bangladeshi and South Indian cohorts. After a further QC step 10 SNPs were analysed 
excluding INDEL15. The genotyping performed at KBiosciences passed their internal 
QC measures.  
 
Quality control criteria for KBiosciences 
KBiosciences criteria for routine quality control measures on all its Genotyping are 
shown below:  
 Water controls must be negative  
 Inter plate duplicate testing of a known DNA  
 Intra plate testing of a known DNA  
 Percentage success rate of calls must be greater than 95%  
 Clusters are clear and distinct  
 
The results released by KBiosciences were further checked as a QC measure by 
comparing with genotyping performed on Taqman. The datasets for Bangladeshi case 
control study, 1958 MRC birth cohort were re-genotyped (Initial genotyping was 
performed on taqman) for the SNPs 2, 10, 11, 13 at KBiosciences as an external quality 
step; there was 99% concordance of genotyping calls between both methodologies. 
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6.4 MINOR ALLELE FREQUENCIES 
 
The minor allele frequencies (MAFs) in the genotyped SNPs varied from 2% to 32% in 
the British Irish resources, 1% to 41% in the Bangladeshi resources and from 1% to 45% 
in the South Indian resources. We compared the MAFs that were obtained in the British 
Irish population with the MAFs quoted in the NCBI/HAPMAP public databases and were 
very similar. There are no publicly available data on either the Bangladeshi or the South 
Indian populations for MAF. (Table 6.d) 
 
Table 6.d: Minor allele frequencies 
 
 
Hapmap CEU-30 mother-father-child trios from the CEPH collection (Utah residents 
with ancestry from northern and western Europe), representing one of the populations 
studied in the International HapMap project 
 
—* Novel SNPs 
 
Marker Minor Allele 
Frequency 
HAPMAP 
(CEU) 
British Irish Bangladeshi South Indian 
rs number  N=6112 N=985 N=998 
  MAF MAF MAF 
1805165 0.35 0.28 0.39 0.45 
867529 0.26 0.28 0.41 0.44 
6750998 0.24 0.27 0.25 0.30 
10189080 —* 0.08 0.02 0.01 
7579242 —* 0.08 0.03 0.02 
1805164 0.35 0.30 0.19 0.09 
4449134 —* 0.32 0.22 0.13 
7605713 —* 0.27 0.25 0.28 
17689440 0.008 0.02 0.01 0.01 
867014 0.35 0.30 0.20 0.11 
  
112 
MINOR ALLELE FREQUENCIES- POPULATION CHARACTERISTICS 
 
Given the possibility of differences in MAF in the three different cohorts we proceeded to 
compare the MAFs among the cohorts utilising a chi squared test (χ2); British Irish with 
South Indian (SI), British Irish with Bangladeshi (Bang), South Indian with Bangladeshi. 
The results (p-values) are shown in table 6.e. Comparing the minor allele frequencies 
(MAFs) in the 3 ethnic groups showed that 9 of the 10 minor alleles had frequencies that 
differed between UK whites and the South Indians and all 10 minor alleles differed 
between UK whites and the Bangladeshi, whereas in the South Asian sub-groups MAFs 
were very similar. 
 
 
Table 6.e: Minor allele frequency- Population characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
rs number 
British Irish 
vs. SI 
British Irish  
vs. Bang SI vs. Bang 
1805165 
 
1.3 ×10
-32 
1.7 × 10
-23
 0.16 
867529 9.3 ×10
-32
 1.2 ×10
-22
 0.14 
6750998 0.0360394 1.1 × 10
-05
 0.83 
10189080 5.6 ×10
-12
 0.000791481 0.78 
7579242 5.9 ×10
-8
 0.0081 0.07 
1805164 1.1 × 10
-110
 3.0 ×10
-25
 0.14 
4449134 3.3 ×10
-13
 2.4 ×10
-32
 0.37 
7605713 0.18 1.2 ×10
-05
 0.98 
17689440 0.0009 0.00089 0.70 
867014 1.5  × 10
-31
 5.8 × 10
-08
 0.30 
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6.5  HARDY-WEINBERG EQUILIBRIUM  
 
The results showed majority of the SNPs were in HWE in all three cohorts. (Table 6.f) 
The SNPs that failed HWE are highlighted in red. SNP rs4449134 was not in HWE in all 
three population sub groups. SNPs rs10189080 and rs4449134 were not in HWE in the 
Bangladeshi and South Indian subjects. SNP rs17689440 was not in HWE in South 
Indian population. 
 
 
Table 6.f: Hardy-Weinberg equilibrium results for 3 populations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Marker British Irish Bangladeshi South Indian 
rs number HWE PValue HWE PValue HWE PValue 
1805165 0.71 0.88 0.41 
867529 0.90 0.82 0.41 
6750998 0.67 0.86 0.17 
10189080 0.99 6.24  ×10
-49  
* 0.005* 
7579242 0.84 0.53 0.15 
1805164 0.93 0.29 0.10 
4449134 0.02*  9.3  ×10
-08
  * 0.001* 
7605713 0.64 0.90 0.18 
17689440 0.54 0.81 2.24  × 10
-13
 * 
867014 0.52 0.62 0.06 
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HARDY-WEINBERG EQUILIBRIUM  
 
The details of the observed and expected genotype counts for the markers not in HWE 
are shown in the following tables- (Table 6.g-1, 2, 3, 4, 5 and 6) 
 
Table 6.g-1, 2, 3, 4, 5 and 6: HWE Failures 
 
 
1. rs 4449134 (British Irish) 
 
 
Observed TT CT CC NUM   
 2184 1925 494 4603   
Expected TT CT CC     
 2150.872 1991.257 460.8717 4603   
 0.510252 2.204612 2.381329 5.096193 chi=sq 
       0.023978 p-value 
 
 
2. rs 4449134 (Bangladeshi) 
 
 
 
 
 
 
 
 
 
 
3. rs 4449134 (South Indian) 
 
 
Observed TT CT CC NUM   
 335 128 28 491   
Expected TT CT CC     
 324.2383 149.5234 17.23829 491  
 0.357189 3.098228 6.71844 10.17386 chi=sq 
    0.001424 p-value 
 
 
 
 
 
Observed TT CT CC NUM   
 652 344 101 1097   
Expected TT CT CC     
 618.9389 410.1222 67.93892 1097  
 1.765982 10.66058 16.08849 28.51505 chi=sq 
    9.3 ×10
-08
 p-value 
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4. rs10189080 (Bangladeshi) 
 
 
Observed AA GA GG NUM   
 996 38 17 1051   
Expected AA GA GG     
 980.2331 69.53378 1.233111 1051  
 0.253608 14.30066 201.5996 216.1539 chi=sq 
 
    6.24 × 10
-49  
 p-value 
 
 
5. rs10189080 (South Indian) 
 
 
Observed AA GA GG NUM   
 474 23 2 499   
Expected AA GA GG    
 472.3652 26.26954 0.36523 499  
 0.005658 0.406931 7.317219 7.729808 chi=sq 
    0.005432 p-value 
 
 
 
6. rs17689440 (South Indian) 
 
 
Observed TT TC CC NUM  
 491 4 1 496   
Expected TT TC CC   
 490.0181 5.96371 0.018145 496   
 0.001967 0.646604 53.12926 53.77783 chi=sq 
       2.2 ×10
-13  
 p-value 
 
 
 
SNP rs4449134 was not in HWE in all three population sub groups and was not analysed 
for association study. SNPs rs10189080 and rs4449134 were not in HWE in the 
Bangladeshi and the South Indian subjects, SNP rs17689440 was not in HWE in the 
South Indian population and were not analysed for association study. 
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CHAPTER SEVEN: GENOTYPING RESULTS 
 
7.1  DISEASE ASSOCIATION STATISTICS- GENOTYPING RESULTS 
  
Genotyping analysis for candidate gene association for the 10 single nucleotide 
polymorphisms (SNPs) of the EIF2AK3 gene was performed using the program - 
UNPHASED 3.0.6 log likelihood ratio tests. We generated clean data with the quality 
control measures aforementioned.  
 
There were three ways in which the statistical analysis was approached (hierarchical 
approach to statistical analysis of the three populations). The reasoning behind our 
approach to statistical analysis of all the subjects for a combined analysis was to look for 
a trend or positive signal for any of the markers. Following on after the combined 
analysis our effort was to delve into the ethnic specific sub-groups and further sub-group 
analysis within the ethnic groups for all three populations studied. The rationale to take 
this approach was to avoid false positive results in the candidate gene association study.  
 
 All three groups were combined which included geographical region as a 
confounder. The way we performed the statistical analysis with the help of 
program UNPHASED using log likelihood ratios facilitated the analysis of all 
three groups combined, i.e. British Irish cohort, South Indian cohort and 
Bangladeshi cohort. This analysis includes the Warren 2 trios, Warren 2 diabetes 
cases and Warren 2 controls from the British Irish cohort, the Bangladeshi young 
diabetes cases and controls, the Bangladeshi diabetes case-control study cohort, 
the South Indian urban survey diabetes cases and controls, the South Indian 
Newham diabetes cases and controls and the South Indian family trios. 
Geographical confounders may have values that could influence the population 
frequency of minor allele frequency and UNPHASED allowed for modelling of 
interactions between haplotype and geographical covariates. 
 
 Within each of the ethnic group the various datasets were analysed as a combined 
group. The British Irish combined analysis includes the Warren 2 T2DM cases 
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and controls, Warren 2 trios. The Bangladeshi combined analysis includes the 
Young diabetes cases and controls, Bangladeshi case-control study. The South 
Indian combined analysis includes urban survey diabetes cases and controls, the 
South Indian Newham diabetes cases and controls and the South Indian family 
trios. Age was applied as a confounder when testing as a combined data set within 
the particular ethnic group as different data sets had differences in age. For 
example, the young Bangladeshi cohort had a mean age of 18 years and the rest of 
the Bangladeshi cohort had a mean age of 36 years. 
 
 We studied all three ethnic groups in detail and analysed each subset in a 
particular ethnic group separately. For example, the young Bangladeshi cohort 
was analysed on its own and the Bangladeshi Whitechapel and Sylhet cohort was 
analysed separately. 
 
 
SUBJECTS STUDIED - 
 
a) All 3 groups combined (British Irish, Bangladeshi, South Indian) 
b) Warren2 British Irish population 
c) Bangladeshi population 
d) South Indian population 
e) Replication set from Dundee 
 
 SNP rs1805185 (previously referred to as 15INDEL) failed QC by 2 separate 
assays and therefore was not included in the final analysis.  
 Ten SNPs were included in the final analysis except those SNPs that failed HWE 
 Four SNPs failed QC by Taqman in the W2trios plates. 
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Genotyping results / UNPHASED Output  
 
Combined analysis (British Irish, Bangladeshi, South Indian) 
 
The following table (Table 7.a) summarizes the results and the p-values generated as a 
measure of significance of the association of the marker, i.e. the SNP, with being a case 
(Type 2 diabetes) for all samples in the combined analysis of the British Irish, the 
Bangladeshi and the South Indian subjects. The p-values were generated for each SNP 
using the log likelihood ratio for all samples- combined group of British Irish, 
Bangladeshi and South Indian resources. Since there was a significant difference in allele 
frequencies between regions we included geographical region as a confounder (which is a 
type of covariate) with discrete levels. (i.e. treated as a ―factor‖ by UNPHASED). The 
results are detailed in the following table (Table 7.a) that has all samples combined for all 
our data sets.  
 
Disease association statistics- Genotyping results- p-values 
 
Comparing the alleles between cases and controls and allelic transmission in the family 
studies showed that in 8 of 9 SNPs analysed for EIF2AK3 gene in the UK white cohort 
there was no statistically significant difference; in the 7 SNPs analysed in the South 
Indian cohort there was no statistically significant difference. In the novel SNP in the 5' 
UTR (rs7605713) an equivocal p-value was obtained that was individually significant in 
the UK whites and a subset of the Bangladeshi cohort and further replication study was 
carried out for this marker in the white population. An equivocal p-value was also seen 
for the marker rs6750998 in the Bangladeshi cohort alone. None of the 9 SNPs in the 
combined analysis for all three populations showed any statistically significant difference 
between type 2 diabetes cases and the controls (Table 7.a). The results for the combined 
analysis within the British Irish, Bangladeshi and South Indian cohorts and their 
summarized information for these analyses are given in the future tables. 
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Table 7.a: Genotyping results – p-values all SNPs, 3 groups 
 
Marker All samples British Irish Bangladeshi South Indian 
 p-value p- value p- value p- value 
rs number N= N=6112 N= 985 N=998 
1805165 0.82 0.40 0.91 0.26 
867529 0.45 0.12 0.78 0.24 
6750998 0.63 0.48 0.04* 0.37 
10189080 0.78 0.78 — — 
7579242 0.40 0.43 0.58 0.83 
1805164 0.15 0.22 0.19 0.66 
4449134 — — — — 
7605713 0.44 0.05*** 0.05** 0.36 
17689440 0.97 0.88 0.56 — 
867014 0.14 0.31 0.11 0.92 
 
 
—rs4449134 failed HWE in all 3 cohorts  
—rs10189080 failed HWE in South Asian cohorts 
—rs17689440 failed HWE in South Indian cohort 
*** p=0.05 in British Irish combined dataset/ W2 trios 
**   p=0.007 in the young Bangladeshi dataset  
*     p=0.005 in the young Bangladeshi dataset  
 
 
All p- values were generated using UNPHASED 3.0.6 (p-value is a measure of 
significance of the association of the SNP with being a case) 
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British Irish cohort combined analysis 
The following table (Table 7.b) summarizes the results and the p-values generated as a 
measure of significance of the association of the marker, i.e. the SNP, with being a case 
(Type 2 diabetes) in the combined analysis of the British Irish subjects which include the 
W2 T2D cases, Sib pair probands and OCDEM_OXGN Cases (Total cases=2206). It also 
includes the analysis of 418 W2 trios (n=1254). The control population includes the 
MRC Birth cohort and the ECACC (Total control group= 2652).  
 
Table 7.b: Genotyping results – p-values all SNPs, British Irish Cohort 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The table 7.b shows the reference SNPs in 2
nd
 column, the alleles studied in the 3
rd
 
column, and the p- values generated using log likelihood ratios. The results also show the 
frequency of the alleles in the cases and controls respectively. rs449134 failed HWE. 
SNP rs7605713 (novel 5' of EIF2AK3 SNP) in the British Irish combined analysis 
showed a nominally significant p-value of 0.05. 
British Irish 
combined 
 rs 
numbers Allele 
p- 
values 
Case 
Freq 
Control 
Freq 
 1 rs1805165 G 0.4 0.286 0.277 
    T   0.714 0.723 
 2 rs867529 C 0.12 0.707 0.722 
    G   0.293 0.278 
 3 rs6750998 A 0.48 0.733 0.726 
    T   0.267 0.274 
 4 rs10189080 A 0.78 0.918 0.917 
    G   0.082 0.083 
 5 rs7579242 C 0.43 0.082 0.082 
    T   0.918 0.918 
 6 rs1805164 A 0.22 0.704 0.693 
    G   0.296 0.307 
 7 rs7605713 A 0.05 0.734 0.720 
    C   0.266 0.280 
 8 rs17689440 C 0.88 0.019 0.019 
    T   0.981 0.981 
 9 rs867014 A 0.31 0.702 0.694 
    C   0.298 0.306 
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British Irish case-control cohort 
 
The following table (Table 7.c) summarizes the results and the p-values generated as a 
measure of significance of the association of the marker, i.e. the SNP, with being a case 
(Type 2 diabetes) in the analysis of the British Irish W2 T2D cases, Sib pair probands and 
OCDEM_OXGN Cases (Total cases=2206). The control population includes the MRC 
Birth cohort and the ECACC (Total control group= 2652).  
 
Table 7.c: Genotyping results – p-values all SNPs, British Irish case-control 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The table 7.c shows the reference SNPs in 2
nd
 column, the alleles studied in the 3
rd
 
column, and the p- values generated using log likelihood ratios. The results also show the 
frequency of the alleles in the cases and controls respectively. rs449134 failed HWE. 
None of the markers showed any statistically significant difference between cases and 
controls in the British Irish case-control cohort. 
 
British Irish 
case-control 
 rs 
numbers Allele 
p- 
values 
Case 
Freq 
Control 
Freq 
 1 rs1805165 G 0.39 0.286 0.277 
    T   0.714 0.723 
 2 rs867529 C 0.12 0.707 0.722 
    G   0.293 0.278 
 3 rs6750998 A 0.47 0.733 0.726 
    T   0.267 0.274 
 4 rs10189080 A 0.92 0.917 0.916 
    G   0.083 0.084 
 5 rs7579242 C 0.91 0.085 0.084 
    T   0.915 0.916 
 6 rs1805164 A 0.21 0.704 0.693 
    G   0.296 0.307 
 7 rs7605713 A 0.27 0.734 0.724 
    C   0.266 0.276 
 8 rs17689440 C 0.83 0.020 0.020 
    T   0.980 0.980 
 9 rs867014 A 0.34 0.703 0.694 
    C   0.297 0.306 
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Warren 2 trios (family study) 
 
 
The results in table 7.d show the analysis of the Warren 2 family study subjects analysed 
separately using the log likelihood ratio test. rs449134 failed HWE and four markers 
failed QC measures (rs867529, rs6750998, rs1805164 and rs1805165) leaving 5 markers 
which could be analysed in the family study.  
 
 
Table 7.d: Genotyping results – p-values all SNPs, Warren 2 trios 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The table 7.d shows the reference SNPs in 2
nd
 column, and the p- values generated using 
log likelihood ratios. rs7605713 showed a nominally significant p-value of 0.05 in the 
Warren 2 trios family study.  
 
 
 
 
 
 
British Irish 
trios 
 rs 
numbers 
p- 
values 
 1 rs10189080 0.91 
      
 2 rs7579242 0.81 
      
 3 rs7605713 0.05 
      
 4 rs17689440 0.36 
      
 5 rs867014 0.89 
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Bangladeshi cohort combined analysis 
The following table (Table 7.e) summarizes the results and the p-values generated as a 
measure of significance of the association of the marker, i.e. the SNP, with being a case 
(Type 2 diabetes) in the combined analysis of the Bangladeshi subjects which include the 
T2D cases (n= 426) and controls (n= 559). This group analysis includes the young 
Bangladeshi cohort, Whitechapel and Sylhet Bangladeshi case-control cohort.  
 
Table 7.e: Genotyping results – p-values all SNPs, Bangladeshi Cohort 
 
 
Bangladeshi 
combined   
 rs 
numbers Allele 
p- 
values 
Case 
Freq 
Control  
Freq 
 1 rs1805165 G 0.91 0.396 0.398 
    T   0.604 0.602 
 2 rs867529 C 0.78 0.605 0.599 
    G   0.395 0.401 
 3 rs6750998 A 0.04 0.684 0.727 
    T   0.316 0.273 
 4 rs7579242 C 0.58 0.038 0.033 
    T   0.962 0.967 
 5 rs1805164 A 0.19 0.830 0.806 
    G   0.170 0.194 
 6 rs7605713 A 0.05 0.689 0.729 
    C   0.311 0.271 
 7 rs17689440 C 0.56 0.006 0.008 
    T   0.994 0.992 
 8 rs867014 A 0.11 0.832 0.804 
    C   0.168 0.196 
 
 
 
The table 7.e shows the reference SNPs in 2
nd
 column, the alleles studied in the 3
rd
 
column, and the p- values generated using log likelihood ratios. The results also show the 
frequency of the alleles in the cases and controls respectively. rs4449134 and rs10189080 
failed HWE. SNPs rs6750998 and rs7605713 showed p-value of 0.04 and 0.05 
respectively, a nominally statistically significant difference between cases and controls in 
the combined analysis of the Bangladeshi cohort. 
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Bangladeshi case-control cohort (Young diabetes cohort) 
 
The following table (Table 7.f) summarizes the results and the p-values generated as a 
measure of significance of the association of the marker, i.e. the SNP, with being a case 
(Type 2 diabetes) in the the analysis of the young Bangladeshi subjects which include the 
T2D cases (n= 330) and controls (n= 374).  
 
Table 7.f: Genotyping results – p-values all SNPs, young Bangladeshi case-control 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The table 7.f shows the reference SNPs in 2
nd
 column, the alleles studied in the 3
rd
 
column, and the p- values generated using log likelihood ratios. The results also show the 
frequency of the alleles in the cases and controls respectively. The results are for the 8 
SNPs that passed QC and HWE. SNP rs7605713 was showing a significant p- value of 
0.007. SNP rs6750998 was showing a significant p- value of 0.005 in this sub set alone. 
 
Bangladeshi 
CCS 
 rs 
numbers Allele 
p- 
values 
Case 
Freq 
Control  
Freq 
 1 rs1805165 G 0.61 0.392 0.406 
    T   0.608 0.594 
 2 rs867529 C 0.50 0.607 0.589 
    G   0.393 0.411 
 3 rs6750998 A 0.005 0.672 0.741 
    T   0.328 0.259 
 4 rs7579242 C 0.54 0.037 0.031 
    T   0.963 0.969 
 5 rs1805164 A 0.17 0.832 0.803 
    G   0.168 0.197 
 6 rs7605713 A 0.007 0.677 0.743 
    C   0.323 0.257 
 7 rs17689440 C 0.33 0.006 0.011 
    T   0.994 0.989 
 8 rs867014 A 0.06 0.838 0.800 
    C   0.162 0.200 
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Bangladeshi Whitechapel, Sylhet case-control cohort 
 
 
The following table (Table 7.g) summarizes the results and the p-values generated as a 
measure of significance of the association of the marker, i.e. the SNP, with being a case 
(Type 2 diabetes) in the analysis of Bangladeshi subjects (Whitechapel and Sylhet cohort) 
which include the T2D cases (n= 96) and controls (n= 185).  
 
 
Table 7.g: Genotyping results – p-values all SNPs, Bangladeshi  case-control 
Whitechapel and Sylhet cohort 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The table 7.g shows the reference SNPs in 2
nd
 column, the alleles studied in the 3
rd
 
column, and the p- values generated using log likelihood ratios. The results also show the 
frequency of the alleles in the cases and controls respectively. The results are for the 8 
SNPs that passed QC/ HWE. SNPs rs7605713 and rs6750998 which were showing a 
significant p-value in young Bangladeshi sub set were not statistically significant in this 
cohort. 
Bangladeshi 
Whitechapel/ 
Sylhet 
 rs 
numbers Allele 
p-
values 
Case 
Freq 
Control  
Freq 
 1 rs1805165 G 0.58 0.407 0.382 
    T   0.593 0.618 
 2 rs867529 C 0.65 0.60 0.620 
    G   0.40 0.380 
 3 rs6750998 A 0.48 0.725 0.697 
    T   0.275 0.303 
 4 rs7579242 C 0.89 0.039 0.036 
    T   0.961 0.964 
 5 rs1805164 A 0.81 0.822 0.814 
    G   0.178 0.186 
 6 rs7605713 A 0.47 0.731 0.701 
    C   0.269 0.299 
 7 rs17689440 C 0.63 0.006 0.002 
    T   0.994 0.998 
 8 rs867014 A 0.99 0.813 0.813 
    C   0.187 0.187 
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South Indian cohort combined analysis 
 
The following table (Table 7.h) summarizes the results and the p-values generated as a 
measure of significance of the association of the marker, i.e. the SNP, with being a case 
(Type 2 diabetes) in the combined analysis of the South Indian subjects which include the 
T2D cases (n= 203) and controls (n= 322) from the Urban survey and Newham 
collection. It also includes the analysis of the 104 families (n=468).  
 
 
 
Table 7.h: Genotyping results – p-values all SNPs, SI Cohort 
 
 
 
3.South Indian 
combined 
 rs 
numbers Allele 
p- 
values 
Case 
Freq 
Con 
Freq 
 1 rs1805165 G 0.26 0.408 0.430 
    T   0.592 0.570 
 2 rs867529 C 0.24 0.595 0.572 
    G   0.405 0.428 
 3 rs6750998 A 0.37 0.69 0.712 
    T   0.31 0.288 
 4 rs7579242 C 0.83 0.040 0.049 
    T   0.960 0.951 
 5 rs1805164 A 0.66 0.83 0.837 
    G   0.17 0.163 
 6 rs7605713 A 0.36 0.695 0.719 
    C   0.305 0.281 
 7 rs867014 A 0.92 0.829 0.829 
    C   0.171 0.171 
 
 
The table 7.h shows the reference SNPs in 2
nd
 column, the alleles studied in the 3
rd
 
column, and the p- values generated using log likelihood ratios. The results also show the 
frequency of the alleles in the cases and controls respectively. Three SNPs failed HWE 
(rs4449134, rs10189080, rs17689440). None of the SNPs showed any statistically 
significant difference between cases and controls in the combined analysis of the South 
Indian cohort. 
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South Indian Newham case-control cohort 
 
 
The following table (Table 7.i) summarizes the results and the p-values generated as a 
measure of significance of the association of the marker, i.e. the SNP, with being a case 
(Type 2 diabetes) in the analysis of South Indian Newham subjects which include the 
T2D cases (n= 118) and controls (n= 67).  
 
 
Table 7.i: Genotyping results- p-values all SNPs Newham SI case-control cohort 
 
 
South Indian 
Newham 
 rs 
numbers Allele 
p- 
values 
Case 
Freq 
Con 
Freq 
 1 rs1805165 G 0.42 0.410 0.453 
    T   0.590 0.547 
 2 rs867529 C 0.55 0.587 0.555 
    G   0.413 0.445 
 3 rs6750998 A 0.13 0.616 0.695 
    T   0.384 0.305 
 4 rs7579242 C 0.12 0.057 0.023 
    T   0.943 0.977 
 5 rs1805164 A 0.74 0.898 0.91 
    G   0.102 0.09 
 6 rs7605713 A 0.11 0.633 0.714 
    C   0.377 0.286 
 7 rs867014 A 0.69 0.896 0.883 
    C   0.104 0.117 
 
 
 
The table 7.i shows the reference SNPs in 2
nd
 column, the alleles studied in the 3
rd
 
column, and the p- values generated using log likelihood ratios. The results also show the 
frequency of the alleles in the cases and controls respectively. The results are for the 7 
markers that passed QC/ HWE. None of the SNPs showed any statistically significant 
difference between cases and controls in South Indian Newham case-control cohort. 
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South Indian Urban survey 
 
 
The following table (Table 7.j) summarizes the results and the p-values generated as a 
measure of significance of the association of the marker, i.e. the SNP, with being a case 
(Type 2 diabetes) in the analysis of South Indian Urban survey subjects which include the 
T2D cases (n= 85) and controls (n= 260).  
 
Table 7.j: Genotyping results- p-values all SNPs South Indian Urban survey 
 
 
South Indian 
Urban survey 
 rs 
numbers Allele p-values 
Case 
Freq 
Con 
Freq 
 1 rs1805165 G 0.25 0.388 0.446 
    T   0.612 0.554 
 2 rs867529 C 0.16 0.625 0.556 
    G   0.375 0.444 
 3 rs6750998 A 0.90 0.694 0.688 
    T   0.306 0.312 
 4 rs7579242 C 0.12 0.016 0.042 
    T   0.984 0.958 
 5 rs1805164 A 0.01 0.771 0.863 
    G   0.229 0.137 
 6 rs7605713 A 0.82 0.683 0.694 
    C   0.317 0.306 
 7 rs867014 A 0.04 0.779 0.856 
    C   0.221 0.144 
 
 
 
The table 7.j shows the reference SNPs in 2
nd
 column, the alleles studied in the 3
rd
 
column, and the p- values generated using log likelihood ratios. The results also show the 
frequency of the alleles in the cases and controls respectively. The results are for the 7 
markers that passed QC/ HWE. rs1805164 and rs867014 showed a statistically significant 
difference between cases and controls in the South Indian Urban survey cohort but the 
result should be interpreted with caution for this sub-group analysis given the small 
number of cases (n= 85) and disproportionately larger number of controls (n=260) 
whereas there was no difference noted in the combined SI analysis. 
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South Indian families 
 
The results in table 7.k show the analysis of the South Indian family study (n=104 
families, 468 subjects) analysed separately using the log likelihood ratio test. Three 
markers failed HWE leaving 7 markers which could be analysed. And the p- values are 
shown in the following table 7.k. None of the markers showed any statistically 
significant association. 
 
 
Table 7.k: Genotyping results – p-values all SNPs, SI families 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The table 7.k shows the reference SNPs in 2
nd
 column, and the p- values generated using 
log likelihood ratios. None of the SNPs showed any statistically significant association in 
South Indian family study. 
 
 
 
South Indian 
families 
 rs 
numbers p- values 
 1 rs1805165 0.59 
      
 2 rs867529 0.54 
      
 3 rs6750998 0.26 
      
 4 rs7579242 0.43 
      
 5 rs1805164 0.71 
      
 6 rs7605713 0.26 
      
 7 rs867014 0.67 
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Disease association statistics- Genotyping results- p-values 
 
In the novel SNP in the 5' of EIF2AK3 gene (rs7605713) an equivocal p-value was 
obtained that was individually significant in the British Irish subjects in the combined 
analysis and Warren 2 trios and also in the Bangladeshi cohort in the combined analysis. 
In the Bangladeshi young diabetes cohort there was a statistically significant p-value for 
SNPs rs7605713 and rs6750998 (Intron 10 of EIF2AK3 gene). SNP rs1805164 (Exon 11 
of EIF2AK3 gene) and SNP rs867014 (Intron 1 of EIF2AK3 gene)   showed a nominally 
significant p-value in the South Indian urban survey. Further replication study was 
carried out for rs7605713 in the British population. 
 
 
Dundee Replication Study 
 
The following table (Table 7.l) summarizes the results and the p-values generated as a 
measure of significance of the association of the marker, i.e. the SNP, with being a case 
(Type 2 diabetes) using the log likelihood ratio test. SNP rs7605713 which gave an 
equivocal p-value in the Warren 2 trios family study, combined British Irish cohort 
further replication study was undertaken in 3334 cases and 3456 controls for rs7605713 
in the DARTS cohort (Table 7.l) which are all Scottish and therefore similar to the 
Warren 2 cohorts.  
 
          Table 7.l:  Genotyping results – p-values,  Dundee Replication study 
 
 
 
 
 
 
There was no statistically significant difference between cases and controls for the SNP 
rs7605713 in the Dundee replication study. 
Allele 
(rs7605713) 
p- values  Case 
Frequency 
Control 
Frequency 
A 0.56 0.709 0.705 
C  0.291 0.295 
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7.2 LINKAGE DISEQUILIBRIUM STATISTICS 
 
Linkage disequilibrium statistics measuring marker- marker association for the EIF2AK3 
gene calculated by a likelihood ratio test are shown in the LD plot in Figure 7.a. and 
results are presented in the Table 7.m. 
 
Figure 7.a: LD plot for 10 SNPs within and flanking the EIF2AK3 gene 
 
 
 
 
Figure 7.a: LD plot for linkage disequilibrium for the 10 SNPs of EIF2AK3 gene are 
being shown. The LD plot was obtained using the program Haploview(138).The colour 
schemata of the plots highlighted in red colour with D' values of >0.8 indicate SNPs in 
strong LD with each other. The 5 empty red plots are SNPs in perfect LD with each other 
with D' values of ~1.   The plots in pink colour with D' values of <0.8 indicate SNPs not 
in strong LD with each other. 
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Table 7.m: The table in the previous page displays the LD for all 10 SNPs within and 
flaking the EIF2AK3 gene. D' calculated by LDPAIRS below diagonal. P-values 
calculated by LDPAIRS above diagonal.  
 
In order to measure marker-marker association we calculated a likelihood ratio test 
comparing the likelihood for the genotypes assuming LD to that assuming no LD, as 
implemented in the LDPAIRS program. The p values measure the statistical significance 
of the test for linkage disequilibrium between the markers. 
 
D' of 1 equals complete LD. D' of >0.8 indicates strong LD. D' of 0.2- 0.8 indicates 
incomplete LD. D' of <0.2 indicates negligible LD(139). The results show rs7579242 to 
be in complete LD with rs1805165, rs867529 and rs6750998. rs17689440 is in complete 
LD with rs867529. rs7605713 is in complete LD with rs7579242. rs4449134 and 
rs1805164 are in incomplete LD. rs4449134 and rs867014 are in incomplete LD. All of 
the other SNPs, except rs4449134, rs1805164 and rs867014, genotyped in our study are 
in strong LD with each other with a D' of >0.8. 
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CHAPTER EIGHT: DISCUSSION 
 
Type 2 Diabetes is a quintessentially complex disease with significant gaps in our 
knowledge in understanding the pathogenesis of the condition. It is well recognised that 
insulin resistance and insulin secretory failure occur in T2DM, but what is not clear is the 
underlying molecular mechanisms that lead to these defects. The incidence of T2DM 
reaching epidemic proportions in recent times does support the underlying concept that 
calorie excess and sedentary lifestyle have had a major impact on the disease. Successful 
discovery of genes that contribute to T2DM based on candidate gene testing have been 
very few and the risk that is associated with these gene variants low (odds ratio, OR 
~1.3). There has been remarkable progress made in recent years in genetic studies of 
polygenic diseases that has led to the discovery of new loci/ genes associated with T2DM 
using a genome wide approach but again the risk associated with these loci are low (OR 
1.1-1.7). Indeed most of the familial risk of T2DM still remains unexplained, highlighting 
the need for ongoing efforts to detect novel disease associated variants. 
 
 
8.1 Paradigm shift in the study of genetics of common diseases 
 
Since starting work in the laboratory in 2002 to the present day there has been a major 
shift in approaches to identifying the susceptibility genes for type 2 diabetes. It spans the 
era of:  
 
 Investigating candidate genes in small subsets (Studying a few hundred subjects 
in a case-control design and family based candidate gene association study) (140) 
of individuals which resulted in false positive associations that failed future 
replication studies (141,142). The problem of failed association studies, either 
positive or negative signals and the failed replication studies could be attributable 
to low power to detect small effect, i.e. low odds ratios. There was also the 
problem of having low threshold for suggesting a significant p-value, leading to 
wrong interpretation of results and false positive associations. Finally, there was 
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the problem of investigating only a few variants across the gene, i.e. SNPs, which 
led to inadequate capture of gene variation(143). 
 
 Low throughput genotyping which was labour intensive and a relatively slow 
process involving carrying out PCR reaction, post- PCR sample handling and 
running the DNA product on agarose gel, as compared (144) to high throughput 
genotyping (145) facilitating study of large number of samples for association 
studies in a quick and accurate manner and not requiring post- PCR sample 
handling thereby avoiding potential PCR product contamination leading to wrong 
genotype data generation.  
 
 Testing single candidate gene variants with a few SNPs to the now popular 
Genome wide association studies with ~ 0.5 – 1 million SNPs spanning the 
whole genome with the capability to detect novel genes associated with disease.  
 
 
 Studying single SNPs to compiling SNP inventories by direct sequencing and the 
use of publicly available in silico databases as a consequence of the International 
Hapmap project and the Human Genome project(146,147).  
 
In the year 2002 facilities existed for doing a large scale candidate gene association study 
but we did not have the tools to investigate the whole genome for association study. We 
tried to address some of the issues pertaining to power to detect modest effects. However, 
this was only possible in the British Irish cohort. We did a robust large scale association 
study of the EIF2AK3 gene, with thousands of individuals studied, resulting in more 
reliable results dependent on sufficient power to detect the relevant effect. We utilised 
TagSNP information from the International Hapmap project to capture the majority of 
variations across the gene. 
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8.2 Common disease common variants – Genome wide association studies  
 
In the era of Genome wide association studies and advances in high throughput 
genotyping platforms identifying disease susceptibility genes, would mean that new 
genes incriminated in type 2 diabetes are being discovered at a rapid pace. Replication 
studies would further support or refute such candidate genes being associated with type 2 
Diabetes. The power or the numbers needed to study to detect gene variants associated 
with a complex disease such as T2D, in GWAS depends on the effect size and the risk 
allele frequency. The GWAS design of gene association studies in polygenic disease like 
T2DM has been to identify common variants with minor allele Frequency > 5% that 
could be associated with disease, i.e. common disease common variant hypothesis(148). 
The common disease-common variant (CDCV) (C3 in the figure 8.a) hypothesis infers 
that common variants, interacting disease alleles are associated with most common 
diseases. The hypothesis has been the scientific paradigm for genome-wide association 
(GWA) studies that have been conducted on many common diseases.   As an example in 
GWAS the detection of the vast majority of the effect sizes of risk alleles are small, 
typically OR around 1.1 to 1.5, which are the limits of detection given the experimental 
sample sizes employed to date. GWAS SNP panels are limited to polymorphisms with 
MAF >0.01. Rare causal variants are likely to exist but will not be represented by the 
genotyped SNPs in the current GWAS design.  
 
During the process of writing up my thesis there have been GWAS and also GWA meta 
analysis (149) which combined the results across a total of 10,128 samples (4,549 cases 
and 5,579 controls (see table 8.a for the gene variants associated with T2DM) but still 
EIF2AK3 did not come up in the Genome Wide Association studies. However, as will be 
discussed later in this chapter, EIF2AK3 was a potentially good candidate gene to be 
studied in Type 2 diabetes and our study was hypothesized pre-GWAS. GWAS have 
identified several T2DM susceptibility loci and accumulating evidence suggests that 
these loci confer the diabetes risk through their effects on beta cell function.  
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Table 8.a: GWAS and genetic variants associated with T2DM  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SNP Nearest Gene Odds ratio p- value 
rs864745 JAZF1 1.10 5.0 × 10
-14
 
rs12779790 CDC123, 
CAMK1D 
1.11 1.2 × 10
-12
 
rs7961581 TSPAN8, 
LGR5 
1.09 1.1 × 10
-09
 
rs7578597 THADA 1.15 1.1 × 10
-09
 
rs4607103 ADAMTS9 1.09 1.2 ×10
-08
 
rs10923931 NOTCH2 1.13 4.1 ×10
-08
 
rs1153188 DCD 1.08 1.8 × 10
-07
 
rs17036101 SYN2, PPARG 1.15 2.0 × 10
-07
 
rs2641348 ADAM30 1.10 4.0 ×10
-07
 
rs9472138 VEGFA 1.06 4.0 ×10
-06
 
rs10490072 BCL11A 1.05 1.0 × 10
-04
 
rs13266634 SLC30A8 1.12 5.3 × 10
-08
 
rs1111875 HHEX 1.13 5.7 × 10
-10
 
rs8050136 FTO 1.17 1  × 10
-12
 
rs7903146 TCF7L2 1.37 1  × 10
-48
 
rs1801282 PPARG 1.19 1.5  × 10
-7
 
rs10010131 WFS1 1.15 4.5  × 10
-5
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The GWAS findings are consistent with pathophysiology of T2DM occurring due to beta 
cell insulin secretory failure(150,151). The majority of the genes identified at various loci 
were previously unknown to be associated with T2D and they were not even considered 
as potential candidate genes. The finding of these novel genes for T2DM susceptibility 
raises the possibility of exploring the biological pathways by which disease may 
manifest. For example, common variants in SLC30A8 and HHEX were discovered as 
novel T2DM association genes(152). The SCL30A8 gene encodes a zinc transporter and 
is expressed in pancreatic beta cells(153). The HHEX gene encodes a transcription factor 
involved in early pancreatic development(154). The candidacy was confirmed for 
TCF7L2 gene in GWAS which was already identified as strong T2DM candidate gene 
(Linkage studies and Candidate gene association study).  
 
The results from GWAS do not however mean that the insulin resistance genes are not 
there to be found. The two genes identified which are conferring diabetes risk through 
insulin action are the PPARG and FTO gene. In a GWAS in U.K population FTO gene 
has been identified associated with BMI and obesity from childhood to old age that 
predisposed to T2D through an effect on BMI. The adults who have the homozygous risk 
allele (Allele A of rs9939609)  of FTO gene region on chromosome16, weighed 3 
kilograms more and had 1.67 fold increased odds as compared to those who did not have 
the risk allele and OR of 1.27 for T2D(155). In the Finnish GWAS rs8050136 of FTO 
gene giving an odds ratio of 1.17 per at risk allele was identified(156). The reason for 
fewer number of new variants of insulin resistance genes found in GWAS as opposed to 
insulin secretion genes could be potentially multi-factorial- design of the study where 
subjects are matched for BMI or have lean T2D cases, modest affect sizes of at risk 
alleles leading to loss of power, potentially fewer variants that affect insulin resistance 
and potential for strong environmental influences in obesity and metabolic syndrome 
phenotypes(157). This would imply the critical importance of design of the GWAS takes 
BMI/ Obese individuals into account to improve the chances of detecting insulin 
resistance genes.  
 
 
  
139 
Candidate gene association study vs. GWAS  
 
There are several possible explanations why candidate gene studies may identify genes 
missed by GWA studies. Most importantly, depending on the genotyping platform 
(affymetrix, illumina, perlegen) and SNP density (500k-1 million) there may be poor 
coverage of the relevant candidate gene. This is illustrated by the fact that SLC30A3 was 
not identified as a result of WTCC GWA but was identified once tag SNPs were added to 
identify the gene in another GWA scan on a different population (158). Candidate gene 
association studies use more densely spaced SNPs to target the gene in question. Recent 
candidate gene association studies have included more participants and are therefore 
more likely to uncover lower risk alleles. Finally, in a GWA study the results are 
corrected for the large number of tests performed, and the threshold p-value for positive 
associations is lower, leaving room for more type 2 error. Furthermore, Genome wide 
association studies cannot take into account the possibility of rare variants contributing to 
the disease risk- common disease rare variants hypothesis.  
 
 
8.3 Common disease rare variant hypothesis  
 
One emerging hypothesis is that low frequency variants with intermediate penetrance 
effects (B2 in figure 8.a) could be associated with common disease(159). Most 
associated variants that have been detected to date are common (minor allele frequency, 
MAF > 5%), although this is mostly a reflection of study design in terms of SNPs 
selected for genotyping and power of the sample size(160). If susceptibility alleles have 
minor allele frequencies (MAFs) of less than 0.1 i.e. rare, then large sample sizes of 
greater than 10,000 cases and 10,000 controls (or 10,000 families) would be required to 
achieve convincing statistical support for a disease association(161). The exact size of the 
study cohorts would depend on power calculations but the expectation is that these low 
frequency variants would be associated with a high risk predisposition compared to those 
recently identified by GWA. Thereby to achieve adequate power at even lower MAFs 
with the same effect sizes we are talking about sample sizes in excess of 20,000 
individuals. 
  
140 
 
 
Figure 8.a: Common variants- common disease / rare variants- common disease 
 
 
 
Figure 8.a: Common disease common variants (3C), Common disease low frequency 
variants (2B), and Mendelian disease very rare variants (1A) 
 
 
 
8.4 Monogenic disease – common disease 
 
The alternative approach is the study of Mendelian disease, such as Wolcott- Rallison 
Syndrome, and once a causal gene has been identified (A1 in figure 8.a) to follow 
through these findings to see if common variants of the gene is associated with the 
polygenic disease - T2DM, the common disease common variant hypothesis (C3 in 
figure 8.a). The study of monogenic disease to identify polygenic disease has had its 
success, for example- HNF 1a/TCF-1, SUR 1/Kir6.2 E23K, Wolfram syndrome/WFS 1, 
MC4R receptor genes and its variants and their association with common type 2 diabetes. 
Rare mutations of these genes lead to monogenic forms of diabetes. 
 
Mendelian 
disease 
Low 
frequency 
variants 
Common 
variants 
Allele  
frequency 
Penetrance 
1 2 3 
High (A) 
Intermediate(B) 
Low (C) 
Very 
rare 
rare common 
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Mutations of transcription factor 1 (TCF1, or hepatocyte nuclear factor-1 ) affect -cell 
function. Common variants in the HNF-1  gene influences transcriptional activity and 
insulin secretion in vivo. These variants have been shown to be associated with a 
modestly increased risk of type 2 diabetes in elderly overweight individuals (162). 
In pancreatic β-cells ATP-sensitive potassium (K+ATP) channels control insulin secretion 
by coupling metabolism to changes in electrical activity. The K
+
ATP channels are 
composed of two subunits, the sulfonylurea receptor (SUR1 or ABCC8) and the inwardly 
rectifying potassium channel Kir 6.2. Mutations in the SUR1 gene cause decreased K
+
 
ATP channel activity and congenital hyperinsulinemia. E23K variant in the Kir 6.2 gene 
has been shown in several studies in various ethnic groups to be associated with type 2 
diabetes (163). 
 
Mutations in the WFS1 gene cause β-cell death, resulting in a monogenic form of 
diabetes known as Wolfram syndrome. The role of variation in WFS1 in type 2 diabetes 
susceptibility was investigated in various ethnic populations and data provide strong 
evidence that variation in WFS1, a gene with an essential role in the endoplasmic 
reticulum stress response in insulin-producing pancreatic β- cells, contributes to risk of 
common type 2 diabetes (164). 
 
Mutations in the melanocortin 4 receptor gene (MC4R) are a common cause of 
monogenic human obesity. The common SNP rs17782313 near MC4R gene was 
significantly associated with higher intakes of total energy and dietary fat and was shown 
to be related to greater long-term weight change and increased risk of type 2 diabetes in 
women. (165) 
 
The studies into monogenic syndromes and the gene mutations and their positive 
associations seen with the common type 2 diabetes underlies the fact that such studies 
could bear fruitful results and could potentially invoke a new aetiopathogenesis for type 2 
diabetes. This hypothesis would argue that common and rare variants of genes that lead 
to monogenic disease should be studied as plausible candidate genes in the common form 
of T2DM. 
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8.5 EIF2AK3 gene- polygenic Type 2 Diabetes 
 
When the study was envisaged in the yea2002, the best approach for performing 
candidate gene association study was to identify a suitable candidate gene which had 
strong a priori credentials to be associated with type 2 diabetes. The candidate gene was 
selected on the basis of prior linkage evidence, biological plausibility and mechanistic 
model of action of the gene product- protein, animal model with underlying gene defect 
and a monogenic model. However, as explained in the previous chapters ―a priori‖, even 
in the era of GWAS, there are good reasons to investigate the candidacy of EIF2AK3 as a 
cause of non-auto immune diabetes. In our study we selected the WRS gene- EIF2AK3, 
which satisfied most of the criteria and appeared to be a promising gene to investigate for 
candidacy for type 2 diabetes. EIF2AK3 was a very attractive candidate gene to test given 
its role in Walcott- Rallison syndrome (monogenic form of insulin dependent diabetes), 
its role in attenuating endoplasmic reticulum stress in the pancreas, animal model of 
diabetes in EIF2AK3/PEK deficient mice and preliminary association data on the South 
Indian and UK Warren 2 type 2 diabetes patients; although it is acknowledged that the 
preliminary study was grossly underpowered. 
 
EIF2AK3 gene- Wolcott- Rallison syndrome 
Wolcott- Rallison syndrome (WRS) is a rare autosomal recessively inherited disorder. 
The syndrome, as previously explained, is characterised by a short trunk compared to arm 
span, multiple epiphyseal dysplasia, bone demineralisation, multiple fractures, tooth 
discolouration, abnormal skin, hepatosplenomegaly and renal insufficiency in addition to 
pancreatic exocrine insufficiency and non autoimmune insulin dependent diabetes. 
 
Aetio-pathogenesis of type2 diabetes and the role of ER stress  
Type 2 Diabetes is characterized by the insulin resistance in the liver, muscle and adipose 
tissue. In the initial stages of the disease there is relative hyperinsulinaemia to 
compensate for the insulin resistance. But, there is progressive β cell loss necessitating 
escalation of diabetes treatment and frequently needing insulin treatment in type 2 
diabetes to achieve normoglycaemia. This process highlights the β cell failure in the 
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development and progression of Type 2 diabetes(166). The decreased β cell mass is due 
to increased β cell apoptosis and decreased β cell replication and regeneration. This was   
shown in the post mortem studies of pancreatic specimens of T2D patients(167). 
Glucotoxicity and lipotoxicity leading to oxidative stress causes pancreatic β cell 
dysfunction. This glucolipotoxicity is a feature of both obese and lean T2D phenotype 
individuals. However, glucotoxicity is proposed as a prerequisite for β cell lipotoxicity 
(168). ER stress pathways have been proposed as potential route involved in pancreatic β 
cell apoptosis. ER stress response also known as unfolded protein response (UPR) can be 
trigger of pancreatic β cell dysfunction and apoptosis under situation of chronic stress 
(High glucose and high free fatty acid exposure). ER is a dynamic organelle involved in 
protein (insulin) biosynthesis in the pancreatic islets. ER stress due to lipotoxicity and its 
role in pancreatic dysfunction has been shown in in-vitro experiment. Palmitate and 
oleate caused apoptosis in the well differentiated insulin producing INS-1E cells by 
triggering ER stress response(169). ER has an important role in calcium storage and 
signalling. Any disruption of the ER function potentially has a deleterious effect on 
pancreatic insulin secretory function. In the PERK knock out mice due to the ER stress 
there is disruption of ca
2+ 
signalling complexes and ca
2+
 regulation in pancreatic 
cells(170).  
 
The ER in pancreatic β cells has a major function of synthesis of insulin, folding and 
processing of the protein. There are many ER stress signals as discussed previously. The 
response to ER stress is called the unfolded protein response to protect the β cells. PERK/ 
EIF2AK3 has a central role to play in UPR. EIF2AK3 enriched in pancreatic cells, is 
uniquely located to the endoplasmic reticulum and is activated by the accumulation of 
unfolded proteins in the ER lumen. EIF2AK3 phosphorylates eukaryotic initiation factor- 
2 alpha (eIF2 α) which then inhibits eIF2 β, leading to cellular events that inhibit mRNA 
translation. Downregulation of protein synthesis occurs by phosphorylation of the alpha 
subunit of eukaryotic translation initiation factor-2 (eIF2-alpha). This is one of the 
fundamental responses to ER stress and prevents further β cell damage by apoptosis(171). 
Targeted mutation of the mouse EIF2AK3 gene abolishes phosphorylation of eIF2 α, and 
the resultant phenotype in mice homozygous for the mutation is characterised by non- 
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autoimmune insulin deficiency, hyperglycaemia, growth retardation, steatorrhoea and 
high mortality between 2 and 4 weeks of life and heterozygous mice have impaired 
glucose tolerance. 
 
The candidate gene association study was carried out with a plan to have a large sample 
size (total study size = 8095 subjects) to have adequate power to either implicate or refute 
EIF2AK3 as a candidate gene for T2DM, as it is accepted in genetic research into 
polygenic diseases that small sample sizes looking into SNP polymorphisms and 
associations with disease can lead to mostly false positive results. We did a robust 
association study for T2DM looking into a plausible gene EIF2AK3 and had a good 
admixture of Caucasian and South Asian resources. The Caucasian resources were the 
largest cohort with 6112 subjects.  
 
In T1DM study there was evidence for an association between T1DM and particular 
EIF2AK3 marker combinations (overall global P<0.001), with excess transmission of 
both the 15INDEL allele 1/D2S1786 allele 4 and 15INDEL allele 1/D2S1786 allele 3 
combination (both P<0.0001), and decreased transmission of 15INDEL allele 1/D2S1786 
allele 5 combination (P<0.001) in South Indian families. Preliminary T2DM studies in 
UK Warren 2 trios (n = 150) showed marked deviation from expected transmission for 
haplotypes for SNPs 2, 10, 11 and 13 of the EIF2AK3 gene. These preliminary results 
however were not adequately powered and only a few SNPs across the EIF2AK3 gene 
were investigated. 
 
We carried out a case-control study as well as a family based association study. A 
detailed SNP inventory of EIF2AK3 was compiled in the British Irish and the South 
Asian subjects and 19 SNPs were identified. Four SNPs were not found in the public 
databases. Four markers were subsequently not found to be polymorphic. Our final 
analysis included three exonic and three intronic SNPs within the EIF2AK3 gene and four 
SNPs in the 5' and 3' of the EIF2AK3 gene. 
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8.6 Genotyping Quality control issues 
 
Quality control is critical to avoid pitfalls leading to false interpretation of the genotyping 
results. In our study we had to undertake a large amount of work for quality control 
purposes. The reason for the QC checks is to obtain reliable and clean data and to 
eliminate the likelihood of generating false positive or false negative associations. When 
processing large number of samples these problems would be magnified and is therefore 
especially important to pay attention to Quality control. The stringent criteria set for QC 
pass enabled us to identify the data sets that could be identified for further analysis as 
discussed in chapter six. In the year 2002, less attention was focussed on QC issues. This 
led to false positive associations which failed future replication studies(172). There have 
been standards recommended by leading experts in the complex disease genetics field to 
address QC issues(173). These standards have been followed in my work for quality 
control checks. 
 
The DNA samples from ECACC and 1958 MRC birth cohort were of good quality and 
easily passed QC- the genotyping was performed at Genome Centre by taqman 
methodology. However, there were a lot of QC problems with the results generated from 
Warren 2 trios by taqman methodology as was thoroughly discussed in chapter six. The 
conclusion from the experiments carried out was that the wells were lacking DNA- 
W2trios DNA samples were either dried up or were inadequately aliquoted in the first 
place. The DNA resources that were available at KBiosciences were of better quality and 
all the 10 SNPs that were analysed by Amplifuor technology passed QC according to 
their internal quality control measures, except INDEL15, which also failed by taqman 
previously. Indeed the majority that was successfully genotyped were those DNA that 
were available at KBiosciences.  
 
The process of QC checks and the results obtained highlights the importance of 1) good 
quality DNA to be available for genotyping and 2) robust quality control measures in 
genotyping and data analysis phase to give reliable data. 
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8.7 Sequencing  
 
Sequencing of the EIF2AK3 gene together with 1800bp 5' and 3000 base pairs 3' was 
performed on ABI 3100 capillary sequencer utilising Big Dye terminator chemistry. 
Direct sequencing of all 17 exons and intron/ exon boundaries was performed on 48 
individuals (29 T2DM cases, 2 possible WRS cases and 17 controls- subjects were 
chosen from Chennai WRS family, British/ Irish T2DM and controls, South Asian T2DM 
and controls). 19 SNPs were identified by direct sequencing. Four of these SNPs were 
monomorhic SNP (i.e. only one form of allele present in the population of interest). 
Previously identified SNPs (174) detected in EIF2AK3 gene were also detected in our 
study. No mutations were detected that would be predicted to contribute to T2DM. Four 
of these SNPs detected were novel and were further studied in the candidate gene 
association study in both the British Irish and the South Asian cohorts. The novel SNPs 
rs7579242 and rs7605713 were located 5' of EIF2AK3 gene and the novel SNPs 
rs10189080 and rs4449134 were located 3' of EIF2AK3 gene. We also utilised two 
TagSNPs within the EIF2AK3 gene -rs867014 and rs17689440- from the HapMap2 
project for the purpose of EIF2AK3 gene candidate gene study to give extensive coverage 
of SNPs across the whole gene.  
 
8.8 Minor allele frequency- Population characteristics  
 
Genetic heterogeneity is a feature which has particular relevance when it comes to doing 
candidate gene association study in different ethnic groups. There could be differences in 
the minor allele frequencies among different ethnic groups. This difference in MAFs will 
have a bearing on the power of the study to detect association with the disease. The 
analysis showed several of the SNPs had different minor allele frequencies between the 
British/Irish Caucasians as compared to the South Asians (see table 6.e in results section 
on MAFs differences). However, comparisons between Bangladeshi and South Indians 
showed very similar minor allele frequencies despite the genetic heterogeneity among 
these groups. Bangladeshis are of Aryan origin with genetic structure more closely 
related to Caucasians whereas the South Indians are of Dravidian origin with genetic 
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structure more closely related to the Africans. This might suggest that for genetic studies 
of these markers for the WRS gene in the South Asian populations it may not be 
necessary to study the gene in different ethnic groups within the Indian sub-continent, 
although it should be borne in mind that culturally there are differences between South 
Indians and Bangladeshis. Therefore the environmental impact on a disease like T2DM 
may be different in these groups. Furthermore, in a recent extensive population study in 
India differences in allele frequency have been found at the genetic level in people from 
different regions within India(175).  
 
The minor allele frequencies obtained in the British Irish cohort in our study compared 
very favourably with the MAFs quoted in the public databases (HAPMAP CEU). This 
comparison adds further support to the quality control measures that were undertaken in 
our study. Since the MAFs for some of the SNPs were different in the South Asian 
population- it underlies the need for caution in using MAFs in HAPMAP for the South 
Asian population unless they are independently studied and quoted in HAPMAP.  
 
8.9 Hardy- Weinberg equilibrium results  
 
The principle of Hardy- Weinberg equilibrium is that in a randomly mating population 
the genotype frequencies remain constant from generation to generation. HWE testing 
was carried out on all datasets after the genotyping phase. Three reference SNPs failed 
HWE among the three populations studied (British Irish, Bangladeshi, and South 
Indians). The SNP rs4449134 was not in HWE in all three populations and therefore 
genotyping analysis was not undertaken for this marker. The SNP rs10189080 was not in 
HWE in the Bangladeshi and South Indian population. Finally, rs17689440 was not in 
HWE in the South Indian population. The reason for the deviation from HWE was an 
excess of homozygote rare alleles as compared to the expected number (see table 6.f in 
HWE failures) in the studied subjects.  
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8.10 Genotyping results on EIF2AK3 gene  
 
Single nucleotide polymorphisms within the EIF2AK3 gene have not been shown to be 
associated with type 2 diabetes previously. Our effort was to investigate the EIF2AK3 
gene for a candidate gene association study in T2DM in a case-control and family based 
association study. Genotyping was performed at two different sites- one at Genome 
centre in London and the other at KBioSciences. The technology used was the best 
available at the time the study was conducted for a large scale candidate gene association 
study. Taqman technology was utilised at Genome centre and Amplifluor/ KASPAR 
technology was utilised at KBioSciences. These technologies facilitated analysis of large 
sets of samples and provided us with robust data for the genotyping analysis. Genotyping 
analysis was performed in-house in ICMS London using the programme UNPHASED 
Log likelihood ratio tests. Statistical analysis was supported by Dr. Anna Vine under 
supervision from Professor David Curtis.  
(Website address: www.wolfson.qmul.ac.uk/psychiatry/staff/curtis_d.html) 
 
In order to measure marker-marker association of the EIF2AK3 gene we calculated a 
likelihood ratio test comparing the likelihood for the genotypes assuming LD to that 
assuming no LD, as implemented in the LDPAIRS program. The results showed the 
novel SNP rs7579242 to be in complete LD with rs1805165, rs867529 and rs6750998. 
rs17689440 is in complete LD with rs867529. rs7605713 is in complete LD with 
rs7579242. SNPs rs4449134 and rs1805164 are in incomplete LD. SNPs rs4449134 and 
rs867014 are in incomplete LD. All of the other SNPs, except SNPs rs4449134, 
rs1805164 and rs867014, genotyped in our study are in strong LD with each other with a 
D' of >0.8. These results highlight the fact that we could have reached similar 
conclusions by genotyping a few of the markers without genotyping all the markers that 
were in strong and complete LD. The aforementioned results were not anticipated prior to 
the LD analysis phase. There were four SNPs which were novel and we did not have LD 
structure in Hapmap. Furthermore, there is no LD information for the South Asian 
subjects and the information to this date is restricted to Guajarati Indians living in 
America. Therefore, we took the decision to genotype all the ten SNPs in the EIF2AK3 
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gene candidate gene association study in all the subjects. In retrospect it could be argued 
at least in the British Irish population we should have restricted the markers studied, since 
LD relationships in six of the markers is found in Hapmap. 
 
Allele frequencies and the p-values generated using UNPHASED 3.0.6 for all SNP 
markers of the EIF2AK3 gene are shown in Tables 7.a. to 7.k. 
 
The statistical results generated from our study for SNP rs7605713 (novel 5' of EIF2AK3 
SNP) in the British Irish combined analysis and in the Warren 2 trios showed a nominally 
significant p-value. A significant increase in the major allele of the SNP rs7605713, allele 
A, was seen in subjects with type 2 diabetes in the Warren 2 trios and British Irish 
combined genotyping analysis (P= 0.05). The rest of the SNPs showed no association 
between any of the reference SNPs/ markers of the EIF2AK3 gene and type 2 diabetes in 
the British Irish cohort. 
 
The statistical results generated from our study for SNP rs7605713 (novel 5' of EIF2AK3 
SNP) in the Bangladeshi combined analysis and young Bangladeshi case-control study 
showed a nominally significant p-value. A significant increase in the minor allele of the 
SNP rs7605713, allele C, was seen in subjects with type 2 diabetes in the Bangladeshi 
combined analysis (P= 0.05) and subjects with type 2 diabetes in the young Bangladeshi 
case-control study (P= 0.007).  
 
The statistical results generated from our study for SNP rs6750998 (Intron 10 SNP of 
EIF2AK3) in the Bangladeshi combined analysis and the young Bangladeshi case-control 
study showed a nominally significant p-value. A significant increase in the minor allele 
of the SNP rs6750998, allele T, was seen in subjects with type 2 diabetes in the 
Bangladeshi combined analysis (P= 0.04) and subjects with type 2 diabetes in the young 
Bangladeshi case-control study (P= 0.005).  
 
It is pertinent to note that the young Bangladeshi cohort was small (330 cases and 374 
controls). The patients with diabetes were lean with a mean BMI ~ 18. This is not the 
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typical phenotype of T2DM. Whether the SNPs- rs6750998 and rs7605713 are really 
showing a positive signal needs further study in a larger cohort with the same phenotype. 
Our study did not have adequate power for the young Bangladeshi cohort to arrive at a 
firm conclusion. To avoid false positives large numbers of subjects need to be studied (at 
least nearly 4,500 individuals) in candidate gene studies. Moreover it is important to have 
an independent replication cohort.  
 
The statistical results generated from our study showed no association between any of the 
reference SNPs/ markers and type 2 diabetes in the South Indian cohorts, even though 
SNP rs867014 (Intron 1 SNP of EIF2AK3)  and SNP rs1805164 (Exon 11 SNP of 
EIF2AK3) showed a nominally significant p-value in the South Indian urban survey. A 
significant increase in the minor allele of rs867014, allele C, was seen in subjects with 
type 2 diabetes in the South Indian urban survey (P= 0.04). A significant increase in the 
minor allele of rs1805164, allele G, was seen in subjects with type 2 diabetes in the South 
Indian urban survey (P= 0.01). The results should be interpreted with caution for this sub-
group analysis given the small number of cases (n= 85) and disproportionately larger 
number of controls (n=260) whereas there was no difference noted in the combined South 
Indian analysis. 
 
In the one marker, rs7605713, that showed a nominal significance in the British Irish 
combined analysis and Warren 2 trios family study, further replication studies in a similar 
population group, the Dundee Wellcome Trust UK T2DM Genetic consortium Case-
control cohort (3334 diabetes cases and 3456 controls) proved to be negative (P= 0.5) 
thereby avoiding a false positive association. This replication work is an important step in 
a robust candidate gene association study.   
 
We therefore concluded in our candidate gene association study that no association 
exists between common variants of EIF2AK3 gene and type 2 diabetes.  
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The following SNPs that were studied in our group- rs867529, rs1805164, rs1805165, 
rs867014- were also independently studied by Geneticists in Cambridge, U.K (176) in a 
case-control study (9533 cases and 11389 controls) and they found no association with  
for these SNPs with type 2 diabetes. All three SNPs are in tight LD (D' >0.9) with 
rs7605713. This would further support the likelihood the association between rs 7605713 
and T2DM in the original British Irish cohort in our study was a false positive 
association.  
 
Rare mutations of EIF2AK3 and association with type 2 diabetes have not been excluded 
in our case-control and family study. However no coding variants that would lead to an 
amino acid change or regulatory region variants were identified in sequencing work of 48 
subjects in our study including a South Indian family with phenotype for WRS. Our 
findings are further supported by a French study of young type 2 diabetes individuals (30 
T2DM cases) (177) in whom direct sequencing of 17 exons and intron- exon boundaries 
of EIF2AK3 did not detect any mutations in the cases. The results of these two datasets 
and experiments taken as a whole make it very unlikely that the common disease rare 
variant hypothesis would apply to the EIF2AK3 gene. But this can by no means be ruled 
out. In order to exclude the common disease rare variant hypothesis, at least 1000 people 
would need sequencing(178). This approach will be made substantially easier once the 
1000 Genomes project is completed. 1000 Genomes project (web link: 
www.1000genomes.org) is an international research effort to establish the most detailed 
catalogue of human genetic variation by sequencing approximately 1200 individuals 
across the globe over the next few years. 
 
It is likely that the association we described previously between T1DM and markers 
D2S1786 and INDEL15/rs1805181 of EIF2AK3 gene (179) is a false positive result 
(Type 1 error) likely related to the small sample size thereby once again reinforcing the 
need to conduct a study on a large scale with large number of individuals. Furthermore, if 
the Bonferroni correction set the threshold of significance at p= 0.05/n to avoid errors of 
association, where n is the number of markers studied, statistical significance would not 
have been observed. 
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Despite having very good coverage of markers throughout the EIF2AK3 gene which were 
in tight LD with each other none of our markers tagged INDEL15/rs1805185. Ideally we 
would have wanted to identify a good tag SNP for rs1805185 to complete the analysis but 
searching the Hapmap database (Web link: www.hapmap.org) no appropriate marker 
exists. 
 
In view of the overwhelming negative EIF2AK3 candidate gene association study in 
T2DM there seemed little point pursuing any functional aspects of EIF2AK3 gene that 
were originally envisaged.  
 
 
8.11 Study design as of 2009-2010 
There have been major advances in technology- automation and high throughput 
techniques, the International Hapmap project with readily available SNP inventory and 
Genome wide scanning approach, that if I were to do the study in the present time I 
would approach it in a different way   
 Find evidence of a preliminary association by genotyping of Tag SNPs identified  
     in silico and establishing minor allele frequencies in all the ethnic groups. 
 Adequately powered data sets within each ethnic group. 
 Technology advances for single gene SNP analysis 
 Study design to account for common disease- common polymorphisms (current 
GWAS design) vs. common disease- rare polymorphisms (Future study designs). 
 
Tag SNPs 
Tagging SNPs exploit the extensive linkage disequilibrium that is present in the genome. 
Genotyping a few variants with extensive linkage disequilibrium resulting in extensive 
coverage across the whole gene- EIF2AK3 is a practical approach. We carried out this 
process for the identification of SNPs to be studied. Even though we have SNP 
information for the European cohort, tag SNP data is not currently available in the 
Hapmap project for the Bangladeshi and South Indian population; indeed we found 
different MAFs in these ethnic groups for some of the markers.  
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For cost effectiveness, we could do a candidate gene association study by testing the tag 
SNPs in the first phase. And if they were positive, we could proceed using a denser set of 
markers/SNPs to extensively cover the gene, especially when there is strong a priori 
evidence for the gene to be associated with the disease. One could argue that the tagging 
option is not warranted if the a priori evidence for a gene is strong and proceed with the 
classical design for a candidate gene association study. We had four Tag SNPs which we 
genotyped in our candidate gene association study. 
 
Power 
Ideally we should have done power calculations before we embarked on the candidate 
gene association study. Furthermore, at the time it would not have been predicted that 
majority of T2DM candidate genes would only have an odds ratio between 1.1- 1.3 as has 
been revealed by recent GWAS.    
    
Table 8.b: Power calculations for gene association study 
(Assuming 80% power and p value of 0.05) 
Relative 
risk 
Minor 
allele 
frequency 
Case-
control 
1.1 0.1 18,493 
1.2 0.1 4,888 
1.3 0.1 2291 
1.1 0.2 10,503 
1.2 0.2 2,801 
1.3 0.2 1,324 
1.1 0.3 8,080 
1.2 0.3 2,174 
1.3 0.3 1,037 
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Nonetheless, the British Irish cohort for the case-control candidate gene association study 
comprised of 2206 cases and 2652 controls. Thereby the study had adequate power to 
detect a relative risk of 1.2 with 80% power and a p- value 0.05, assuming a MAF of 0.3. 
However, we had smaller numbers in the Bangladeshi and the South Indian populations 
in our study. Ideally we would have liked to have a bigger sample size for the purpose of 
the study. There were logistical constraints to recruit more individuals of South Asian 
origin. For instance, we would have needed a sample size of at least 4,348 individuals 
from the different ethnic groups to give us the power to identify a relative risk of 1.2 with 
80% power and a p- value 0.05, assuming a MAF of 0.3 (Website- 
http://stat.ubc.ca/~rollin/stats/ssize/caco.html) as indicated in the table 8.b. As would 
have been predicted all the South Asian datasets in our study are therefore underpowered 
for an ethnic specific analysis.   
 
Technology advances for single gene SNP analysis 
Technological advances for conducting a single candidate gene association study have 
also taken place since the time of our study. Taqman and Amplifuor technologies would 
still be considered adequate at present for a study of similar size to our study (Analysis of 
10-11 SNPs in a single candidate gene). However, technology exists for simultaneous 
genotyping of multiple SNPs (From 10 up to 48 SNPs can be multiplexed). SNaPshot 
Multiplex system enables multiplexing up to 10 SNPs for genotyping (180). The 
Snapshot chemistry is based on dideoxy single base extension of an unlabeled 
oligonucleotide primer. Each of the primers bind to a complementary template in the 
presence of fluorescently labeled ddNTPs and AmpliTaq DNA polymerase. The DNA 
polymerase extends the primer by one nucleotide, adding a single ddNTP to the 3' end. 
The generated products are analysed with GeneScan analysis software. SNPlex 
genotyping system enables simultaneous genotyping of up to 48 SNPs (181). SNPlex 
assay utilizes an oligonucleotide ligation assay followed by PCR. It uses capillary 
electrophoresis instrument to separate selectively amplified gene regions and identifies 
the eluted probes with the aid of GeneMapper software. The technologies are available 
from Applied Biosystems. (Web address: www.appliedbiosystems.com) 
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Common disease- common polymorphisms (current GWAS design) vs. common 
disease- rare polymorphisms (Future study designs) 
The GWAS design of gene association studies in T2DM has been to identify common 
variants with minor allele Frequency > 5% that could be associated with disease, i.e. 
common disease common variant hypothesis. If as suspected susceptibility alleles have 
minor allele frequencies (MAFs) of less than 0.1 i.e. rare, then large sample sizes of 
greater than 20,00 would be required to achieve convincing statistical support for a 
disease association studies. The study design will therefore depend on the power 
calculations based on minor allele frequencies in various ethnic cohorts. 
 
In an ‘ideal world’ scenario adequately powered cross sectional cohort ethnic study 
design would be appropriate. Furthermore, we would have done power calculations for 
each ethnic population prior to genotyping to have a robust study design. We would have 
had access to DNA from more subjects in the South Asian cohorts to boost the power for 
the study. There could also be an argument made for analysing each ethnic group as one 
sampling frame rather than having sub group analysis as we have done in our study. We 
studied EIF2AK3 as a T2DM candidate gene in isolation in the various cohorts. We could 
have strengthened our study to include genes that were the main regulators and effectors 
of the EIF2AK3 gene. Therefore studying common variants of eukaryotic initiation 
factor- 2 alpha (eIF2 α) eIF2 β, and the ER stress pro- apoptotic downstream signaling 
genes which include CHOP, IRE 1, JNK, CFOS/ JUN, IL- 1β, would have enabled us to 
enquire about the complete biological system of endoplasmic reticulum stress and type 2 
diabetes rather than testing an individual component in the EIF2AK3 gene. Furthermore, 
if we were to argue that the gene variants could be linked to pancreatic insufficiency in 
subjects with T2DM with lean body habitus and low BMI; having detailed phenotypic 
data on all the cohorts would have been ideal to pursue this line of investigation. 
Moreover, comparing allelic frequencies for the EIF2AK3 gene in type 2 diabetes in 
young individuals below the age of 30 years vs. controls would further strengthen the 
study design for establishing or refuting candidacy.  
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8.12 The future 
 
Detecting heritability in complex disease such as type 2 diabetes is a hard and arduous 
task. We have seen progression from family based linkage studies, case-control candidate 
gene association studies and family association study to the currently popular genome 
wide association studies. We are realising the scale and magnitude of understanding 
heritability in complex disease such as type 2 diabetes. The signals from the GWAS are 
identifying novel susceptibility variants and mostly pointing towards pancreatic β cell. 
However, the realisation there is missing heritability especially in insulin resistance genes 
due to lack of adequate power of GWAS or inappropriate marker selection needs to be 
addressed in future studies. Thus far the variants discovered in T2D gene association 
studies account for only 5-10% of inherited predisposition. Obviously there is scope for 
ongoing efforts to detect the missing heritability. There is a trend to progress from 
common disease common variant hypothesis testing in the current GWAS to common 
disease rare variant hypothesis testing. There is lot more work needed to be done in the 
genetics of complex disease, involving various consortia across the globe working 
closely. The need of the hour is to obtain large data sets numbering in tens to hundreds of 
thousands, to improve power and identify the missing heritability. Some of these factors 
have led to the first GWAS meta- analysis (135). The DIAGRAM consortium (Diabetes 
Genetics, Replication And Meta-analysis), a collaborative effort by the investigators from 
3 major GWAS groups world wide, boosted the power to detect common susceptibility 
loci with modest effects, although the power to detect smaller effect remained low. The 
way forward in the history of gene discovery in T2D needs to be focused on even more 
such collaborative efforts and also to utilize the fast emerging technology to study the 
genome in much further detail. Indeed a further comprehensive meta-analysis of all 
GWAS study for T2DM has recently been completed (DIAGRAM plus consortium); 
unpublished data suggest that there are now 35 genes identified for T2DM. However, the 
identified gene variations still only accounts for ~10% genetic component of T2DM. The 
other area of effort in the field is comparative genomics with GWAS underway in diverse 
ethnic groups where the LD structure is likely to be different to the Caucasians already 
studied(182). 
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A complimentary approach to GWAS SNP based analysis, would be to focus on copy 
number variations (CNV). CNV are the number of variations in DNA sequence (1 kb to 
several megabases) in the genomes of different individuals with some individuals having 
more copies of specific genes than others. CNVs can be caused by deletions, 
duplications, inversions and translocations leading to significant differences among the 
genomes of different individuals. A study of eight individuals with diverse geographic 
ancestry revealed novel insertion sequences many of which were CNV between 
individuals(183). This study was a high resolution sequence map of human structural 
variation employing a clone based sequencing methodology. Another study involving 
270 individuals from four different population groups discovered that copy number 
variants covered 12% of the human genome(184). These observations have ignited 
interest in researchers that CNV might underlie disease susceptibility in complex 
diseases. The study of CNV to detect association in complex diseases (eg- Crohn‘s 
disease, Schizophrenia, Autism) have been undertaken and CNV are likely to be involved 
in disease susceptibility; results in T2DM is still awaited. The current commercial GWAS 
platforms include ―CNV aware‖ chips in addition to SNP genotyping(185). The data 
generated from such GWAS analysis can enable integrated analysis of SNPs and CNVs. 
The same constraints faced by SNP analysis could also be relevant to CNV, i.e. common 
variants vs. rare variants. Such enquiries of common disease rare variant hypothesis will 
eventually lead to efforts in large scale sequencing studies to detect the missing 
heritability in complex diseases.  
 
The search for rare variants in common disease will be enabled by large scale 
sequencing studies with technology expanding at a rapid pace. Our study concluded that 
common variants of WRS gene do not contribute to development of type 2 diabetes. But 
rare variants of WRS gene have not been excluded in contributing to T2DM, and clonal 
sequencing would be the most robust approach to investigate rare variants in the 
EIF2AK3 gene and possible association with T2DM.The alternative approach to our 
study will be whole genome sequencing to the whole dataset, i.e. clonal sequencing 
using Solexa. Nonetheless, the future will be non hypothesis driven genome wide 
sequencing. The principles of clonal sequencing are exemplified by Solexa Sequencing 
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technology(186). The Sequencing is performed by synthesis on arrays. Single DNA 
molecules are clonally amplified in spatially separate locations in a highly parallel array. 
The use of clonal single-DNA molecule templates is very useful for detecting SNP alleles 
in the DNA. Because each sequencing template is clonal in origin, high quality base calls 
are generated separately for each variant. Sequencing templates are immobilized on a 
proprietary flow cell surface designed to present the DNA in a manner that facilitates 
access to enzymes while ensuring high stability of surface-bound template and low non-
specific binding of fluorescently labelled nucleotides. Single molecules are covalently 
attached to a planar surface and amplified in situ.  Solid phase amplification is employed 
to create up to 1,000 identical copies of each single molecule in close proximity 
(diameter of one micron or less). Sequencing by synthesis is carried out by adding a 
mixture of four fluorescently labelled reversible chain terminators and DNA polymerase 
to the template. This results in addition of a single reversible terminator to each template. 
The fluorescent signal is detected for each template, and the flourophore and the 
reversible block are removed. The terminator–enzyme mix is then added to start the next 
cycle, and the process is reiterated until the end of the run. Solexa sequencing technology 
can achieve densities of up to ten million single molecule clusters per square centimeter. 
Solexa sequencing uses four proprietary fluorescently labelled modified nucleotides to 
sequence the millions of clusters present on the flow cell surface. Given that all four are 
present in the reaction, the risk of misincorporation is minimised, increasing sequencing 
accuracy. The Illumina Genome Analyser has the capability to generate over a billion 
bases of DNA sequence per run. The 454 system is one of the other next generation 
sequencing technology and it uses the pyrosequencing technology (187).  
 
At the same time as efforts are directed to the study of genome, the critical study of gene- 
environment interaction and its role in disease pathogenesis needs to be addressed(188). 
An important interface between gene and environment is the epigenome. Epigenetics 
studies the heritable changes occurring in gene function during cellular replication, in the 
absence of changes in the DNA sequence. Epigenetics are often involved in switching on 
or switching off the gene without any changes in the base sequence leading to different 
phenotypes. Epigenetic mechanisms, such as DNA methylation, histone acetylation, 
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RNA interference, and their effects on gene activation and inactivation, are opening new 
insights into gene regulation, RNA transcription, and protein homeostasis. Even though 
all human cells contain the same genome, the gene function is different in different cells 
and organelles. The cells contain different epigenomes based on cell type, function, 
developmental age and stage of the cell. The study of epigenetics is of significant 
importance in type 2 diabetes for obvious reasons. The realisation is that epigenetic 
alteration by DNA methylation, histone acetylation and deacetylation can introduce 
epigenetic changes during the life time. Such changes may influence age related changes 
in gene-expression and thereby contribute to age-related diseases like T2DM.  
 
Research is being directed at the gene-environment interaction, as this will indicate the 
appropriate population strategies to combat the increasing incidence of T2DM. Methods 
to investigate epigenetics are rapidly advancing and this can now be studied at the whole 
genome level(189). Regulation of gene expression is a complex process. The influence 
that epigenetic phenomena may have on disease onset and outcomes is also becoming 
clearer, paving the way for the development of new diagnostic and therapeutic strategies. 
Intra uterine growth retardation has been linked to development of T2DM in adult life. 
Foetal programming and the effect of abnormal intra uterine environment modifies the 
gene expression of cells like the pancreatic cells. Altered gene expression persists after 
birth and epigenetic mechanisms are thought to be involved. This links up nicely with the 
Barker and Hale thrifty phenotype theory of developmental origins of metabolic 
disorders. The current terminology ―Developmental Origins of Health and Disease‖ 
DOHaD model hypothesises the phases of IUGR, foetal programming, rapid childhood 
growth increases the susceptibility to type 2 diabetes in later life. Research has 
highlighted the possible role of methyl donors like vitamin B12 and folate playing a 
major role of epigenetics in foetal programming. Low maternal B12 levels along with 
normal to high folate levels have been shown to predict adiposity and insulin resistance in 
Indian children(190).  
 
The Human Epigenome Project (HEP) aims to identify genome wide DNA methylation 
patterns of all human genes in all major tissues(191). The goals of HEP are to generate 
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methylation reference maps, to identify methylation variable positions (MVPs) in the 
genome and to correlate methylation with gene activity, and thus with a specific 
phenotype or disease. Hence DNA methylation leading to change in gene function under 
environmental influence constitutes the main and so far missing link between genetics, 
disease and the environment that is widely thought to play a decisive role in the aetiology 
of many human pathologies. In the human genome methylation occurs naturally on 
cytosine bases at CpG sequences (Cytosine-phosphate- Guanine sequence in DNA) and is 
involved in controlling the correct expression of genes(192). Differentially methylated 
cytosines give rise to distinct patterns specific for tissue type and disease state. Such 
methylation variable positions (MVPs) are studied as the common epigenetic markers 
given their stability in the genome. Similar to the study of single nucleotide 
polymorphisms (SNPs), the study of MVPs promise to significantly advance our ability 
to understand chronic disease like Type 2 Diabetes.  
 
Technologies for DNA methylation analyses  
 
PCR based (193) technology after bisulphite conversion of unmethylated cytosines to 
uracil. At present, bisulphite conversion of DNA followed by PCR and sequencing 
remains the gold standard of methylation analysis. Real time PCR approaches enable to 
quantitatively detect methylation specific amplicons. Pyrosequencing assays that enable 
high-throughput analyses of up to 10 CpGs in an amplicon size of 300 bp have been 
developed(194). 
 
Restriction enzyme based methylation analysis followed by PCR- For example the 
utilisation of restriction enzyme HpaII‘s differential ability to recognise and cleave 
methylated and unmethylated regions of CpG DNA sites(195). The restriction enzyme 
will only cut if the cytosine is unmethylated and is unable to cut the DNA if the cytosine 
is methylated.  
 
Immunoprecipitation of methylated DNA targeted towards a genome wide assessment of 
methylation (MeDIP)(196). Microarray technology and comparative genomic 
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hybridization have further opened the field for high-throughput methylation analyses 
MeDIP- chip and Illumina 27K are technologies available to generate genome wide 
methylation data. MeDIP-seq combines MeDIP with the next generation sequencing 
technologies such as Solexa, SoLiD and 454(197). 
Modifications of the methodology include using matrix-assisted laser desorption/ 
ionization mass spectrometry (MALDI-MS) for quantitative detection of methylation 
after primer extension for discrimination between methylated and unmethylated CpGs on 
bisulphite treated DNA(198).  
 
Epigenetics could be used to study either a selected candidate gene such as EIF2AK3 
gene or an unbiased approach of studying the whole methylome. For instance if a study 
of EIF2AK3 gene was proposed, one approach would be to do bisulphite conversion of 
unmethylated cytosines to uracil followed by pyrosequencing. This methodology is also 
used to validate top hits of a whole methylome analysis. It is unclear how useful it would 
be to study leukocyte DNA for EIF2AK3 gene study, since this would depend on an early 
life environmental event affecting all three germ cell layers. As in relationship to insulin 
secretion the epigenetic mark may be tissue specific, thereby requiring access to human 
islets to carry out the study. 
 
Thus whole genome studies in T2DM with integrated approach of genome wide 
association studies, study of rare variants and common disease and methylation studies 
would be a comprehensive investigative approach for type 2 diabetes genetic link. 
 
 
 
 
 
 
 
 
 
  
162 
8.13 CONCLUSIONS 
 
Genome wide association studies are throwing up new genes associated with T2DM and 
other chronic diseases at a rapid pace. They promise to greatly enhance our understanding 
of the genetic basis of common and complex diseases. Thus far the results generated in 
type 2 diabetes from GWA studies highlight the genes involved in pancreatic β cell 
development and function.  The ideal approach would be to follow through on this initial 
success and investigate these genes further by way of replication studies in various ethnic 
groups to confirm their candidacy.  The results from GWAS do not however mean that 
the insulin resistance genes are not there to be found in T2DM. Missing heritability is 
likely to be identified by integration of common disease rare variant hypothesis, genome 
wide epigenetic and genome wide expression studies with genome wide association 
studies in a range of different ethnic groups. Furthermore, functional studies of the gene 
and its protein to elucidate the aetio-pathogenetic basis of type 2 diabetes should be 
conducted. Proteomics (199) (large-scale study of proteins) and metabolomics (200) 
(study of metabolites linked to metabolic dysfunction and type 2 diabetes and the study of 
metabolic responses to drugs, environmental changes and diseases), utilising tools such 
as nuclear magnetic resonance and mass spectrometry, will eventually lead to insights in 
the pathogenesis of this common condition and the ideal drug treatments for type 2 
diabetes. With the knowledge of the precise biochemical variants involved in disease 
pathogenesis, we may be in a better position to classify the disease, identify novel drugs 
and design more rational therapeutic manoeuvres to prevent and ameliorate this 
condition. Nonetheless, as of 2008-9 lifestyle interventions (healthy diet and exercise) 
(201) have been demonstrated to show significant reduction in onset of diabetes in high- 
risk individuals for type 2 diabetes (202,203). The future might see genetic profiling of 
individuals to identify who might respond to such strategies including targeted 
pharmacological treatment.  
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